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ABSTRACT

Author: Morman, Rosemary, E. PhD
Institution: Purdue University
Degree Received: May 2018
Title: BATF Regulation of Nfil3, Wnt10a, and miR155hg during Lymphocyte Activation Critical
for T Cell Differentiation and Antibody Class Switch Recombination.
Committee Chair: Elizabeth Taparowsky

B cell activating transcription factor (BATF), an immune specific AP-1 transcription
factor, functions together with IRF4 and JUNB to regulate genes important for antibody class
switch recombination (CSR) in B cells and for the functional differentiation of distinct CD4+T
helper (Th) subsets, including Th2, Th9, Th17 and T follicular helper cells. At the time this work
was initiated, the expression of BATF in T cells and B cells was known to be critical to the host
response to antigen and for the production of class switched immunoglobulins, yet the precise
details of how BATF functioned in those roles was unknown. I have demonstrated that BATF
expression is increased rapidly, and transiently, immediately following B cell stimulation and I
have generated an inducible mouse model of Batf deletion (Izt mice) to show that BATF induction
is necessary and sufficient, to trigger the program of CSR. My studies identified two genes (Nfil3
and miR155gh) that are positively regulated by BATF and one gene (Wnt10a) that is negatively
regulated by BATF following B cell activation. The molecules encoded by all three of these BATF
targets play essential roles in CSR and my studies have shown that each influences the expression
and/or function of one other. In addition, I generated a conditional T cell knockout mouse (Tzt
mice) in which the Batf alleles are deleted at the double positive stage of T cell development in the
thymus. Using Tzt T cells, a cell-intrinsic role for BATF was demonstrated in the differentiation
of several CD4+ Th cell lineages. Interestingly, the target genes identified as regulated by BATF

xviii
in B cells are regulated by BATF in CD4+ Th cells and the products of these genes are required
for the normal development of Th2, Th17, and Tfh cells. Manipulating the re-expression of BATF,
NFIL3, WNT10A and miR155 through retroviral rescue experiments allowed for the positioning
of these molecules in an interactive network downstream of BATF induction and upstream of the
terminal events of CSR in B cells and cytokine secretion in differentiated Th2, Th17, and Tfh cells.
In conclusion, this work has demonstrated a required role for BATF early in the activation of both
B and T lymphocytes, identified genes whose expression depends upon BATF and extends
knowledge of the molecular network controlling antibody CSR and Th cell differentiation.
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CHAPTER 1. INTRODUCTION

The immune system is composed of a network of cells, tissues, organs that work together
to protect the body against pathogens, parasites, and cancer. When functioning properly, the host
is unaware that the immune system is constantly surveilling the body, but impaired regulation of
the immune system leads to autoimmune disease and lymphoproliferative disorders. Signaling
networks represent the sensing step in the immune response, and transcription factors (TF) carry
out the necessary changes in gene expression. Transcription factors function as both activators
and suppressors of gene expression, and thus enable immune cells to secrete cytokines, signal,
differentiate, and target foreign entities that threaten the host’s survival. By identifying the
proteins and miRNAs that TFs control, we gain a clearer understanding of how immune cells
accomplish these functions.

1.1 T Cell Development and Differentiation
The immune system uses a bifurcated approach of general and specific defense
mechanisms. The innate immune system uses a generalized approach to respond to all pathogens
and is the first response when a pathogen attacks a host.

Innate immune cells create an

inflammatory response and seek to destroy the pathogen. In addition, the innate immune system
uses dendritic cells (DCs) to initiate a response from the adaptive immune system which is delayed
relative to innate immunity but is far more specific toward a pathogen. DCs present antigen to T
cells which differentiate into T-helper (Th) cells that secrete cytokines to modulate inflammation
and activate B cells. B cells are charged with producing antibodies that target pathogens for
destruction. Together, T cells and B cells comprise the adaptive immune system. These cells not
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only specifically target the pathogens that are present, but can also generate cells called memory
T cells and B cells that can respond quickly at later times if the pathogen returns.
T cells are activated by DCs and other antigen presenting cells (APCs) and are
characterized by their surface molecules. All T cells have a functional T cell receptor (TCR) which
is comprised of an  chain and a  chain which recognize antigen bound to the major
histocompatibility complex (MHC) present on APCs. CD4 and CD8 are transmembrane coreceptors of the TCR which serve to activate downstream signals when specific T cells bearing
those co-receptors are activated (L. Klein, Kyewski, Allen, & Hogquist, 2016; von Boehmer &
Fehling, 1997).
T cells originate from a common lymphoid progenitor (CLP) in the bone marrow and
migrate to the thymus where they differentiate into cells which lack a TCR, MHC, CD4, and CD8.
These are double negative (DN) T cells. In the thymus, these cells further develop to express a
pre-TCR complex from TCR  chain rearrangement, and then form a mature TCR with both an 
and a  chain and express both CD4 and CD8 co-receptors. These are double positive (DP) T
cells. DP T cells comprise 80%-90% of the T cell repertoire in the thymus (L. Klein et al., 2016).
Finally, the cells undergo selection. Self-antigens are expressed on MHC molecules of cortical
epithelial cells. Positive selection determines if the T cell can interact appropriately with the MHC
molecules. If the interaction is too strong or too weak, the T cell will die by “death by neglect”
(Hernandez, Newton, & Walsh, 2011). DP cells that interact well with MHCII molecules will
mature into CD4+ T cells, while DP cells that interact well with MHCI molecules will down
regulate their CD4 receptors and develop into CD8+ cells. The cells next go through negative
selection where they are again presented with self-antigens expressed on MHC molecules of
medullary thymic epithelial cells (mTECs). If the thymocyte interacts too strongly, it will receive
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an apoptotic signal (Takaba & Takayanagi, 2017). However, a few of these cells that interact
strongly develop into T regulatory cells (Tregs) necessary for central tolerance (Ohkura, Kitagawa,
& Sakaguchi, 2013). Fully mature T cells migrate to the periphery where they are ready to respond
(L. Klein et al., 2016).
MHC class I and MHC class II molecules are regulated by cytokines, particularly
interferons released during the immune response, enhancing a cell’s ability to load peptides onto
the MHC molecules. CD8+ cytotoxic T cells are specialized cells that can target viruses. Because
viruses can infect any nucleated cell, almost all cells express MHC class I molecules and can be
targeted by CD8+ T cells (Killeen, Moriarty, Teh, & Littman, 1992). In contrast, CD4+ T cells
recognize MHC class II molecules to activate effector cells. MHC class II molecules are found on
B cells, DCs, and macrophages, but are not found on cells of other tissue types (Ting & Trowsdale,
2002).
CD4+ T-helper (Th) cells are comprised of a variety subsets depending on their cytokine
environment and are so named because they assist B cells and other T cells by secreting cytokines
themselves. Th1 and Th2 cells were the first Th cells identified. Th1 cells are activated by
interleukin (IL) IL-12 and IL-2 which signal through signal transducer and activator (STAT) 4 to
upregulate Tbet, a TF that controls interferon (IFN)  secretion (Lighvani et al., 2001). Th1 cells
provide immunity against intracellular micro-organisms (Zhou, Chong, & Littman, 2009). In
addition, IFN secretion by Th1 cells activates macrophages and upregulates MHCI receptors to
help cytotoxic T cells recognize antigen (Schroder, Sweet, & Hume, 2006; Welsh, Bahl, Marshall,
& Urban, 2012). Th2 cells arise from exposure to IL-4 which signals through STAT6 to induce
expression of GATA3 (Kaplan, Schindler, Smiley, & Grusby, 1996; W. Zheng & Flavell, 1997).
Th2 cells predominantly secrete IL-4, but also secrete IL-15, IL-10, and IL-13 to fight helminths
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and extra-cellular pathogens (Mowen & Glimcher, 2004). Th2 cytokine secretion can lead to the
differentiation of more Th2 cells, to the repression of Th1 differentiation and can stimulate B cells
to induce immunoglobulin (Ig) class switch recombination (CSR)(Abbas, Murphy, & Sher, 1996;
Ferrara, 2000). Together, Th1 and Th2 cells help activate the immune system to fight pathogens
(Figure 1.1).
More recently, additional CD4+ Th subsets have been identified based on the unique
cytokines they produce when stimulated. Th17 cells differentiate when exposed to TGF-, IL-6,
IL-21, and IL-13 and predominantly secrete IL-17, but also IL-21 and IL-22 (Harrington, Mangan,
& Weaver, 2006). Because these cytokines are pro-inflammatory (Aggarwal, Ghilardi, Xie, De
Sauvage, & Gurney, 2003), Th17 cells have been identified as significant contributors to
autoimmune diseases inducing rheumatoid arthritis (Ouyang, Kolls, & Zheng, 2012). However,
when Th17 cells function properly, they work to clear extracellular bacteria and fungi at mucosal
surfaces (Schmidt-Weber, Akdis, & Akdis, 2007; Weaver, Harrington, Mangan, Gavrieli, &
Murphy, 2006; Zhou et al., 2009). CD4+ T regulatory cells (iTreg, nTregs, and Tr1 cells) are
activated by TGF- stimulation (Y. Zheng & Rudensky, 2007) and signal through small body size
(sma) mothers against decapentaplegic (mad) protein (SMAD) 3 and signal transducer and
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Figure 1.1 CD4+ T Cell Differentiation and B Cell Activation.
CD4+ Th cells develop in the thymus and B cells develop in the bone marrow before migrating
to the periphery. Upon activation, the CD4+ T cells differentiate into different Th cell subsets
depending on the cytokine environment. Commitment to a specific CD4+ Th cell subset results
in expression of a signature transcription factor and cytokine secretion. B cells can be activated
by T cells or independently of T cell help. B cell activation results in proliferation and class
switched antibody production.
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activator of transcription protein (STAT) 5 to act in an immunosuppressive capacity. In addition
to secreting IL-10, an anti-inflammatory cytokine, these cells can block the activation and
expansion of other Th cells (Sakaguchi, Wing, Onishi, Prieto-Martin, & Yamaguchi, 2009). T
follicular helper (Tfh) cells express chemokine receptor 5 (CXCR5) and secrete IL-21 (Kim et al.,
2001). Tfh cells differentiate when exposure to IL-21 activates STAT3 and causes the TF B cell
lymphoma 6 protein (BCL6) to be expressed (Fazilleau, Mark, McHeyzer-Williams, & McHeyzerWilliams, 2009; Nurieva et al., 2008). Tfh cells home to the spleen and lymph node follicles and
stimulate B cells to undergo CSR (Kim et al., 2001).
The most recent T cell subset to be identified are Th9 cells (Veldhoen et al., 2008). These
cells differentiate in response to IL-4 and TGF- and are dependent on the TFs, interferon
regulatory factor 4 (IRF4) and PU.1 (encoded by Spi-1) (Chang et al., 2010). Th9 cells secrete IL9 and function primarily to mediate airway inflammation, asthma, and other pleural conditions
(Jabeen et al., 2013; Schmitt, Klein, & Bopp, 2014; Z. J. Ye et al., 2012). In addition, Th9 cells
have been shown to promote intestinal inflammation (Weigmann & Neurath, 2017) and central
nervous system inflammation (Cua et al., 2003), and mediate tumor immunity (Purwar et al.,
2012).

1.2 B Cell Development and Activation
B cells are a highly specialized cell population of the adaptive immune system that
produces antibodies. These cells undergo a stepwise differentiation process starting from the same
CLP as T cells in the bone marrow and ending as professional antibody producing plasma cells
(PC). Lineage decision-making in B cells is controlled by epigenetic modifications and by the
expression of a number of B cell TFs (Mandel & Grosschedl, 2010). Specialized stromal cells
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guide this process through cell-cell interactions as well as by secreting cytokines and chemokines
(Panaroni & Wu, 2013).
Unlike T cells which commit early to their lineage, B cells retain a limited B/T cell
plasticity into the pro-B cell stage of development (Rumfelt, Zhou, Rowley, Shinton, & Hardy,
2006). Ly6D marks CLPs as B-cell biased lymphoid progenitors (BLP) (Inlay et al., 2009), but it
is the expression of B220 and CD19 that coincides with commitment to the B cell lineage (Mandel
& Grosschedl, 2010). B cell differentiation begins in the bone marrow. After B220 expression
commits lymphoid cells to the B cell lineage, programs are initiated to begin rearrangement of the
immunoglobulin heavy chain (IgH) genes in a recombination activating genes (RAG)-dependent
manner (Chowdhury & Sen, 2001). Successful rearrangement culminates in the pairing of the
heavy chains and light chains into a pre-B cell receptor (Pre-BCR). Further rearrangement of the
Ig and Ig loci in pre-B cells results in the surface expression of IgM on the B cells (Loder et al.,
1999). Only a small subset of these immature B cells leave the bone marrow to complete their
development in the spleen and join the mature B cell pool (Boller & Grosschedl, 2014).
Upon exiting the bone marrow, immature B cells take up residency in the spleen or lymph
nodes as resting, or naïve, B cells and are now mature, but not activated, B cells. The majority of
naïve B cells are found in follicles (Nutt, Hodgkin, Tarlinton, & Corcoran, 2015), and it is these
follicular B cells that can respond to both T cell dependent (TD) stimulation and T cell independent
(TI) activation signals (Mond, Lees, & Snapper, 1995; Snapper et al., 2001; Vos, Lees, Wu,
Snapper, & Mond, 2000) (Figure 1.1). B cells in the periphery are composed of 3 subsets.
Marginal zone (MZ) B cells and B1 cells are present as specialized subsets for rapid response to
TI antigens including bacterial components (Vos et al., 2000). While all B cells can make antigenspecific antibodies in the short term, only follicular B cells are capable of differentiating into long-
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lived plasma cells antibody secreting cells (ASC) and memory B cells (McHeyzer-Williams &
McHeyzer-Williams, 2005).

Upon activation, follicular B cells proliferate and begin to

differentiate into plasmablasts that undergo class switch recombination (CSR) (Nutt et al., 2015).
In the process of undergoing rapid proliferation in response to T dependent stimulation, these cells
form a germinal centers. Here the cells initiate the program of somatic hypermutation (SHM) and
undergo clonal selection (Silva, Klein, Irving, Cancer, & Biology, 2015). A subset of these cells
fully differentiates into plasma cells (professional antibody secreting cells) and others remain
dormant as memory B cells. These memory cells maintain a B cell phenotype, but can rapidly
differentiate into ASCs following re-exposure to their antigen (McHeyzer-Williams & McHeyzerWilliams, 2005).
Many genes have been characterized that play a role in B cell activation and differentiation
(Hardy & Hayakawa, 2001; Mandel & Grosschedl, 2010; Méndez & Mendoza, 2016) However,
there are a few that merit special mention. Paried box TF 5 (Pax5) encodes B cell lineage-specific
activator protein (BSAP)(Adams et al., 1992), and functions as the master regulator of the B cell
program (Cobaleda, Schebesta, Delogu, & Busslinger, 2007). Pax5 expression is induced at the
pre-pro-B cell stage, and serves to repress non-B cell lineage genes while activating important B
cells genes that express components of pre-BCR signaling , including CD19, CD79a, MB-1 and
BLINK, and the TFs IRF4, IRF8, and BACH2 (Adams et al., 1992; Medvedovic, Ebert, Tagoh, &
Busslinger, 2011; Pridans et al., 2008; Schebesta et al., 2007). Pax5 is down regulated as B cells
differentiate. Mice deficient in Pax5 display a developmental arrest of B cell development at the
pro-B cell stage (Horowitz et al., 2004).
B cell lymphoma 6 (Bcl6) encodes a zinc finger TF which is the master regulator of Tfh
differentiation (Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS et al., 1993) and
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also is critical for the proliferation and differentiation of germinal center B cells (B. H. Ye et al.,
1997). BCL6 is a transcriptional repressor and functions to promote proliferation and enable SHM
by inhibiting the DNA damage response (Basso & Dalla-Favera, 2012; Kumagai et al., 1999).
Deregulation of Bcl6 leads to diffuse B cell lymphomas resulting from an over-expression of protooncogenes (Cattoretti et al., 2005; Phan & Dalla-Favera, 2004; B. H. Ye et al., 1997). Antibody
secreting cells down regulate Bcl6 during activation to enable B cells to express positive regulator
domain 1 binding protein (Prdm1) which encode PR domain zinc finger protein 1 (BLIMP1), and
to upregulate IRF4 (Basso & Dalla-Favera, 2012). Bcl6 knockout mice display slow growth and
die before 5 weeks of age (Fukuda et al., 1997). In addition, these mice are unable to generate
germinal centers in response to a TD antigen, but can produce class switched antibodies when
challenged with a TI antigen (Dent, Shaffer, Yu, Allman, & Staudt, 1997; Fukuda et al., 1997).
BTB domain and CNC homology 2 protein (BACH2) is a basic leucine zipper
transcriptional repressor of B cell differentiation (Sasaki et al., 2000). It is activated by BSAP,
and cooperates with BCL6 during B cell activation to insure that cells proliferate (Huang, Geng,
Boss, Wang, & Melnick, 2014). BACH2 is down-regulated along with BCL6 to allow PRDM1
(BLIMP1) to be expressed and for B cells to undergo CSR and differentiate into ASCs (Muto et
al., 2010; Ochiai, Muto, Tanaka, Takahashi, & Igarashi, 2008). In Bach2 deficient mice, BLIMP1
is prematurely expressed propelling B cells through the GC B cells stage into ASCs. However,
these ASCs do not express class-switched Ig and Bach2-/- mice do not respond to TD or TI antigens
(Muto et al., 2010).
Another transcription factor that is a critical regulator of CSR and plasma cell
differentiation is IRF4. The IRFs family of TFs contain a unique pentad tryptophan DNA binding
motif (Escalante et al., 2002; Escalante, Yie, Thanos, & Aggarwal, 1998). IRF4 is transiently
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expressed and it is the amount of IRF4 expressed in B cells that determines its function. At a low
to moderate level of expression, IRF4 induces the expression of Bcl6 and other genes required for
CSR during the GC response.

As IRF4 expression increases, IRF4 promotes plasma cell

generation and antagonizes the formation of more GC B cells (Ochiai et al., 2013). IRF4 forms
complexes with different proteins and binds different DNA motifs depending on its level of
expression (Sciammas et al., 2006). At moderate levels of expression, IRF4 dimerizes with
PU.1/SpI-1 or SPIB to bind EICE motifs (Brass, Zhu, & Singh, 1999; Eisenbeis, Singh, & Storb,
1995) or functions with BATF:JUN complexes to bind AICE motifs (AP1-IRF composite
elements) (Glasmacher et al., 2012). At high concentrations, IRF4 forms homodimers and binds
to an interferon response element (IRSE) to activate genes involved in plasma cell differentiation
and secretory functions (Eisenbeis et al., 1995; Ochiai et al., 2013). Irf4-/- mice display a block in
the transition of B cells to a mature stage (Mittrucker et al., 1997). A conditional knockout of
IRF4 in germinal center B cells revealed that IRF4 is critical to CSR and plasma cell differentiation
(U. Klein et al., 2006).
Aicda is the gene that encodes the enzyme, activation-induced cytidine deaminase (AID).
AID is essential for secondary antibody diversification by initiating somatic hypermutation using
its ability to deaminate cytosines and by participating in the DNA cleavage required for class
switch recombination (Xu et al., 2007).

While necessary for the antibody response, AID

expression is tightly regulated to avoid genomic instability (Zan & Casali, 2013). Expression of
the Aicda gene is controlled at the level of transcription, and through mechanisms that regulate the
cellular localization and enzymatic function of AID (Keim, Kazadi, Rothschild, & Basu, 2013).
Both TD and TI B cell activation induce Aicda expression, and cytokines released by T cells can
enhance Aicda expression (Zan & Casali, 2013). Once cells terminally differentiate into ASCs,

11
Aicda expression is repressed, preventing cells from undergoing further rounds of CSR and SHM
(Stavnezer, 2011). In Aicda-/- mice, B cells develop but, in the presence of antigen, the cells hyperproliferate and produce only IgM (Fagarasan et al., 2002). Humans with type II hyper-IgM
syndrome were found to carry mutations that compromise the function of AID (Revy et al., 2000).

1.3 AP-1 Proteins and BATF
Gene regulation through transcription factors is required for T cell and B cell development,
differentiation of the different T cell subsets, B cell activation, and plasma cell differentiation.
There are signature transcription factors for each T cell lineage as well for each stage of B cell
development. Although there are many classes of transcription factors which interface with
different proteins and bind different consensus DNA, the basic leucine zipper (bZIP) transcription
factors are the most prominent. This class of transcription factors is characterized by an -helical
region comprised of at least 3 repeats of an often charged group of 7 amino acids surrounding a
central hydrophobic leucine residue (Deppmann, Alvania, & Taparowsky, 2006; Landschulz,
Johnson, & Mcknight, 1998). Dimerization occurs as a result of favorable interactions between the
leucine zippers of two TFs. Basic amino acids that are located adjacent to the leucine zipper region
(bZIP) are available to bind DNA. The consensus element that the bZIP dimer binds varies based
on the proteins which are interacting (Pu & Struhl, 1991; Rasmussen, Benvegnu, O’Shea, Kim, &
Alber, 1991).
Activator protein -1 (AP-1) proteins comprise a family of bZIP TFs involved in
proliferation, differentiation, cellular transformation and apoptosis. First identified in 1987 as a
cellular protein complex binding to the enhancer region of the simian virus 40 (SV40) DNA
genome and to the human metallothionein promoter (Lee, Mitchell, & Tjian, 1987), AP-1 is
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expressed in almost every cell type (Eferl & Wagner, 2003). The most widely expressed AP-1
transcription factors are the JUN (C-JUN, JUNB, and JUND) and FOS (C-FOS, FOSB, FRA1,
and FRA2) proteins (Eferl & Wagner, 2003; Shaulian & Karin, 2002).

JUN and FOS

heterodimerize to bind genes containing a 12-O-tetradecanolyphorbol-13-acetate (TPA) response
element (TRE, also referred to as an AP-1 site) (Hai, Liu, Coukos, & Green, 1989), and are
associated with positive growth responses and the activation of gene transcription (Angel & Karin,
1991; van Dam & Castellazzi, 2001).

In addition, JUN proteins are capable of forming

homodimers and can dimerize with the MAF and ATF classes of bZIP TFs as well (Hess, 2004;
Kerppola & Curran, 1991). While FOS proteins cannot homodimerize, they can interact with the
family of MAF transcription factors (MAFB, MAFF, MAFG, and MAFK) (Hess, 2004; Porte,
Oertel-Buchheit, John, Granger-Schnarr, & Schnarr, 1997). These alternative AP-1 dimers contact
different DNA sites and have different effects on gene transcription (Porte et al., 1997).
B cell activating transcription factor (BATF), renamed by NCBI and HUGO as basic
leucine zipper transcription factor ATF-like, is the founding member of a subfamily of AP-1
transcription factors composed of BATF, BATF2 and BATF3 (Murphy, Tussiwand, & Murphy,
2013). Unlike other AP-1 proteins, BATF expression is restricted to the immune system. Together
with JUN and FOS, BATF is expressed in almost every immune tissue and is involved in regulating
transcription programs critical for T cell subset differentiation, cytokine expression, B cell
activation and CSR (Murphy et al., 2013; Sopel, Graser, Mousset, & Finotto, 2016). BATF and
BATF3 are similar in that they are small proteins (124 amino acids and 118 amino acids,
respectively), and bind to AP-1 consensus DNA as heterodimers with JUN (Murphy et al., 2013).
BATF2 is a larger protein (189 amino acids), and has a broader range of expression in non-immune
tissues (Su et al., 2008). The ability of BATF2 to bind DNA as a BATF2:JUN heterodimer has not
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been demonstrated. All three BATF proteins lack a defined transactivation domain (TAD)
(Murphy et al., 2013). As a result, all three are considered to be transcriptional repressors of classic
AP-1 regulated gene activity (Aronheim, Zandi, Hennemann, Elledge, & Karin, 1997; Echlin, Tae,
Mitin, & Taparowsky, 2000; Hildner et al., 2008; Iacobelli, Wachsman, & McGuire, 2000; Lim et
al., 2006). BATF proteins are unable to form homodimers and prefer to form heterodimers with
JUN-family members (Murphy et al., 2013).
BATF was first characterized as a mRNA induced in B cells infected with Epstein-Barr
virus (EBV) (Dorsey et al., 1995; Johansen et al., 2003). BATF expression was next identified as
a gene upregulated in human T cells activated with human T cell leukemia virus (HTLV-1)
(Hasegawa et al., 1996). In immune cells, BATF competes with c-FOS to dimerize with JUNB,
repressing gene transcription when bound to genes containing an AP-1 motif (Echlin et al., 2000)
(Figure 2A).

Recently, BATF: JUNB complexes have been shown to interact with the

transcription factor IRF4. When an IRSE is located near an AP-1 motif bound by JUN: BATF,
IRF4 interacts with BATF to be recruited to its site on the gene. These motifs are AICE (AP-1
and IRF4 composite element) consensus DNA sites (Glasmacher et al., 2012) (Figure 2B). IRF4
binds to BATF through a region of the leucine zipper containing a key histidine residue and
mutation of this histidine has been shown to be required for BATF function in T cells (Tussiwand
et al., 2012).

Interestingly, since IRF4 is a positive regulator of gene transcription,

JUN:BATF:IRF4 complexes trans-activate genes when bound to AICEs. There are two variants
of AICEs (AP-1-IRF4 and AP-1-NNNN-IRF4) (Glasmacher et al., 2012; P. Li et al., 2012) and
the presence of these motifs in genes is required for their expression. Thus, whether BATF
activates or represses gene transcription depends upon whether a gene is controlled by an AICE or
an AP-1 regulatory element.
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BATF variants that display altered DNA binding properties, dimerization properties, and
transcriptional effects have been identified (Deppmann et al., 2003; Tussiwand et al., 2012;
Deppmann and Taparowsky, unpublished data). BATF is a phosphorylated protein and our studies
have identified several serine and threonine

Figure 1.2 Models for BATF Function.
(A) FOS:JUN dimers activate AP-1 transcription on AP-1
motifs while BATF:JUN dimers repress transcription on
AP-1 motifs. (B) On AICE motifs, FOS:JUN dimers
repress transcription while BATF:JUN dimers activate
transcription. In this model, BATF dimerizes with JUN
and recruits IRF4 enabling the complex to activate
transcription via AICE motif.
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residues that are modified by phosphorylation in vivo and in vitro. Mutating the serine residue at
position 43 in the DNA binding domain to mimic phosphorylated BATF (S43D) or
unphosphorylated BATF (S43A) revealed that BATF retains its ability to bind to JUN in either
form, but that BATF S43D: JUN dimers cannot bind DNA. Interestingly, BATF S43D and S43A
were still capable of inhibiting the activity of an AP-1 reporter gene construct (Deppmann et al.,
2003). In addition, a BATF variant mimicking phosphorylation of BATF on residue 48 (T48D)
reduces the ability of BATF to dimerize with JUN and increases the ability of BATF to form
homodimers. Expressing BATF T48 D in cells releases more JUN to form dimers with other
proteins and results in a positive activation of AP-1 transcription (Deppmann and Taparowsky,
unpublished data). Lastly, as mentioned previously, there is a histinine in BATF (H55) whose
integrity is essential for IRF4 to interact with the BATF:JUNB heterodimer. Mutation of H55
results in the repression of genes containing AICE motifs (Tussiwand et al., 2012) (Figure 1.3).

1.4 BATF Expression and Function in Lymphocytes
To elucidate the role of BATF in the immune system, mouse models have been generated.
There are 2 mouse models which over-express BATF in immune cells and 3 Batf-deficient models.
The first model overexpresses BATF with a hemagglutinin-tag (HA) under the control of a
proximal murine p56lck promoter which is thymus-specific (Williams et al., 2003). The second
model expresses the same HA-tagged BATF using a human CD2 promoter which is activated
beginning at the DN stage of thymic T cell development and continuing and mature in the
periphery
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Figure 1.3 Key Amino Acids Regulating BATF.
BATF, JUNB, and FOS are bZIP transcription factors which form dimers to activate or
repress gene expression. BATF has three amino acids that, when altered, alter its function.
Phosphorylation of S43 in the DNA binding domain prevents BATF from binding DNA.
Phosphorylation of T48 in the hinge region enables BATF to form homodimers. Mutation
of H55 in the leucine zipper region prevents BATF from recruiting IRF4 to AICE motifs.
This prevents BATF, JUNB, IRF4 dimers from forming and activating genes regulated by
AICE.

(Logan, Jordan-Williams, Poston, Liao, & Taparowsky, 2012; Thornton, Zullo, Williams, &
Taparowsky, 2006). The first mouse model generated to knockout BATF is the Batf-/- mouse
where exons 1 and 2 are deleted through homologous recombination (Schraml et al., 2009).
Shortly after, our lab generated the BatfKI/KI mouse using homologous recombination of a floxed,
HA-tagged Batf exon3 expressing BATF with a C-terminal HA tag. Genetic exposure to a
constitutively expressed E2A Cre protein generated the BatfZ/Z mouse (Betz et al., 2010). The
third Batf knockout model replaces exon 1 with a green fluorescent protein (GFP, Batfgfp/gfp) and
has been used as a way to isolate cells where BATF should normally be expressed (Kuroda et al.,
2011). In my studies, I have utilized both the BatfKI/KI model to generate new mouse models
(Chapter 4 and Chapter 5) to study the conditional deletion of Batf in T cells and B cells.
BATF expression varies across different stages of T cells development in the thymus, and
it has been observed that BATF impacts T cell development and cytokine expression (Williams et
al., 2001, 2003). Overexpression of BATF demonstrated an inability for natural killer T (NKT)
cells to develop properly and thus provide cytokines such as IL-2, IL-4, IL-5, IL-10, and IL-13 to
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the immune environment. Interestingly, the residual NKT cells in BATF overexpressing mice are
skewed toward an IL-17 producing phenotype.

Deletion of Batf leads to a modest increase in

NKT cell numbers that are skewed toward an IL-4 (not an IL-17) producing phenotype (JordanWilliams, Poston, & Taparowsky, 2013).
Chronic overexpression of BATF in T cells impacts both T cells and B cells. By 12 months
of age, CD2-HA-BATF transgenic mice experience lymphoid tumors consisting of a polyclonal T
cell population. T cells isolated from these lesions do not demonstrate increased proliferative
capacity compared to WT T cells. Instead, these T cells are impaired in their ability to undergo
apoptotic regression following an immune response. In addition, CD2-HA-BATF mouse B cells,
which are not over-expressing BATF in this T cell model, produce an increase in all class switched
Ig, including self-reactive Ig. This is a result of self-activation of the B cells in response to the
overproduction of IL-17, IL-21, IL-22, and IL-4 by the CD4+ T cells (Logan et al., 2012).
Batf knockout models display no major physiological problems, but do have measurable
phenotypes in most immune cell subsets and are generally resistant to pathogens and to
autoimmune disease. The major reason for this resistance is the inability of Batf deficient CD4+ T
cells to differentiate into Th17, Tfh, or Th9 cells. As a byproduct of this failed differentiation,
BatfZ/Z mice do not produce a number of cytokines including IL-17, IL-21, IL-22, IL-4, and IL9 (Figure 1.4). The role of BATF in regulating CD4+ Th17 differentiation has been studied
extensively (Betz et al., 2010; Ise et al., 2011; Schraml et al., 2009). BATF has been shown to be
required for maintaining the expression of RAR-related orphan receptor gama (Rort), the gene
encoding the hallmark TF of the Th17 lineage (Ivanov et al., 2006) BATF also has been shown to
bind several sites within the regulatory regions of the IL-17, IL-21 and IL-22 cytokine genes, and
is presumed to be a direct modulator of their expression. The IRF4:BATF:JUN transcription
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activator complex was discovered largely using Th17 cells and the trans-activation of Il-17 gene
expression as a model (Ciofani et al., 2012; Glasmacher et al., 2012; P. Li et al., 2012). Recently,
a group proposed that BATF functions as a “pioneering” TF in T cells (Ciofani et al., 2012). They
showed that Batf is rapidly induced upon TCR engagement in naïve T cells, well in advance of the
chromatin remodeling and expression of Th subset TFs that specify the various Th lineages,
including Th17 (Ciofani et al., 2012).
The role of BATF in CD8+ T cells has mainly been associated with chronic viral infection.
During a chronic viral infection, severe defects develop in the CD8+ T cell response (Moskophidis,
Franziska, Pircher, & Zinkernagel, 1993; Shin & Wherry, 2007). This was first described in a
mouse model infected with lymphocytic choriomenigitis virus (LCMV). Over time, CD8+ T cells
continue to persist but their effector function is lost in a hierarchical manner (Zajac et al., 1998).
First, secretion of IL-2, cytotoxicity, and proliferation are functions are exhausted. Production of
IFN- can endure longer, but is eventually also lost (Wherry et al., 2007; Wherry, Blattman,
Murali-krishna, Most, & Ahmed, 2003). CD4+ T cells can help CD8+ cells to perform their effector
functions longer, but will eventually also exhaust when the viral load is high (Fuller, Khanolkar,
Tebo, & Zajac, 2004; Fuller & Zajac, 2003). In LCMV infection, BATF expression is rapidly upregulated and, through cooperation with IRF4, is required for maintaining CD8+ T cell effector
function (Grusdat et al., 2014) and for the development of CD8+ memory cells (Man et al., 2017).
Batf-/- CD8+ T cells exhibit cell-intrinsic defects in effector CD8+ T cell differentiation. Initially
there is a 400-fold decrease in the peak number of effector cells. Although, Batf-/- CD8+ T cells
show sustained activation during the mid-expansion phase of the immune response, they also
exhibit increased cell death (Kurachi et al., 2014). In addition, BATF is also required for CD4+ T
cells to help CD8+ T cells sustain their effector functions through IL-21 production (Xin et al.,
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2015). During HIV infection, silencing of BATF specifically in CD8+ T cells increases cell
proliferation, IFN production and IL-2 production by HIV-specific CD4+ T cells

Figure 1.4 CD4+ Th Cell Defects in Batf-/- Mice.
The CD4+ Th cells in Batf-/- do not differentiate into all of the CD4+ Th cells subsets when
activated. As a result, many of the cytokines produced by the Th cell subsets in wild type mice
are not produced.
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(Quigley et al., 2010). It has been demonstrated that the absence of BATF in CD8+ T cells results
in limited immunopathology and promotion of viral persistence. (Grusdat et al., 2014).
BATF was discovered in B cells and so it is not surprising that B cells in Batf-/- mice are
impaired in function. Batf-/- mice possess normal numbers of B cells that express IgM, but they are
unable to undergo CSR to generate class switched antibodies (Betz et al., 2010; Ise et al., 2011)
(Figure 1.5). While initially it was thought that the Batf-/- defects in the T cell subsets important
for presentation of TD antigens may be to blame (Th17, Th2, Tfh), Batf-/- mice are unresponsive
to a TI antigen. B cells from Batf-/- mice proliferate normally when stimulated with antigen in
culture (Betz et al., 2010; Ise et al., 2011) (Figure 1.5). However, their expansion is not
accompanied by the proper activation of intracellular signaling events that lead to the expression
of Aicda and antibody CSR (Betz et al., 2010) (Figure 1.5). An RNA-seq comparison of Batf null
and wild type B cells stimulated with IL-4 has been performed (P. Li et al., 2012) and identified
multiple genes containing AP-1 and/or AICE motifs that are mis-regulated in the absence of Batf.
While this study was used to solidify the role of an IRF4:BATF:JUN complex in regulating gene
expression, no investigative studies on the roles of the products of these putative BATF target
genes in the Batf-/- B cell phenotype were performed.
The critical role of BATF in the adaptive immune response has been review above, but it
is important to note that BATF plays additional roles in the immune system. In hematopoietic
stem cells, BATF expression is elevated after DNA damage and functions to limit cell renewal
and promote lymphoid differentiation in response to DNA
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Figure 1.5 BATF is Required for AID Expression and CSR in B Cells.
Batf-/- B cells are unable to produce any class switched Ig when activated. Although the cells
proliferate normally upon activation, AID is not expressed which is why the cells only express
and secrete IgM.
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damage by upregulating STAT3 (J. Wang et al., 2012). Without Batf expression, IL-3 dependent
mast cells do not develop, impairing the response to airway allergens. (Ubel et al., 2014). In
addition, BATF is required for the growth arrest that proceeds the IL-6 induced differentiation of
M1 myeloid leukemia cells into macrophages (Liao, Humphrey, Poston, & Taparowsky, 2011).
BATF clearly is a critical factor in the functioning of both innate and adaptive immunity.

1.5 Rational for Dissertation Research
Previous studies have placed BATF in an intricate signaling pathway required for B cell
CSR and T cell differentiation and function (Betz et al., 2010; Ise et al., 2011; Logan et al., 2012;
Murphy et al., 2013; Schraml et al., 2009; Sopel et al., 2016; Williams et al., 2003). These studies
have established phenotypes associated with Batf-/- mice and T cell specific transgenic mice. The
goal of my research was to investigate the role of BATF in regulating gene expression programs
specific to B cells and T cells, and to further elucidate how BATF exerts its effects in lymphocyte
biology.
There are two hypotheses that my research has tested. The first hypothesis is that BATF
directly impacts a program of gene transcription critical for CSR in mouse B cells. To test this
hypothesis, I identified genes in the BATF transcriptional network directly regulated by BATF
and used re-expression studies to examine their roles in Batf-/- B cell phenotypes. In conjunction
with these studies, I characterized the DNA binding and transcriptional properties of BATF that
are important to the regulation of these genes. My second hypothesis is that BATF has distinct
roles intrinsic to B cells and T cells that could not be identified using Batf-/- mice. To test this
hypothesis, I generated two lines of conditional knockout mice (Izt mice and Tzt mice) and used
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these mice in strategies to compare lineage-specific Batf knockout phenotypes to phenotypes
observed in Batf-/- mice.
The ability to control BATF activity could have a major impact on immune system
function, yet as a transcription factor, BATF represents a difficult therapeutic target.

By

characterizing genes directly regulated by BATF and testing how the products of those genes carry
out lineage-specific BATF functions, we can expand our understanding of how BATF exerts it
influence on different stages of B cell activation and T cell differentiation. This could lead to the
identification of new targets downstream of BATF that might provide a more feasible way to
intervene and control autoimmune disease, inflammatory diseases, acute allograft rejection, and
cancer.
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CHAPTER 2. MATERIALS AND METHODS

2.1 Mouse Lines
C57BL/6J mice were provided by the Transgenic Mouse Core Facility (TMCF) of the
Purdue University Center for Cancer Research. BatfKI/KI mice and BatfZ/Z mice on the C57BL/6J
background have been described previously Betz et al. (2010). Both C57BL/6 mT/mG (JAX;
Stock No: 007576) and Tg(Cd4-cre) (JAX Stock No: 022071) mice were used in crosses with Batf
KI/KI

mice to obtain the Tzt (BatfKI/KI, Rosa26mtmG/+, CD4Cre) mice. C57BL/6 mT/mG (JAX; Stock

No: 007576) and C.Cg-Cd19tm1(cre)Cgn Ighb/J (JAX Stock No: 004126) mice were used in crosses
with Batf KI/KI mice to generate the Bzt (BatfKI/KI, Rosa26mtmG/+, CD19Cre) mice. C57BL/6 mT/mG
(JAX; Stock No: 007576) and UBC-Cre-ERT2 (JAX Stock No: 007001) mice were used in crosses
with Batf

KI/KI

mice to obtain the Izt (BatfKI/KI, Rosa26mtmG/+, UbcCre-ERT2) mice. All experiments

used 7-14 week old sex-matched animals when possible. Mice were housed in the TMCF and all
experiments conducted in compliance with the NIH Guide for the Care and Use of Laboratory
Animals and the Purdue University IACUC guidelines. Protocols used were approved by the
IACUC of Purdue University. Approval Numbers: 111000005723 (EJT) and 1110000037 (SFK).

2.2 PCR Genotyping of Mouse Lines
Mouse tails were digested overnight in tail lysis buffer and proteinase K. DNA was isolated
by ethanol precipitation. Primer sequences are listed in Table 1. PCR conditions for Batf KI primer
sets and Batf flox primer sets are in Table 2, and PCR conditions for mTmG primer sets and Cre
primer sets are in Table 3. The KI PCR product is resolved on a 3% agarose gel giving a 600 bp
band for endogenous Batf and a 675 bp for KI Batf-HA. The BatfZ/Z PCR is resolved on a 2%
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agarose gel yielding a WT band at 600kb and a band indicating the floxed BATF gene at 450bp.
The mTmG PCR resolved by a 2% agarose gel yielding a WT band at 300bp and a band indicating
the floxed mTmG gene at 270bp. Mice are bred as heterozygous for the mTmG transgene and will
therefore have 2 bands for RosamTmG/+ mice used for these studies. The Cre PCR is resolved on a
2% agarose gel yielding a 700kb band in mice cre positive. No band is present in Cre negative
PCR samples.

Table 1. Genotyping PCR Primer Sequences
Genotype

Forward Primer

Reverse Primer

Batf KI

5'-GAATTCTCAGTTGCCCTCTTCATG-3'

5'-CCAGTACATTGGCTCGACTTC-3'

Batf flox

5'-GCTTGTCTCTCACTAGTGAG-3'

5'-CTGTAGAGTGACTGGCTC-3'

mTmG

5'-CTCTGCTGCCTCCTGGCTTCT-3'

5'-CGAGGCGGATCACAAGCAATA-3'

5'-TCAATGGGCGGGGGTCGTT-3'

Cre

5'-TGCTGTTTCACTGGTTATGCGG-3'

5'-TTGCCCCTGTTTCACTATCCA-3'

Table 2. PCR Conditions for Batf KI and Batf flox Primer Sets
Steps

°C

Time

1

94

1min

2

94

30sec

3

60

30sec

4

72

1min

5

72

5 min

6

4

hold

Go To

Loops

2

33

Table 3. PCR Conditions for mTmG and Cre Primer Sets
Steps

°C

Time

1

94

1min

2

94

30sec

3

65

30sec

4

72

1min

5

72

5 min

6

4

hold

Go To

Loops

2

33
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2.3 Primary Cell Isolation
For total splenocyte isolation, mice were euthanized with CO2 asphyxiation and the spleen
was harvested from the mice onto a 70 m cell strainer. Spleens were crushed with the rubber end
of a 6mL syringe in 500 L of primary T cell media (RPMI, 5% FBS, 100U/mL penicillinstreptomycin, 50 M -Mercaptoethanol, 20mM Hepes pH 7.4, 1mM L-glutamine, and 2mM
sodium pyruvate). Splenocytes were then filtered through the 70 m cell strainer and rinsed with
an additional 3mL of primary T cell media. 10mL of ammonium chloride lysis buffer (ACK)
(0.15M NH4CL, 10mM KHCO3, 0,1mM Ethylenediaminetetraacetic acid (EDTA)) was added and
the cells were incubated on ice for 4 minutes. To dilute the ACK lysis buffer, 20mL of phosphate
buffered saline (PBS) were added to the cell suspension and tubes were pelleted at 1300 RPM for
10 minutes at 4°C. The cell pellets were suspended in 5mL of primary T cell media and cell
number was determined using a hemocytometer.
To isolate B cells, mice were euthanized with CO2 asphyxiation. The spleen was harvested
from the mice and in a 60mm tissue culture dish with 2mL of primary B cell media (RPMI, 5%
fetal bovine serum (FBS), 100U/mL Penicillin/Streptomycin, 50 M -mercaptoethanol) and
crushed using two frosted slides. Splenocytes were filtered through a 70 m cell strainer which
was rinsed with 3mL of primary B cell media. To lyse the red blood cells, 10mL of ACK lysis
buffer was added to the cells which were then incubated on ice for 4 minutes. Next, 20mL of PBS
were added and cells were centrifuged at 1300 RPM for 10 minutes at 4°C. The pellet was resuspended in 1mL of MACS buffer (PBS, 2% FBS, 1mM EDTA) and 100uL of CD43 (Ly48)
MACS beads were added. Cells were incubated on ice for 15 minutes. Cells and beads were
washed in 15mL of MACS buffer and pelleted at 1300 RPM for 10 minutes. MACS LS columns
(Miltenyi) were primed with 3mL of MACS buffer. Splenocyte pellets were suspended in 500µL
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of MACS buffer and added to the primed LS columns. Columns were washed 3x with 3mL of
MACS buffer, and the flow through was pelleted at 1300 RPM for 5 minutes. B cells were resuspended in 1mL of primary B cell media and rested overnight at 4°C before being cultured at
37°C, 5% CO2. A 1:100 dilution of B cells in phosphate buffered saline (PBS) was counted using
a hemacytometer to determine the number of cells isolated.
Naïve T cells were isolated from mouse spleens by first crushing the spleens in a 60mm
culture dish containing 2mL of primary T cells media. Cells were washed through a 70 m cell
strainer and the strainer was washed with an additional 3mL of primary T cell media. Next, 10mL
of ACK lysis buffer were added and the cells were incubated on ice for 4 minutes before being
pelleted at 1300 RPM at 4°C for 10 minutes. To label non-CD4+ T cells, the cell pellet was resuspended in 400µl of MACS buffer and 100uL of CD4+ T cell biotin-antibody cocktail (Miltenyi)
and incubated on ice for 10 minutes. Next, 300 µL of MACS buffer and 200µL of anti-biotin
microbeads (Miltenyi) were added to cells which were than incubated for 15 minutes on ice. Cells
were washed by adding 10mL of MACS buffer and centrifuged at 1300 RPM at 4°C for 10
minutes. The pellet was re-suspended in 500µL of MACS buffer. LS columns were prepared by
rinsing the column with 3ML of MACS buffer. Cells were then applied to the column and the
unlabled cells were collected through washing the column 3x with 3mL of MACS buffer for each
wash. The flow through was pelleted at 1300 RPM at 4°C for 10 minutes and the cells were resuspended in 800µL of MACS buffer. To isolate the CD4+CD62L+ cells, 200µL of CD62L (Lselectin) microbeads (Miltenyi) were added to the cells which were subsequently incubated on ice
for 15 minutes. The cells were then washed by adding 10mL of MACS buffer and centrifuging at
1300 RPM at 4°C for 10 minutes. MS columns (Miltenyi) were prepared by rinsing them with
500µL of MACS buffer. Pelleted cells were re-suspended in 500µL of MACS buffer, added to
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the MS columns, and rinsed 3x with 500µL of MACS buffer. The column was removed from the
separator apparatus and placed on a new collection tube. 1mL of MACS buffer was added to the
column which was immediately flushed by pushing the plunger into the column. The cells were
then pelleted at 1300 RPM at 4°C for 5 minutes, suspended in 1mL of primary T cell media, and
rested overnight at 4°C before being cultured at 37°C, 5% CO2. A 1:100 dilution of naïve CD4+
T cells in phosphate buffered saline (PBS) was counted using a hemacytometer to determine the
number of cells isolated.
CD4+ T cells were isolated from splenocytes isolated and activated as stated above using
the Miltenyi CD4+ T cell isolation kit. For this protocol, cells pelleted at 1300 RPM for 5 minutes
and washed 1x in MACS buffer. The cell pellet was re-suspended in 80µL of MACS buffer
containing 20µL of Biotin-antibody cocktail (Miltenyi). Cells were incubated on ice for 5 mintutes,
and 60µL of MACS buffer containing 40µL of -Biotin microbeads were added to each sample.
Cells were incubated on ice for an additional 10 minutes. To wash the cells, 10mL of MACS
buffer were added to each sample and cells were pelleted at 1300RPM at 4°C for 10min. LS
columns were prepared by rinsing them with 3mL of MACS buffer. Cell pellets were re-suspended
in 500µL of applied to the primed columns. Flow through from the columns contains the CD4+ T
cells which were pelleted at 1300 RPM at 4°C for 5 minutes. CD4+ T cells were returned to culture
in primary T cell media containing 50ng/mL PMA, 500ng/mL Ionomycin, and 10 L of Golgi Stop
for 4 hours at 37°C, 5% CO2.

2.4 In Vivo Studies
To characterize IzT mice, oral gavage was used to treat Izt mice with tamoxifen (SigmaAldrich), 0.5µM/g body weight, daily for 5 days. To prepare the tamoxifen, 5 mL of corn oil were
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added to scintillation vial and heated to 42°C in a water bath for 30 minutes. 100mg of tamoxifen
were added to the vial for a concentration of20 mg/ml tamoxifen. The vial was covered in
aluminum foil and tamoxifen was dissolved into solution using an incubator shaker at 37°C for 4
hours. Tamoxifen was stored at 4°C in the dark until use for the next day. Izt mice treated with
corn oil daily for 5 days were used as the control. On day 6, spleen, thymus and pancreas were
fixed in 10% neutral buffered formalin (0.028M sodium phosphate monobasic, 0.045 M sodium
phosphate dibasic, 37% formaldehyde) for 48 hours before being processed and for embedding in
paraffin. Sections were cut 4 m thick and placed on slides for analysis. This experiment was
repeated 3x with 4 mice per each group using female Izt mice that were 8-10 weeks old.
To test the T cell dependent response in Tzt mice, 7 week old Tzt mice were injected
intraperitoneally with 5x108 sheep red blood cells (SRBC) in 200 L PBS, or 200 L of PBS as a
control. Eight days after the injection, mice were sacrificed by CO2 asphyxiation and spleen,
thymus, and pancreas were fixed in 10% neutral buffered formalin for 48hrs, processed, and
embedded in paraffin blocks for sectioning. 4 m thick sections were placed on slides for analysis.
For this study, 4 wild type mice, 4 BatfZZ mice, and 4 Tzt mice were included in each treatment
group. This experiment was repeated twice.
To test the T cell independent response in Tzt mice, 30 g of TNP-LPS (Santa Cruz, sc286968) were diluted in 300 L of PBS. Mice were injected with either TNP-LPS or mock injected
with 300 L of PBS for the control. On day 5, the mice were sacrificed by CO2 asphyxiation. The
spleen, thymus, and pancreas were fixed in 10% neutral buffered formalin for 48 hours before
being processed and embedded into paraffin blocks for sectioning. 4 m thick sections were placed
on slides for analysis. For this study, 4 wild type mice, 4 BatfZZ mice, and 4 Tzt mice comprised
each treatment group. This experiment was repeated twice.
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2.5 Immunohistochemistry and Immunofluorescence
Paraffin sections on slides were deparaffinized by 2 minute incubations in a series of
xylenes followed by a 2 minute incubation in each of the following solutions to rehydrate the
tissue: 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and water. Antigen retrieval was
performed by boiling the sections in citrate buffer (Vector). For immunohistochemistry (IHC),
sections were treated with 3% peroxidase for 10 minutes to inhibit endogenous peroxidase activity.
Sections were then washed 3x in PBS and blocked for endogenous mouse Ig using the biotin/avidin
kit (Vector) followed by staining with hematoxylin (H) and counterstaining with eosin (E) to
visualize structures in the organs.

Germinal centers were detected through staining with

biotinylated peanut agglutinin (PNA) (1:100) and visualized with Vectastain R.T.U ABC reagent
(Vector) and 3,3'-diaminobenzidine (DAB) peroxidase (Vector).
For immunofluorescence (IF) , paraffin sections were deparaffinized by 2 minute
incubations in a series of xylenes followed by a 2 minute incubation in each of the following
solutions to rehydrate the tissue: 100% ethanol, 95% ethanol, 70% ethanol, 50% ethanol, and
water. Antigen retrieval was performed by boiling the sections in citrate buffer. Tissues were
blocked for endogenous mouse Ig for 1 hour at room temperature using the biotin/avidin kit.
Sections were incubated in mouse on mouse (M.O.M) diluents for 5 minutes at room temperature.
The primary antibody was diluted with M.O.M diluents and biotin solution was added. 100 L of
primary antibody solution were applied to each side and incubated for 1 hour at room temperature
(Antibodies are listed in Table 4). Sections were washed 3x in PBS and tissues were incubated in
100 L of secondary antibody in M.O.M diluents for 10 minutes. (Antibodies are listed in Table
4). Sections were washed 3x in PBS and coverslips added over VectaShield
mounting solution. Slides were stored at -20°C until visualized.

+

DAPI (Vector)
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Table 4. Antibodies for Immunohistochemistry and Immunofluorescence
Clone
Number

Application

Source

Goat anti-mouse PNA

Polyclonal

IHC

Vector

Rabbit anti mouse IgM

DA4-4

IHC

Novus Biologics

Rabbit anti- mouse IgG1

11711

IHC

Rat anti–mouse B220

RA3-6B2

IHC/IF

Novus Biologics
eBioscience

Rabbit anti-mouse GFP

Polyclonal

IF

ThermoFisher

Rabbit anti-mouse RFP

Polyclonal

IF

ROCKLAND

Ab

Goat anti-Rabbit Oregon Green 488

Polyclonal

IF

ThermoFisher

Goat anti-Rabbit Alexa Flour 594

Polyclonal

IF

ThermoFisher

Cells from primary cell cultures were pelleted, re-suspended in 1mL of B cell media, and
counted using a hemocytometer. 0.5x106 cells were diluted into 200 L which was applied to each
cytospin cuvette and spun at 800 RPM for 3 minutes to transfer cells to slides. Slides were stored
overnight at room temperature to dry before being fixed. For fixation, cells were fixed in 4%
formaldehyde for 15 minutes and washed once with PBS. IF staining was performed after first
blocking endogenous mouse Ig for 1 hour at room temperature using the biotin/avidin kit. Slides
were then incubated in M.O.M diluents for 5 minutes at room temperature before primary
antibody, diluted into M.O.M diluents and biotin solution was added for 1hr. Slides were washed
3x in PBS and incubated 10 minutes 100 L of secondary antibody in M.O.M diluents. Slides were
washed 3x in PBS and coverslips applied over VectaShield + DAPI (Vector) mounting solution.
The stained slides were stored at -20°C until imaging.

2.6 Cell Culture
Primary B cells from mouse spleens were isolated using CD43(Ly48) microbeads
(Miltenyi Biotec) and cultured at 5x105 cells/mL in RPMI 1640 (Gibco) supplemented with
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100U/mL penicillin-streptomycin (Gibco), 10% heat inactivated fetal bovine serum (FBS) (Gibco)
and 50 M -mercaptoethanol (Sigma-Aldrich). Medium containing 20 g/mL LPS (Sigma) and
20ng/mL IL-4 (BD Biosciences) was used to induce CSR.

HeLa 229 cells (CCL-2.1; ATCC)

were maintained in DMEM (HyClone) supplemented with 100U/mL penicillin-streptomycin and
10% fetal bovine serum.
For stimulating primary T cells from the spleen, 100mm tissue culture dishes were coated
with 2 g/mL -CD3 in 5mL of PBS at 4°C overnight with rocking. Plates were washed 3x with
10 mL of PBS before solenocytes were plated. Splenocytes were plated at 5x105 cells/mL in 15mL
of Primary T cell media (RPMI, 5% FBS, 100U/mL penicillin-streptomycin, 50 M Mercaptoethanol, 20mM Hepes pH 7.4, 1mM L-glutamine, and 2mM sodium pyruvate) containing
2 g/mL -CD28 for 3 days to activate the cells
For conversion of primary T cells to the various Th cell lineages, naïve CD4+ T cells were
isolated from spleens using magnetic separation with CD4+CD62L+ microbeads (Miltenyi, 130104-453). The cells were cultured for 3 days with 2 g/mL plate bound -CD3 and 2 g/mL CD28. In addition, the following skewing conditions were used for each of the T cell subsets. For
Th1 cells: 20U/mL recombinant mouse (rm) IL-2 (R&D Systems), 2ng/mL rm IL-12 (R&D
systems), 2ng/mL rm IFN (Peprotech), and 10 g/mL -IL4 (11B11; Biolegend). For Th2 cells:
20U/mL recombinant human (rh) IL-2 (R&D systems), 20ng/mL rm IL-4 (R&D systems),
10 g/mL -IFN, (Biolegend) and 10 g/mL anti-IL-12 (C17.8; BD Bioscience). For Th17 cells:
5ng/mL rh TGF, (Peprotech), 20ng/mL rm IL-6 (Peprotech), 10ng/mL rm IL-21 (Peprotech),
10ng/mL rm IL-23 (R&D systems), 10ng/mL rm IL-1 (Peprotech), 20ng/mL TNF (Peprotech),
10 g/mL -IL-4 (11B11; Biolegend), and 10 g/mL -IFN (XMG1.2; Biolegend). After 3 days
of treatment, cells were expanded for an additional 2 days by transferring the cells to new tissue
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culture plates coated with 2 g/mL plate bound -CD3 and in media containing 2 g/mL -CD28.
Th1 cell cultures were supplemented with 2.5ng/mL IL-12, Th2 cells cultured in media
supplemented with 5ng/mL -IL-4, and Th17 cells were cultured in media supplemented with
50ng/mL IL-6. After a total of 5 days in culture, cells were harvested for RNA isolation and other
analyses.

2.7 Retroviral Infection
A murine stem cell virus (MSCV) containing a Cluster of Differentiation 90.1 (CD 90.1 or
Thy-1.1) marker (MSCV-THY1.1-IRES) was obtained from Addgene (#17442). Derivatives
expressing hemagglutinin-tagged mouse BATF (MSCV-Thy1.1-IRES-BATF), Myc tagged mouse
NFIL3 (MSCV-Thy1.1-IRES-NFIL3), Myc-tagged mouse WNT10A (MSCV-Thy1.1-IRESWNT10A) and Myc-tagged mouse IRF4 (MSCV-Thy1.1-IRES-IRF4) were generated by PCR
cloning. MSCV-Thy1.1-IRES-miR155 was generated by PCR cloning of miR155 from the
MSCV-miR155-eGPF vector, a generous gift of Ricardo Aguiar (Bouamar et al., 2015).
pMSCVgfp::AID (Plasmid #15925) was obtained from Addgene. Virus containing supernatants
were produced by the Sanford Burnham Prebys Medical Discovery Institute. Levels of protein (or
microRNA) expression from these viruses were assessed following transduction of primary B cells
(BATF) or HeLa cells (NFIL3, WNT10A and miR155). For the retroviral rescue experiments,
primary B cells were stimulated with 20 g/mL LPS and 20ng/mL IL-4 for 4 hours prior to
spinfection for 1 hours with virus supernatant or primary splenocytes were cultured on plates
coated with 2 g/mL -CD3 and in media supplemented with 2 g/mL -CD28 for 24 hours prior
to spinfection for 1 hour with virus supernatant. B cells were cultured an additional 42 hours in
media supplemented with 20µg/mL LPS and 20ng/mL IL-4. Splenocytes were cultured for an
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additional 48 hours on plates coated with 2 g/mL -CD3 and in media supplemented with 2 g/mL
-CD28. Cells were then harvested and blocked for 30 minutes at 4°C in media containing
fragment, crystallizable (Fc) block (BD Bioscience) at a dilution of 1:100 to prevent non-specific
interactions. To label transduced cells, -PE-Thy1.1 was used to stain cells at a 1:500 dilution for
20 minutes at 4°C. FACS was used to sort for Thy1.1+ and Thy1.1- cells. Protein, mRNA, or
miRNA was immediately harvested from the sorted cells for analysis.

2.8 Immunoblot
Cells were pelleted and washed 2x in 1mL of PBS. Cells were lysed in 100uL of RIPA
buffer (30mM NaCl, 0.5% v/v deoxycholic acid, 5% v/v NP-40, 50mM Tris pH 8.0, 0.1% SDS,
and 2mM EDTA) supplemented with a 1:1000 dilution of phosphatase inhibitor cocktail (PIC)
(Fisher). Lysates were sonicated 3x for 10 seconds each. Protein concentration was determined
using a bicinchoninic acid (BCA) assay kit (Pierce). To detect protein, 50 g of protein were
resolved on a 12% SDS-PAGE or 15% (BATF only) SDS-PAGE, and transferred to a
nitrocellulose membrane (Biorad). Primary antibodies used for blotting along with concentrations
are listed in Table 5. A 1:5000 dilution of horseradish peroxidase conjugated -rabbit secondary
antibody was used for reacting to all primary antibodies (Vector) with the exception of Myc which
utilized a horseradish peroxidase conjugated to -mouse secondary antibody (Vector). Super
Signal Dura substrate (Pierce) was used for chemiluminescence detection.
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Table 5. Antibodies for Immunoblotting and ChIP
Clone
Number

Application

Rabbit anti-mouse BATF

D7C5

Immunoblotting/ChIP

Source
Cell Signaling

Rabbit anti-mouse AID

30F12

Immunoblotting

Cell Signaling

Rabbit anti-mouse NFIL3

D5K8O

Immunoblotting

Cell Signaling

ab106522

Immunoblotting

Abcam

Rabbit anti-mouse IRF4

H-140

Immunoblotting

Santa Cruz

Rabbit anti-mouse PAX5

D19F8

Immunoblotting

Cell Signaling

Rabbit anti-mouse HSP90

H-114

Immunoblotting

Santa Cruz

Rat anti-mouse HA-biotin

3F10

Immunoblotting/ChIP

Roche

Ab

Rabbit anti-mouse WNT10a

2.9 Analysis of RNA
RNA was isolated using the RNeasy mini kit or miRNeasy mini kit (Qiagen). cDNA was
prepared with the iSCRIPT kit (Bio-Rad) or miSCRIPT II RT kit (Qiagen). Quantitative RT-PCR
was performed using FastStart Universal SYBR Green Master (Roche) and a Light Cycler 96
System (Roche). Primer sequences are listed in Table 6. The annealing temperature for the qPCR
was 59°C for 30 seconds and extension was performed at 72°C for 30 seconds. Reactions were
performed for 28 cycles. Results were normalized using -actin mRNA expression unless
otherwise noted in the Figure legends. CT values were used to calculate relative expression of
each mRNA.
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Table 6. QPCR Primer Sequences
Gene

Forward Primer

-actin

Qiagen QT00095242

Reverse Primer

Batf

5'-GTTCTGTTTCTCCAGGTCC-3'

5'-GAAGAATCGCATCGCTGC-3'

Aicda

5'-TGCTACGTGGTGAAGAGGAG-3'

5'-TCCCAGTCTGAGATGTAGCG-3'

Pax5

5'-AGTCTCCAGTGCCGAATG-3'

5'-TCCGTGGTGGTGAAGATG-3'

Irf4

5'-GGACTACAATCGTGAGGAGGAC-3'

5'-ACGTCACAGGACATTGATATGG-3'

Bcl6

5'-TCGTGAGGTCGTGGAGAAC-3'

5'-AGAGAAGAGGAAGGTGCTGAG-3'

Prdm1

5'-AACACGTGGTACAACCCAAAG-3'

5-AGGCTGCAGAGATGGATGTAG-3'

Pou2af1

5'-ACCAGGGTGTTCGAGTAAG-3'

5-CCTCTGTCACTGTGGAAGCA-3'

Nfil3

5'-AAGATTGGTCCCTCAAATCG-3'

5-TCGGTTGTGTGGCTATGAAT-3'

Wnt10a

5'-ATGAGTGCCAGCATCAGTTC-3'

5-ACCGCAAGCCTTCAGTTTAC-3'

Il-6

5'-TGATGCACTTGCAGAAAACA-3'

5'-TCTGAAGGACTCTGGCTTTG-3'

Lat2

5'-ATTATTGCGCTGCTGTTGG-3'

5'-TTGTTTGGAGCTGTGTCCAT-3'

Slamf6

5'-ACCCTGGAATGCAAGTTATGGT-3'

5'-CTGCATTGGACGAGTGACTT-3'

Egr2

5'-CAAGGCCGTAGACAAAATCC-3'

5'-CAGGGGTCTCTTCTCTCCAG-3'

Ezh2

5'-CAGTGTGCTGGAGTCAAAGG-3'

5'-CACCACTCCACTCCACATTC-3'

Serpinb9

5'-TCTCCTTTGCTGAAGAAGCA-3'

5'-AAGGGCATGTCCATTGTGTA-3'

Il-10

5'-CCAAGCCTTATCGGAAATGA-3'

5'-TCACTCTTCACCTgCTCCAC-3'

miR155hg

5'-CAGCTCATCTGAGAAAACAGC-3'

5'-GTAGGAGTCAGTCAGAGGC-3'

Gata3

5'-AGAACCGGCCCCTTATCAA-3'

5'-AGTTCGCGCAGGATGTCC-3'

Il-4

5'-AGATCATCGGCATTTTGAACG-3'

5'-TTTGGCACATCCATCCCCG-3'

Ifn

5'-GGATGCATTCATGAGTATTGC-3'

5'-CCTTTTCCGCTTCCTGAGG-3'

T-bet

5'-CAACAACCCCTTTGCCAAAG-3'

5'-TCCCCCGGCAGTTGACAGT-3'

Il-17a

5'-CTCCAGAAGGCCCTCAGACTAC-3'

5'-AGCTTTCCCTCCGCATTGACAC-3'

Il-21

5'-ATCCTGAACTTCTATCAGCTCCAC-3'

5'-GCATTTAGCTATGTGCTTCTGTT-3'

Rort

5'-TGTCCTGGGCTACCTACTG-3'

5'-GTGCAGGAGTAGGCCACATT-3'

Il-9

5'-TCCACCGTCAAAATGCAGCTGC-3'

5'-CCGATGGAAAACAGGCAAGAG-3'

GL Iµ-Cµ

5'-ACCTGGGAATGTATGGTTGTGGC-3'

5'-TCTGAACCTTCAAGGATGCTCT-3'

GL I1-C1

5'-GGCCCTTCCAGATCTTTGAG-3'

5'-ATGGAGTTAGTTTGGGCAGCA-3'

GL Ia-Ca

5'-CAAGAAGGAGAAGGTGATTC-3'

5'-GAGCTGGTGGGAGTGTCAGTG-3'

miR155

Qiagen MS00031486

RNU6

Qiagen MS00033740
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2.10

RNA-Seq
Total RNA was isolated from B cells harvested from 4 wild type and 3 BatfZ/Z mice

using E.Z.N.A. Total RNA Mini Kit (Omega Bio-Tek) and submitted to the Purdue Genomics
Core Facility. Paired-end libraries were constructed for each sample and sequenced on an
Illumina HiSeq System to a depth of >30 million reads per sample. Reads were filtered using the
FASTX toolkit (v 0.0.13) to remove bases with a Phred score below 30 and then aligned with
Tophat (v 2.0.6) to the mouse genome (mm10). Read counts for each gene were generated using
HTSeq (v 0.5.3p7). Differential expression was determined using edgeR (v 3.03) with a false
discovery rate of < 0.05 and a fold-change cut-off of 2. The heatmap was created in edgeR using
the heatmap.2 function from the gplots package. Gene Ontology analysis was performed using
the PANTHER Classification System webtool with p-values adjusted for multiple testing using
the Bonferroni correction.

2.11

ChIP Assay
Chromatin from wild type, BatfKI/KI, and BatfZZ B cells stimulated for 48 hours was

prepared using the Simple ChIP Enzymatic Chromatin IP Kit (Cell Signaling). For this kit,
cultured cells were transferred to a 15mL conical tube suspended in 10mL of PBS with protease
inhibitor cocktail (PIC). To crosslink proteins to DNA, 16% formaldehyde was added to each tube
and rocked at room temperature for 5 minutes. The reaction was quenched by adding 10mL of
Glycine to each tube which was subsequently rocked at room temperature for 5 minutes. Cells
were centrifuged at 1500 RPM for 5 minutes at 4°C. The cells were re-suspended in 10mL of icecold Buffer A (Simple Chip Kit II, Cell signaling), dithiothreitol (DTT), and PIC, incubated on
ice for 10 minutes inverting the tubes every 3 minutes, and pelleted at 3000 RPM for 5 minutes at

38
4°C. The cells were re-suspended in LB3 buffer (1mM EDTA, 0.5M ethylene glycol-bis (aminoethyl

ether)

-N,N,N',N'-tetraacetic

acid

(EGTA),

10mM

tris

(hydroxymethyl)

aminomethane- hydrochloric acid (Tris-HCL) pH 7.5, 100mM sodium chloride (NaCl), 0.1% NaDeoxycholate, 0.5% N-lauroyl sarcosine)+ 1x PIC and transferred to a 1.5mL microcentrifuge
tube. DNA was fragmented by sonication (3X for 30 sec) on ice. Debris was pelleted at 10000
RPM for 10 minutes at 4°C and supernatant was moved to a new tube.
To analyze the concentration of the chromatin as well as the digestion efficiency, 50µL of
DNA chromatin were removed. To this, 100 L of nuclease free water, 6 L of 5 M NaCl and 2µL
of Protinase K were added to remove protein. Samples were vortexed and incubated at 65°C for
2 hours. The DNA was purified using DNA purification spin columns (Qiagen). 2 L of DNA
were added to 98 L of water, and the concentration was determined using a Nano Drop
spectrophotometer. In addition, 10 L of the sample were resolved by electrophoresis on a 1%
agarose gel to determine the DNA fragment size.
For each chromatin immunoprecipitation, 8 g of chromatin were diluted into 400 L of
ChIP buffer and PIC. 10 L of diluted chromatin was set aside for the 2% input control and stored
at -20°C. Next, 10 g of the -BATF mAb (Santa Cruz) or 10 g -JUNB mAb (Santa Cruz) or
2 g of -H3 acetylation mAb (Cell Signaling) were added to each sample to be
immunoprecipitated. Tubes were incubated overnight at 4°C with rotation. 30 L of protein G
magnetic beads were added to each IP reaction and incubated for 2 hours at 4°C with rotation. The
protein G magnetic beads were pelleted by placing the tubes in the magnetic separation rack and
waiting 2 minutes for the solution to clear. Pelleted protein G magnetic beads were washed 3x by
adding 1mL of low salt wash buffer (Cell Signaling) to the beads and incubating at 4°C with
rotation. Protein G magnetic beads were washed a 4th time using 1mL of high salt wash buffer
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(Cell Signaling) and incubating at 4°C with rotation. To elute the chromatin from the antibody,
150 L of ChIP elution buffer were added to each immunoprecipitation sample and to each 2%
input sample. Each IP sample was incubated for 30 minutes at 65°C with gentle vortexing. The
protein G magnetic beads were pelleted by placing the tubes in the magnetic separation rack and
waiting 2 minutes for the solution to clear. Clear chromatin supernatant was transferred to a new
tube and 6 L of 5M NaCl and 2 L of Proteinase K were added to every tube, including the 2%
input tubes to digest away proteins. All of the samples were incubated for 3 hours at 65°C with
gentle vortexing.
To purify the DNA for ChIP qPCR, 750 L of DNA binding buffer were added to each
sample and vortexed briefly. Each sample was transferred and DNA was isolated by centrifuged
at 14000 RPM for 30 seconds at room temperature. 750 L of DNA wash buffer (Qiagen) were
added to each DNA spin column and re-spun at 14000 RPM for 1 minute at room temperature.
The spin columns were placed into a 1.5mL microfuge tube and 50 L of DNA elution buffer were
added to each tube. The tubes were then centrifuged at 14000 RPM for 30 seconds at room
temperature. Purified DNA was stored at -20°C. QPCR was performed using 7 L of water, 1 L
of primer, 10 L of FastStart Universal SYBR Green Master (Roche) and 2 L of DNA. Each
sample was run in duplicate on a Light Cycler 96 System (Roche). The primer sets used for the
ChIP QPCR are listed in Table 7.
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Table 7. ChIP QPCR Primer Sequences

2.12

Gene

Forward Primer

Reverse Primer

ChIP Myb (N)

5'-CATGCACTCAGAGACAGAG-3'

5'-GCAAATCATTCAAACGCCGC-3'

ChIP Myb (E)

5'-GCTGGAGGCATGCTGTAAG-3'

5'-GCCATTTTGCCTCACAACC-3'

Nfil3 (A)

5'-ATGTCTCCATCCTTGAAGTG-3'

5'-GCTTGCATTTTCTGTCTTTT-3'

Nfil3 (B)

5'-TGGTTTTTGAGACGTTTTCT-3'

5'-GTTTAATCCCCAAAGCCTAT-3'

Nfil3 (C)

5'-CAAGGGCTTTATCATCTGAG-3'

5'-CCATCTGTGAGCTACTCTCC-3'

ChIP Bic (A)

5'-GGTCCTAAAGGGAACCACAG-3'

5'-TGCTGTTTCCTGTTAGAGTTG-3'

ChIP Bic (B)

5'-AGGTCAAAAGGCAACCAAAG-3'

5'-TGGATTTCCCACCAGAATTT-3'

ChIP Wnt10a (A)

5'-TTAATGAGAGTGGGAGCCGG-3'

5'-CCCCAGCAGAACCCAAGG-3'

ChIP Wnt10a (B)

5'-TGCTCAATGGTTAAGGGCAC-3'

5'-AGAGCCAAAACATGATGCCG-3'

ELISA
To determine immunoglobulin concentration in serum, blood was collected from mice by

cardiac puncture and allowed to clot at room temperature in a Microtainer Serum Separator tube
(BD Bioscience). Serum was isolated by centrifugation at 5000 RPM for 10 minutes at room
temperature. OptEIA kits (BD Bioscience) were used to detect SRBC specific or TNP-LPS
specific IgM and IgG.

Reactions were visualized with streptavidin-HRP and 3,3',5,5'-

Tetramethylbenzidine (TMB) substrate reagent. Absorbance was measured at 405nm with a
Multiskan FC plate reader (Thermo Fisher).
For ELISA using media from cultured cells, media was diluted in Assay Dilutent (BD
bioscience) and applied to antibody coated 96 well Maxisorp plates (Nuc). Coating antibodies and
detection antibodies are listed in Table 8. Positive reactions were visualized with streptavidinHRP and TMB substrate reagent (BD Bioscience). Reactions were stopped and the absorbance
was measured at 405nm with a Multiskan FC plate reader (Thermo Fisher).
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Table 8. ELISA Antibodies
Ab
Purified anti–mouse IgM
Biotin anti–mouse IgM

2.13

Clone Number

Application

Source

II/41

ELISA

BD

II/41

ELISA

BD

Purified anti–mouse IgG1

A85-3

ELISA

BD

Biotin anti–mouse IgG1

A85-1

ELISA

BD

Anti-SRBC-IgM Elisa Kit

ELISA

Anti-SRBC-IgG Elisa Kit

ELISA

Anti-TNP-LPS-IgM Elisa Kit

ELISA

Anti-TNP-LPS-IgM Elisa Kit

ELISA

Life Diagnostics
Life Diagnostics
Life Diagnostics
Life Diagnostics

Flow Cytometry
For the analysis of cell surface markers by flow cytometry, cells were harvested by

pelleting at 1300RPM for 5 minutes, suspended in 1mL of media, diluted at 1:1000, and cell counts
were determined using a hemocytometer. 1.0x106 cells were blocked for 30 minutes on ice in
media containing Fc block (BD Bioscience) at a dilution of 1:100 to prevent non-specific
interaction. Cells were then stained with the appropriately labeled antibodies for flow cytometry.
Antibodies and concentrations are listed in Table 9. Antibody staining was performed in media
and on ice for 20 minutes. Cells were then washed in 1mL of media and re-suspended in 1mL of
media for analysis. Flow cytometry profiling was performed on the LSRFortessa (BD Bioscences)
and sorting was performed using a FACS Aria III (BD Biosciences) in the Flow Cytometry and
Cell Separation Facility at Purdue University.

Data were analyzed with FlowJo software

(TreeStar).
For cell surface and intracellular antibody staining of T cells, splenocytes were activated
with 2 g/mL plate bound -CD3 and in primary T cell media supplemented with 2 g/mL -CD28
at 37°C, 5% CO2. After 72 hours, CD4+ T cells were isolated using Miltenyi columns (see primary
T cell isolation). CD4+ T cells were returned to culture in primary T cell media containing
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50ng/mL PMA, 500ng/mL Ionomycin, and 10 L of Golgi Stop for 4 hours at 37°C, 5% CO2.
Cells were washed 2x with 5mL of MACS buffer, and pelleted through a 70 m filter at 1100 RPM.
1.0 x106 cells were blocked on ice for 30 minutes in Fc block at a 1:100 dilution. The appropriate
cell surface flow cytometry antibodies were added at a dilution of 1:200, and cells were incubated
for 20 minutes on ice. Cells were washed 2x in 1mL of MACS buffer to remove excess antibody.
To

fix

and

permeabolize

the

cells,

the

cells

were

re-suspended

in

250 L of

fixation/permeabilization solution (BD Bioscience), vortexted for 30 seconds and incubated at
room temperature in the dark for 20 minutes. Perm/Wash buffer (BD Bioscience) was used to
wash the cells. Intercellular antibody staining was performed in Perm/Wash buffer for 25 minutes
in the dark on ice. Antibodies added are listed in Table 2. Cells were washed 2x in Perm/Wash
buffer and re-suspended in MACS buffer for flow cytometry. Profiling of the cells was performed
on the LSRFortessa and FlowJo software was used for the data were analysis.

Table 9. Flow Cytometry Antibodies
Ab
Anti–mouse IgM

Clone Number

Application

Source

II/41

eBioscience

Anti–mouse IgG1

A85-1

Flow cytometry
Flow cytometry

Anti–mouse IgE

R35-72

Flow cytometry

BD

11B11

Flow cytometry

BD

TC11-18H10.1

Flow cytometry

Biolegend

XMG1.2

Flow cytometry

Biolegend

anti-CXCR5

L138D7

Flow cytometry

Biolegend

anti-PD-1

J43

Flow cytometry

eBioscience

Anti-CD4

L3T4

FACS/Flow cytometry

eBioscience

Anti-mouse CD90.1 (Thy1.1)

HIS51

FACS/Flow cytometry

eBioscience

anti-IL-4
anti-IL-17a
anti-Ifn

BD
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2.14

CFSE Staining
B cells at a density of 10x106 cells/mL were labeled with 1 M CFSE (Cell Division

Tracker Kit, BD Biosciences). To stain cells, a 5mM stock solution of CFSE dye was prepared by
reconstituting 1 vial of CFSE in 36 L of DMSO. To prepare the working solution, CFSE was
diluted into 1mL of PBS for every 1mL of cell suspension for a final concentration of 1 M CFSE.
B cells were spun down at 1300 RPM at room temperature and resuspended in the CFSE working
solution. Cells were incubated for 20 minutes at 37°C protected from light. Next, the CFSE
solution was quenched by adding 5 times the original staining volume of cell culture media
containing 10% FBS. The B cells were pelleted and washed an additional 2 times in pre-warmed
B cells media. After a 10 minute incubation at 37°C protected from light, the B cells were plated.
To compare wild type, BatfKI/KI, and BatfΔZ/ΔZ B cells proliferation, the cells were activated with
20 g LPS and 20ng IL-4 for 72 hours. Analysis was performed by flow cytometry. To analyze B
cell proliferation after viral transduction, B cells were plated in B cell media containing 20 g LPS
and 20ng IL-4 for 4hrs, spinfected for 1hr with the intended virus, and re-plated in B cell media
containing 20 g LPS and 20ng IL-4. Media was changed every 24hrs, and flow cytometry was
used to analyze cell proliferation 72 hours after viral transduction.

2.15

Cloning
To generate MSCV-HA-BATF-IRES-THY1.1, HA-BATF was sub-cloned from a pGEM-

T vector by cutting the vector using a PCR cloning strategy to add BglII sites onto both the Nterminus and C-terminus of HA-BATF. Cloning primers sets are listed in Table 10. A BglII digest
was performed on the PCR product, and subsequently inserted into the MSCV-IRES-THY1.1
vector that had been opened with a BAMHI digestion. Plasmids were ligated with the digested
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PCR product at room temperature for 30 min, and transformed into DH5 competent cells by heat
shocking the cells at 42°C for 45 seconds. The cells recovered in Super Optimal broth with
Catabolite repression (SOC) media for 45 minutes at 37°C.

Cells were then plated on

Lysogeny Broth Ampicilin (LB-AMP) plates overnight at 37°C. Colonies were harvested and
grown overnight at 37°C. DNA was harvested through a mini-prep (Qiagen). Sequencing was
used to detect clones that contained HA-BATF in a forward orientation.
A PCR cloning strategy was used to generate the MSCV-NFIL-MYC/HIS-IRES-THY1.1
and MSCV-IRF4-MYC/HIS-IRES-THY1.1. The primers used are listed in Table 10. XbaI and
KpnI sites were added to each side of the NFIL3 and IRF4 fragments through PCR. The pcDNA
3.1C MYC/HIS plasmid was opened with a XbaI and KpnI double digest in a 37°C water bath
for 1 hour. Concurrently, the Nfil3 and Irf4 PCR fragments were digested with XbaI and KpnI in
a 37°C water bath for 1 hour. By inserting NFIL3 and IRF4 into the pcDNA 3.1 plasmid, a
Myc/His tag was added to the C-terminus of their coding region. NFIL3 and IRF4 were
subsequently subcloned into the MSCV plasmid by opening the MSCV-IRES-THY1.1 plasmid
with BamH1 and XhoI and cutting the pcDNA-NFIL3 and pcDNA-IRF4 plasmids with BglII
and XhoI. BglII and BamHI have compatible ends to allow this subcloning strategy. Plasmids
and DNA inserts were ligated at room temperature for 30 minutes and transformed into DH5
cells by heat shocking them at 42°C for 45 seconds. The cells were recovered in SOC media for
45 minutes at 37°C, and plated on LB-AMP plates overnight. Individual conies were grown
overnight at 37°C and DNA was harvested by a mini prep. Sequencing was used to confirm that
the plasmids were correct. I will refer to these retroviral plasmids generated as MSCV-IRF4 and
MSCV-NFIL3.
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Wnt10a was cloned into the pcDNA vector by adding XbaI and NotI sites through PCR.
Primer sequences are listed in Table 10. The pcDNA3.1C MYC/HIS vector was opened with an
XbaI/NotI double digest at 37°C for 1 hour. The Wnt10a PCR product was also digested with an
XbaI/NotI double digest at 37°C for 1 hour. The ligated plasmid was transformed into DH5
cells. Following a DNA isolation, sequencing was used to ensure the gene was not altered and
was inserted in the correct orientation. By inserting Wnt10a into the PcDNA3.1C MYC/HIS
vector, a Myc/His tag was successfully added to the C-terminal domain. WNT10A-MYC/HIS
was sub-cloned into the MSCV-IRES-THY1.1 vector. To accomplish this, the MSCV vector
was opened with a BglII and SalI digest at 37°C for 1 hour. BglII and Xho double digest at 37°C
for 1 hour was used to cut Wnt10a out of the pcDNA vector. XhoI and SalI have compatible
ends enabling this subcloning strategy. The MSCV vector and Wnt10a fragment were ligated at
room temperature for 30 minutes and transformed into DH5 cells through heat shocking the
cells with the DNA for 45 seconds. The cells were recovered in SOC media and grown
overnight on LB-AMP plates. Single colonies were cultured over night at 37°C. DNA isolated
from cells was sequenced to verify that Wnt10a was correctly inserted into the MSCV vector to
generate MSCV-WNT10A-MYC/HIS-IRES-THY1.1. I will refer to this virus simply as MSCVWNT10A. To generate the MSCV-miR155-IRES-THY1.1 plasmid miR155, Subcloned from an
MSCV-miR155-GFP vector by digesting the vector with XhoI and HindIII at37°C for 1 hour to
cut the miR155 fragment out of the vector. The MSCV-IRES-THY1.1 plasmid was double
digested with XhoI
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Table 10. Cloning Primer Sequences
Gene

Forward Primer

Revese Primer

Batf

5'-TGTCCGGGATCCATGCCTCAC-3'

5'-GACATGGATCCGGCGTAATC-3'

Irf4

5'-TAATCTAGACGCGGGGCATGAACCTGGAG-3'

5'-CATTCCTCTATTCAAGAAGCGGCCGCTTA-3'

Nfil3

5'-TAATCTAGACCTTTCTGATGCAGCTGAGA-3'

5'-TCTCGGCTTCGGACTCCAGGGGTACCTTA-3'

Wnt10a

5'-TAATCTAGACCGCGCGCCATGGGCAGCGC-3'

5'-TGGGTCAGCGTCTGCAAGGCGGCCGCTTA-3'

and HindIII at 37°C for 1 hour. The digested MSCV plasmid and miR155 fragment were ligated
at room temperature for 30 minutes. DH5 cells were transformed with the DNA by heat
shocking the cells at 42°C for 45 seconds. The cells were recovered in SOC media for 45
minutes at 37°C before being plated on LB-AMP plates which were incubated over night at
37°C. Single colonies were cultured in LB over night at 37°C. The DNA was harvested and
sequenced was used to confirm that the MSCV-MIR155-IRES-THY1.1 plasmid was generated.
I will refer to this virus simply as MSCV-miR155.

2.16

Site-Directed Mutagenesis
To generate mutations in MSCV-THY1.1.-IRES-HA-BATF plasmid, specific oligos were

created (Table 11) and the Quikchange II Site-Directed Mutagenesis kit (Agilent) was utilized.
The mutated HA-BATF was sequenced to insure that the mutagenesis was successful. Plasmids
were then digested from the mutant plasmid and subcloned back into a MSCV-THY1.1-IRES
plasmid though a PCR cloning strategy. The MSCV-THY1.1-IRES plasmid was digested with
BamHI and the BATF PCR product was digested with BglII at 37°C for 1 hour. Ligation reactions
were performed at room temperature for 30 min. Ligated plasmids were used to transform DH5
competent cells by heat shocking the cells at 42°C for 45 seconds. The cells recovered in SOC
media for 45 minutes at 37°C. Cells were then plated on LB-AMP plates overnight at 37°C.
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Colonies were harvested and grown overnight at 37°C. DNA was harvested through a mini-prep
(Qiagen) and sequenced to confirm that the mutated BATF was in the correct orientation.

Table 11. Site-directed Mutagenesis Primers
Gene

Forward Primer

Revese Primer

S43A

5'-CGCCCAGAAGGCCCGACAGAGGCAGACC-3'

5'-GGTCTGCCTCTGTCGGGCCTTCTGGGCG-3'

S34D

5'-CGCCCAGAAGGACCGACAGAGGCAGACC-3'

5'-GGTCTGCCTCTGTCGGTCCTTCTGGGCG-3'

T48A

5'-GCCGACAGAGGCAGGCCCAGAAGGCC-3'

5'-GGCCTTCTGGGCCTGCCTCTGTCGGC-3'

T48D

5'-GGTGCTGAACAGCCACGAGCCCCT-3'

5'-CAGGGGCTCGTGGCTGTTCAGCACC-3'

2.17

Cell Transfection
Cell transfections were performed using Xtreme Gene9 (Roche XTG9). For this protocol,

the plasmid DNA was mixed with transfection reagent at a 1:3 ratio. Hela cells were plated in a 6
well plate in media (Dulbecco's Modified Eagle's Medium (DMEM), 5% FBS, 100U/mL
Penicillin/Streptomycin) and grown to 70% confluency. Serum free DMEM media was mixed 3 l
of XG9 transfection reagent and 1 g of plasmid DNA. The solution was vortexed for 10 seconds,
and incubated for 30 minutes at room temperature. The transfection mix was added dropwise to
the culture dish/well. Because the XG9 solution is toxic to most cells over prolonged periods of
time, the media was changed after a 12 hour incubation. Cells were harvested 48 hours after
transfection.
2.18

Luciferase Assay
Hela cells were transduced with FIV 3.2 Cre-Luciferase as described above. Subsequently,

a renilla luciferase plasmid pRL-pGK was transfected into cells, as described above, to monitor
transfection. 12-hours post-transfection the media was replaced, and 36-hours pos- transfection,

48
lysates were harvested using 100 l passive lysis buffer (Promega 1941). Samples were placed in
Eppendorf tubes and spun-down briefly to pellet cell debris. 10 l of lysate was mixed with either
renilla luciferin (Promega) or firefly luciferin (Promega) and measured in a luminometer
(Rukstalis et al., 2003). The data was normalized internally with the firefly luciferase/renilla
luciferase ratio and then normalized to untransduced cells.

All data represents at least 3

independent biological replicates.

2.19

Statistical Analysis
P-values were determined using the two-tailed paired Student T-test analysis. The standard

errors were determined using the F-test  0.05. The student T-test using the unequal variance
model was then used. All P-values  0.05 were considered statistically significant. All error bars
represent the standard error of the mean. *P  0.05; **P  0.01; ***P  0.001; Statistical analysis
was performed using Graph Pad Prism.
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CHAPTER 3. IDENTIFICATION AND CHARACTERIZATION OF GENES
REGULATED BY BATF AND IMPORTANT FOR B CELL CSR

3.1 Introduction
BATF expression is modulated by developmental transitions and environmental cues
(Murphy et al., 2013; Sopel et al., 2016). Recent data suggest that BATF functions as a pioneering
transcription factor to reshape the genetic landscape of differentiating immune cells for subsequent
gene expression events (Ciofani et al., 2012; Kurachi et al., 2014). Data from studying BATF
transgenic (Thornton et al., 2006; Williams et al., 2001) and Batf knockout mice (Betz et al., 2010;
Kuroda et al., 2011; Schraml et al., 2009) have shown that BATF is essential for adaptive immune
responses. Although the most prominent role for BATF is in the CD4+ T helper (Th)-17 and T
follicular helper (Tfh) cell lineages (Betz et al., 2010; Schraml et al., 2009), BATF is also critical
for the antibody response in B cells (Betz et al., 2010; Ise et al., 2011). Although the loss of BATF
can be compensated for by the expression of the other members of the BATF protein family
(Tussiwand et al., 2012), co-expression of BATF proteins is rarely observed in vivo, and where it
is, redundancy appears to be directed toward a restricted set of genes (Iwata et al., 2017). In this
regard, it appears that BATF is the only member of the BATF family expressed in B cells (Murphy
et al., 2013; Sopel et al, 2016).
BATF is part of the intricate pathway required for antibody class switch recombination
(CSR) (Betz et al., 2010; Ise et al., 2011; Murphy et al., 2013; Stavnezer, Guikema, & Schrader,
2008). The deletion of Batf in Batf

Z/Z

mice results in the inability of B cells to induce the

expression of Aicda, the gene encoding AID, the enzyme required for the recombination of the
immunoglobulin genes (Okazaki, Kotani, & Honjo, 2007; Stavnezer et al., 2008). In addition,
there are additional genes in Batf deficient B cells that are not appropriately regulated as part of
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the process leading to CSR (Glasmacher et al., 2012; P. Li et al., 2012). These changes result in
Batf deficient mice having no ability to produce class switched antibodies (IgG1, IgG2c,IgA, and
IgE) (Betz et al., 2010; Ise et al., 2011). Interestingly, both Betz et al. (2010) and Ise et al. (2011)
showed that the absence of antibody production was not due to a defect in cell proliferation as Batf
Z/Z

or Batf-/- B cells proliferate as well as wild type cells when stimulated.
Ise et al. (2011) used retroviruses expressing BATF or to test if the phenotype of Batf-/- or

Aicda-/- B cells could be reversed. BATF expressing retroviruses restored close to 60% of CSR in
Batf-/- B cells, but less than 5% CSR in Aicda-/- B cells.

Although Ise et al. (2011) showed that

BATF bound an enhancer element upstream of the Aicda promoter, they were unable to
demonstrate a direct link between BATF and Aicda gene expression.

Using a retrovirus that

expressed AID, they were able to restore 70% CSR in Aicda-/- B cells, but could only restore about
10% CSR in Batf-/- B cells (Ise et al., 2011). Together these results position BATF upstream of
Aicda gene regulation, but also indicate that BATF must be important for the expression of
additional molecules critical for antibody production.
BATF proteins function to regulate gene transcription as heterodimers with other bZIP
proteins, notably the JUN proteins (Dorsey et al., 1995; Kuwahara et al., 2016; H. Wang, Xie, &
Scott, 1996). BATF:JUN heterodimers preferentially bind consensus AP-1 DNA (Dorsey et al.,
1995) or extended AP-1 elements, designated AICE, where members of the interferon regulatory
factor (IRF) family of helix-turn-helix transcription factors are recruited through interaction with
BATF (Glasmacher et al., 2012). Current models suggest that negative regulation of target gene
expression occurs when BATF:JUN dimers bind AP-1 sites, while positive gene regulation is
associated with IRF:BATF:JUN complexes bound to AICE (Murphy et al., 2013). However, as
cellular genes whose expression is impacted by BATF in vivo continue to be identified, this model
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is likely to undergo modification.

In this regard, recent studies have shown that sequences

proximal to an AICE can control how genes respond to variable levels, or to an alternative
composition, of the IRF:BATF:JUN complex (Iwata et al., 2017).
Understanding the role of BATF in specific cell types hinges on identifying BATF target
genes. This approach has been valuable for understanding the regulatory network specifying Th17
cells (Ciofani et al., 2012) and for describing the interaction with IRFs as the means through which
BATF:JUN heterodimers activate gene expression (Glasmacher et al., 2012). In this study, I have
applied this approach to B cells. My studies revealed a biphasic regulation of Batf mRNA and
BATF protein following B cell stimulation and I was able to use a conditional Batf knockout model
to show that the early, transient induction of BATF is sufficient to trigger the program of
immunoglobulin (Ig) CSR. I identified 3 genes, Nfil3, Wnt10a and microRNA 155 (miR155hg),
as targets regulated by BATF early in CSR and showed that this regulation is essential for CSR.
This work extends our knowledge of the molecular network controlling CSR in B cells and
positions BATF induction and function as critical, early events in the process.

3.2 Results
3.2.1 BATF Displays a Biphasic Pattern of Expression in Stimulated B cells.
Previous studies with two independently derived lines of BATF deficient mice revealed a
profound B cell defect in antigen triggered germinal center formation and in the generation of class
switched antibodies (Betz et al., 2010; Ise et al., 2011). B cells isolated from BATF deficient mice
(Batf Z/Z) proliferate appropriately when cultured in the presence of 20 µg/mL lipopolysaccharide
(LPS) and 20 ng/mL IL-4 (Betz et al., 2010) (Figure 3.1A). These cells properly regulate the
expression of many B cell genes, but do not express activation induced cytidine deaminase (AID),
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the enzyme required for Ig CSR (Figure 3.1B). Media harvested from stimulated BatfZ/Z B cells
contains IgM but, as expected, no detectable IgG1 (Figure 3.1C), indicating that the BATF null
cells do not undergo CSR.
To further characterize this observed defect, BatfZ/Z mice and BatfKI/KI were injected with
SRBC or mock injected with PBS. SRBC injection tests the ability of the immune system to
respond to a T cell dependent antigen. SRBCs activate APCs which in turn activate Tfh cells
which bind the B cell receptor and trigger the release of B cell cytokines, the formation of germinal
centers and the production of class switch antibodies. BatfZ/Z mice injected with SRBCs do not
form germinal centers (Figure 3.2A). In addition, splenic tissue stained with antibodies to detect
B cell expression of either IgG1 or IgG2c showed no presence of class switched antibodies (Figure
3.2B). Serum from injected mice was collected and ELISA were performed to quantify the class
switched Ig. The ELISA confirmed that BatfZ/Z stimulated with SRBC do not produce
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Figure 3. 1 BATF Is Required for B Cells to Express AID and Produce IgG1.
(A) BatfKI/KI and BatfZ/Z splenic B cells were labeled with CFSE and cultured with LPS
and IL-4. CFSE dilution was analyzed by flow cytometry. Gating (bar, top panel)
determined the percent of proliferating cells (bottom). n=4 of each genotype. (B) B
cells isolated from BatfKI/KI and BatfZ/Z spleens were cultured (+/-) LPS and IL-4 and
protein extracts immunoblotted to visualize the indicated proteins. Signals were
normalized to HSP90 and values expressed for each protein are relative to the signal in
unstimulated BatfKI/KI B cells (set to 1.0). n=4 for each genotype/treatment. A
representative blot is shown. (C) Media from cultured BatfKI/KI and BatfZ/Z B cells was
screened by ELISA for the indicated Ig. n=4 for each genotype. ***P<0.0001; ns=not
significant.
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Figure 3.2 BatfZ/Z Mice Do Not Respond to T Cell Dependent Antigen.
(A) Immunofluorescence was performed to visualize germinal centers in BatfKI/KI mice
and BatfZ/Z mice injected with SRBCs or Mock injected with PBS. n=4 for each
genotype and treatment. Scale bars indicate 50 M (B) BatfKI/KI mice and BatfZ/Z mice
injected with SRBCs or Mock injected with PBS, and immunofluorescence was
performed on the spleen to visualize class switched Ig. A representative image is
shown. Scale bars indicate 50 M. n=4 mice of each genotype and treatment. (C) Serum
was collected from BatfKI/KI mice and BatfZ/Z mice used in A and B and assayed by
ELISA for the production of IgM and class switched IgG1 antibodies. Assays were
performed in triplicate. n=4 mice of each genotype and treatment. **P<0.01;
***P<0.001; NS=no significance.
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specific class switched IgG1 against this antigen (Figure 3.2C). TNP-LPS is a T cell independent
antigen which directly binds B cell pattern recognition receptors (PRRs) and signals B cells to
differentiate and undergo CSR. Because there is no interaction with Tfh cells, the B cells do not
form germinal centers. Immunohistochemistry was used to visualize class switched Ig production
in TNP-LPS injected mice.

Spleen sections from BatfZ/Z mice injected with TNP-LPS were

negative for CSR while those from control BatfKI/KI mice showed strong reactivity (Figure 3.3A).
ELISA to detect TNP-LPS specific antibodies in serum from BatfKI/KI mice and BatfZ/Z mice
confirmed the staining results (Figure 3.3B). Mock injected BatfKI/KI animals did not produce
IgG1 or IgG2c by staining or by ELISA showing their immune system was not activated through
IP injection alone (Figure 3.3A and 3.3B).

3.2.2 BATF Regulates Gene Targets Critical for CSR after B Cell Activation.
The gene expression program required for CSR is well known (Stavnezer et al., 2008), yet
the role of BATF in that program is poorly characterized. To begin to define this role, a timecourse study was performed to track BATF expression in B cells following stimulation. B cell
transcripts known to be downregulated (Pax5, Bcl6, Pou2af1), or elevated (Irf4, Prdm1, Aicda the gene encoding AID) during CSR were used as controls (Figure 3.4A).

Batf mRNA was

expressed at low, almost undetectable, levels in the resting B cells, but accumulated 6 hrs after
stimulation (Figure 3.4B). Almost as rapidly as Batf mRNA was induced, its levels were downregulated, before gradually increasing again as Aicda mRNA also accumulates (Figure 3.4A and
3.4B). The pattern of BATF protein expression in B cells (Figure 3.4C) mirrors the biphasic

56

Figure 3.3 BatfZ/Z Mice Do Not Respond to T Cell Independent Antigen.
(A)BatfKI/KI mice and BatfZ/Z mice injected with TNP-LPS or mock injected with PBS.
Splenic tissue was stained for immunohistochemistry to detect class switched Ig. A
representative image is shown. Scale bars indicate 50 M n=4 mice of each genotype and
treatment. (B) Serum was collected from BatfKI/KI mice and BatfZ/Z mice used in A. An
ELISA was performed to quantify secreted Ig. Assays were performed in triplicate. n=4 mice
of each genotype and treatment. Error Bars represent SEM. **p<0.01; NS= No Significance.
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Figure 3.4 BATF mRNA and Protein Has a Biphasic Expression Pattern.
(A and B) B cells cultured from a wild type spleen were harvested for RNA at the indicated
times following stimulation with LPS and IL-4. RNA was converted to cDNA and qPCR
performed in duplicate to detect the indicated transcripts. Results are expressed relative to
levels at 0 hr (set to 1.0). n=4 mice. (C) B cells from wild type spleens were harvested for
protein at the times shown following stimulation with LPS and IL-4 and immunoblotted to
detect the indicated proteins. HSP90 serves as the loading control. Cells from 2 spleens were
pooled for each blot. n=8 mice. A representative blot is shown.
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pattern of Batf mRNA expression. This demonstrates, as was previously shown in T cells, that
BATF protein is rapidly turned over in B cells and that Batf mRNA accurately reflects levels of
BATF protein in cells (Thornton et al., 2006).
To further investigate the role of BATF expression in driving CSR early in B cell
activation, RNA-Seq was performed using wild type and BatfZ/Z B cells stimulated with LPS and
IL-4 for only 6 hours. The initial analysis was performed by the Purdue Bioinformatics Center.
Initially, four wild type mice and four BatfZ/Z mice were used for this experiment, but one
replicate for the knockout treatment (KO1163) degraded during the preparation for sequencing and
therefore could not be included in the analysis. Sequence quality was assessed and quality
trimming was performed to remove bases with less than Phred33 score of 30. Only reads of at
least 50 bases were mapped against the bowtie2-indexed mouse genome using Tophat. Counts for
each sample were merged and used for downstream differential gene expression analysis. An
analysis of the data using edgeR identified 353 differentially expressed genes, with 133
upregulated and 220 downregulated in the BatfZ/Z cells compared to wild type (GSE106427).
The top 50 significantly altered genes are presented in a heat map (Figure 3.5A). Additionally,
44% of the Gene Ontology (GO) categories into which these altered genes fit are related to immune
cell processes. The top fifteen of those categories are listed in Figure 3.5B.
To further narrow down the list of BATF targets that would be of highest interest, I used
the EdgR analysis, GO analysis, and a literature search. First, the most significantly altered genes
were identified and compared to the GO analysis. Second, genes were selected with a variety of
functions ranging from transcription factors to secreted proteins already shown to be critical for B
cell development, activation, or

59

Figure 3.5 Transcriptional Analysis of BatfZ/Z B Cells by RNA-Seq.
(A) Heatmap of the top 50 significantly altered genes in Batf ΔZ/ΔZ B cells stimulated for 6
hrs with LPS and IL-4. RNA prepared from 4 wild type and 3 BatfZ/Z mice were compared
using RNA-Seq. (B) The top 25 GO: Biological Processes pathways represented by the
genes identified by the RNA-Seq.
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differentiation. Third, the genes in the RNA-Seq data set were compared to an RNA-Seq data set
generated by Ise et. al (2011) and to 2 different BATF ChIP-seq data sets generated by Glasmacher
et al. (2012) and Li et al. (2012). Through this process, seven potential positive targets of BATF
transcriptional activity (Aicda, Il-6, Egr2, Lat2, Slamf6, Nfil3, and Ezh2) and three potential
negative targets of BATF transcriptional activity (Serpinb9, Wnt10a, and Il-10) were selected for
further investigation. In addition to these genes, I selected an miRNA (miR155) that had been
shown to be critical for Aicda expression and AID function and that a previous student in the lab
had shown was under-represented in BatfZ/Z B cells (Poston and Taparowsky, unpublished data).
The seven genes that are potential positive targets for BATF have also been shown in
previous studies to play different roles in B cell signaling pathways. Aicda is specifically
expressed in GC B cells and is required for SHM and CSR (Okazaki et al., 2007; Stavnezer et al.,
2008). LAT2 is a large heterodimeric amino acid transporter. It is involved in B cell receptor
(BCR) aggregation in B cells which is required for B cells to become antibody secreting cells.
LAT2 also recruits signaling molecules to BCR signaling complexes (del Amo, Urtti, &
Yliperttula, 2008). SLAMf6 is a cell surface glycoprotein involved in B activation. It is required
for effective germinal center formation and generation of high affinity antibody secreting cells (De
Salort, Sintes, Llinàs, Matesanz-Isabel, & Engel, 2011).

NFIL3 is a basic leucine zipper

transcription factor that is induced by IL-4 and IL-10 though the JAK-STAT pathway. It is
involved in CSR, specifically IgE production, and plays an anti-apoptotic role in B cells in a
cytokine dependent manner (Kashiwada et al., 2010). EGR2 is a zinc finger transcription factor
that is important in the development of B cells. It is also involved in the inflammatory response,
in antigen receptor induced AP-1 activation, and in the production of IL-2, which is required for
B cell proliferation. A recent study has shown that EGR2 may directly interact with BATF in an
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early stage of B cell activation (S. Li et al., 2012). Finally, EZH2 is highly expressed in germinal
center B cells to enhance cell proliferation by repressing cell cycle check point genes (Béguelin et
al., 2013).
There are three genes that are potential negative targets for BATF in B cells. SERPINB9
is a potent inhibitor of human granzyme B. Through this pathway SERPINB9 plays an antiapoptotic role in B cells (Kaiserman & Bird, 2010). WNT10A is a secreted growth factor that
binds to FRIZZLED receptors. It induces signaling cascades for cell growth and differentiation at
many points in B cell development. (Lu et al., 2004). In addition, it has been shown that WNT
signaling inhibits ASC differentiation preventing B cells from secreting class switched Ig
(Sertorio, Amarachintha, Wilson, & Pang, 2014).

IL-10 is an anti-inflammatory cytokine

produced by in many different immune cells. In B cells, IL-10 plays a regulatory roll and is
important role in controlling autoimmunity (Fillatreau, Sweenie, McGeachy, Gray, & Anderton,
2002; Mauri & Bosma, 2012).
To verify the selected candidates as BATF targets, B cells isolated from BatfZ/Z mice and
wild type mice were stimulated for 48hr with 20µg/mL LPS and 20ng/mL IL-4. RT-qPCR
confirmed that the absence of BATF correlated with low expression levels of Aicda, Il-6, Egr2,
Lat2 Nfil3,Slamf6, and Ezh2 mRNA (Figure 3.6A) and high expression levels of Wnt10a and Il10 mRNA (Figure 3.6B). Serpinb9 did not show differential mRNA expression in BatfZ/Z B
cells versus BatfKI/KI B cells after 48hr of stimulation and thus was eliminated from my list (Figure
3.6B). Although miR155hg expression is not
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Figure 3.6 Confirmation of BATF Target Genes.
B cells from spleens of BatfKI/KI and BatfZ/Z mice were cultured in media +/- LPS and IL-4 for
48hrs. RT-qPCR was used to detect the indicated transcript levels, in duplicate. Transcript levels
are expressed relative to those in unstimulated BatfKI/KI B cells (set to 1.0). n=4 for each genotype.
(A) Genes identified as potentially positively regulated by BATF. (B) Genes identified as
potentially negatively regulated by BATF. (C) control genes. Error Bars represent SEM. *p<0.05;
**p<0.01; ***p<0.001; NS= No Significance.
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significantly lower in BatfZ/Z B cells stimulated for 6hrs, its expression is significantly altered
after 48hrs of stimulation in BatfZ/Z B cells (Figure 3.6B). For this study, Irf4 and Pax5 were
used as controls as their expression levels do not change in BatfZ/Z mice compared to wild type
mice (Figure 3.6C).
Among the differentially expressed genes in the BatfZ/Z B cells, three genes were chosen
for further study. Nfil3 encodes a bZIP transcription factor which, like BATF, is required for Th17
differentiation (Yu et al., 2013) and for B cell CSR (Kashiwada et al., 2010). Nfil3 shows a 1.7
log fold decrease in BatfZ/Z B cells suggesting that BATF is required for Nfil3 induction following
B cell stimulation.

Wnt10a encodes a secreted glycoprotein whose mRNA is detected at low

levels in normal lymphocytes and in bone marrow, yet shows increased expression in human
leukemia cell lines (Lu et al., 2004; Sercan, Pehlivan, & Sercan, 2010). Wnt10a shows a 1.5 log
fold increase in BatfZ/Z B cells indicating that it is a target of negative regulation by BATF. A
third molecule I chose to investigate is miR155 which is transcribed from the miR155gh (Bic) gene
(Elton, Selemon, Elton, & Parinandi, 2013; Faraoni, Antonetti, Cardone, & Bonmassar, 2009).
MicroRNAs were not captured in the starting material prepared for the RNA-Seq. However,
miR155 has been shown to regulate Aicda expression and CSR (Teng et al., 2008) and the results
of a survey of microRNA expression in BatfZ/Z cells performed by another student in our
laboratory noted that miR155 is barely detectable in both BatfZ/Z B cells and BatfZ/Z T cells
(Poston and Taparowsky, unpublished data).
To further verify that these three genes are potential BATF targets, it was important to
determine when during B cells activation they are expressed. Nfil3
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Figure 3.7 Time-course of Nfil3, MiR155hg, and Wnt10a Expression in B Cells.
Wild type B cells were stimulated with LPS and IL-4 and RNA prepared at the indicated time
points. RT-qPCR was used to assay for the indicated transcripts, in duplicate. Results are
expressed relative to levels at 0 hr (set to 1.0). n=4 mice.

expression begins to rise and Wnt10a expression begins to decrease at 6hrs indicating that these
genes may be affected by BATF early in B cell activation (Figure 3.7). This timing correlates to
when BATF expression first peaks (Figure 3.4B). MiR155hg is not expressed until 12hrs after B
cell activation (Figure 3.7). BATF expression peaks a second time at 48-72 hours after B cell
activation and (Figure 3.4B). It is at this time point that BATF could potentially be regulating
miR155hg as it is still highly expressed (Figure 3.7).
3.2.3 Restoring BATF Expression in BatfZ/Z B cells Using MSCV Retroviruses.
To confirm that that altered gene expression in BatfZ/Z B cells was due to the absence of
BATF and not the result of accumulated defects imposed by the global knockout of BATF through
multiple generations, a retrovirus containing BATF was generated as described in Materials and
Methods (Chapter 2) and used to perform rescue experiments. Resting B cells from BatfKI/KI and
BatfZ/Z mice were cultured in vitro and treated as described with a control MSCV-Thy1.1 or with
the BATF expressing retrovirus, MSCV-BATF (MSCV-Thy1.1-IRES-HA-BATF). Successfully
transduced cells (Thy1.1+) were isolated by FACS (Figure 3.8A). The average transduction
efficiency for MSCV was 70% and the average transduction efficiency for MSCV-BATF was 56%
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(Figure 3.8B). This level of efficiency enabled enough cells to be sorted for both mRNA and
protein analysis.
Not only did the BATF retrovirus restore robust levels of BATF protein in BatfZ/Z B cells,
but restoration of BATF resulted in the induction of AID protein (Figure 3.9A) and Aicda
transcripts (Figure 3.9B). The expression of other CSR associated genes (Pax5, Bcl6, Irf4, and
Prdm1) remained intact (Figure 3.9C). In

Figure 3.8 Determining the Transduction Efficiency of MSCV and
MSCV-BATF Retroviruses.
B cells isolated from spleens of BatfZ/Z mice were transduced with MSCV or
MSCV-BATF, stimulated for 72 hrs and stained for profiling by flow cytometry.
(A) Plots show gating for THY1.1+ B cells from each group. (B) Graphs represent
the percent of total B cells transduced with MSCV or MSCV-BATF. Error Bars
represent the SEM. NS=No Significance
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Figure 3.9 BATF Re-expression Restores Gene Expression and CSR in BatfZ/Z B Cells.
(A) B cells from BatfKI/KI and BatfZ/Z spleens were activated with LPS and IL-4 and transduced
with MSCV or MSCV-BATF retroviruses. Transduced cells (Thy1.1+) were isolated by FACS and
extracts immunoblotted to detect the indicated proteins. Each sample is from one mouse. A
representative blot is shown. n=6 for each genotype and treatment. (B) RNA was isolated from
BatfKI/KI and BatfZ/Z B cells that were activated, transduced and sorted as in A. RT-qPCR was
used to detect Aicda transcripts, in duplicate. n=6 for each genotype and treatment. Results are
expressed relative to levels in unstimulated, BatfKI/KI B cells (set to 1.0 and not shown). (C-E) RNA
and miRNA were prepared from BatfKI/KI and BatfZ/Z B cells cultured as in A. RT-qPCR was
used to detect the indicated RNAs, in duplicate. n=4 for each genotype and treatment. RNA levels
are expressed relative to those in unstimulated BatfKI/KI B cells (set to 1.0 and not shown). Error
Bars represent SEM. *p<0.05; **p<0.01; ***p<0.001; NS= No Significance
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addition, MSCV-BATF was able to restore expression of Nfil3, miR155hg, and Wnt10a verifying
that by re-expressing BATF early during B cell activation, the expression of these potential target
genes can be fully restored (Figure 3.9D). QPCR was used to determine if MSCV-BATF could
rescue the other potential BATF target genes identified by the RNA-Seq. While MSCV-BATF
did restore a wild type expression pattern for Egr2, Slamf6, Ezh2, Lat2, and Il-10, expression of
Il-6 was not rescued (Figure 3.9E).
MSCV-BATF transduced B cells were further analyzed for class switched Ig production.
Flow cytometry was used to determine if MSCV-BATF could restore surface expression of both
IgG1 and IgE (Figure 3.10A and B) and expressing γ1 and ε GLT (Figure 3.10C). In addition, BatfΔZ/ΔZ B cells
transduced with MSCV-BATF also generated cultures capable of producing class switched IgG1 while
MSCV alone failed (Figure 3.10D). As previously observed by Betz et al. (2010) and Ise et al. (2011), IgM
surface expression or IgM secretion was not affected in BatfΔZ/ΔZ B cells (Figure 3.9B and 3.9C).

3.2.4 BATF Binds as Predicted to Target Gene Loci.
Nfil3, Wnt10a and mir155gh contain consensus sequences for binding BATF containing
transcription complexes associated with the activation (AICE) or repression (AP-1) of gene
transcription (Figure 3.11). To test if BATF directly binds to these DNA sites, chromatin
immunoprecipitation (ChIP) was performed using wild type mouse B cells and an antiserum
specific for BATF (see Chapter 2 for details).

Purified DNA was analyzed by PCR for the

presence of fragments spanning key AICE or AP-1 motifs. A previous study by another graduate
student in the lab had identified an AP-1 site from the promoter region of Myb as a direct target
for repression by BATF:JUN in mouse myeloid
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Figure 3.10 Detecting Ig Expression in B Cells Transduced with MSCV Retroviruses.
(A) B cells isolated from spleens of BatfZ/Z mice were transduced with MSCV or MSCV-BATF,
stimulated for 72 hrs, and stained for analysis by flow cytometry. Cells were gated for THY1.1.
IgM+ cells were then profiled for IgG1+ (top) or IgE+ (bottom) as shown. (B) Quantification
surface IgG1 and IgE expression of transduced B cells from (A) n= 6 for each genotype and
treatment. (C) BatfKI/KI and BatfΔZ/ΔZ B cells transduced with the indicated virus were FACS sorted
and RNA was isolated. RT-qPCR was used to detect the indicated transcripts, in duplicate. Results
are normalized to Gapdh and are expressed relative to levels in MSCV-transduced BatfKI/KI B cells
(set to 1.0) n=6 mice of each genotyped and treatment (D) Media from cell cultured in C was used
to perform an ELISA to detect secreted Ig. n=6 mice of each genotype. Error bars represent the
SEM. *p<0.05; **p<0.01; ***p<0.001; NS= No Significance.
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Figure 3.11 Location of AP-1 and AICE Sites in Putative Batf Target Genes.
(A) Schematic of the location of key AP-1 and AICE containing DNA fragments within
the indicated genes. Exons are represented by black boxes. Genes are not drawn to scale
and not all are complete. Numbers indicate the position on the gene, where the AP-1 or
AICE motifs are located in relation to the transcriptional start site (+1).
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leukemia cells (Liao et al., 2011). Detection of this DNA (AP-1E) served as a positive control,
while a second AP-1 site from Myb that is not bound by BATF:JUN (Liao et al., 2011) served as
the negative control (AP-1N) (Figure 3.11).
ChIP-qPCR indicated that BATF binds to AICE (A) of Nfil3 and to AP-1 (B) of Wnt10a 7
hrs following B cell stimulation, but is not bound at these sites 48 hrs post- activation (Figure
3.12A).

Other consensus sites identified within these two genes showed no significant

amplification (Figure 3.12A). On the other hand, BATF binds strongly to AICE (B) motif of
miR155hg at 48hr, but not at 7 hrs, post activation. Again, binding was not observed at the
upstream AICE (A) of miR155hg at either time point (Figure 3.14A). ChIP of the same material
using an antibody to detect acetylation of histone H3 at lysine 27 confirmed that the BATF binding
at AICE (A) of Nfil3 and AICE (B) of miR155hg is associated with an active chromatin
configuration (Figure 12B). As expected, H3 acetylation was not a feature of the AP-1 (A) of
Wnt10a or the AP-1 (E) of Myb (Figure 3.12B) since BATF binding to these genes correlates with
the repression of gene transcription. H3 acetylation was also not associated with any of the other
sites tested from the Nfil3, miR155gh or Wnt10a genes (Figure 3.14B).
To confirm that the BATF antibody was only immunoprecipitating chromatin with BATF
and not containing BATF2 or BATF3, chromatin was isolated from BatfKI/KI mice, which express
BATF tagged with HA, and from BatfΔZΔZ mice, which contain no BATF. The IP was performed
using an α-HA antibody to specifically pull down genes bound by HA-BATF. As previously seen,
HA-BATF binds strongly to the AICE (B) motif of miR155hg only at 48hrs post activation (Figure
3.13A). It was also confirmed that BATF binds only the AICE (A) motif of Nfil3 and the AP-1
(A) motif of Wnt10a
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Figure 3.12 BATF Binding Accompanies Regulation of Nfil3, MiR155hg and
Wnt10a Expression.
B cells isolated from wild type spleens were stimulated for 7hrs or 48hrs with LPS and
IL-4. Chromatin was prepared and ChIP was performed to detect binding of BATF (A)
or acetylation of H3K27 (B) at the indicated AP-1 or AICE motifs of the Nfil3,
Mir155gh and Wnt10a genes (see Figure 11). An -BATF antibody was used for the IP.
BATF binding previously associated with repression of the Myb gene (AP-1E) was used
as a positive control. A non-bound AP-1 site from Myb (AP-1N) was used as a
normalization control for background. n=4 for each time point. DNA associated with
H3K27 acetylation is expressed as a % of total input. n=4 for each time point. Error
bars represent the SEM. **p<0.01; ***p<0.001; NS= No Significance.
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Figure 3.13 Confirmation that BATF Regulates Nfil3, MiR155hg and Wnt10a
Expression using BatfKI/KI and BatfZ/Z Mice.
B cells isolated from BatfKI/KI and BatfZ/Z spleens were stimulated for 7hrs or 48hrs with
LPS and IL-4. Chromatin was prepared and ChIP was performed to detect binding of BATF
using an -HA antibody in BatfKI/KI B cells (A) or in BatfZ/Z B cells (B) at the indicated
AP-1 or AICE motifs of the Nfil3, Mir155gh and Wnt10a genes (see Figure 11). Myb (AP1E) was used as a positive control, and a non-bound AP-1 site from Myb (AP-1N) was used
as a normalization control for background. n=4 for each time point. Error bars represent the
SEM. *p<0.05; **p<0.01; ***p<0.001; NS= No Significance.

73

Figure 3.14 BATF Does Not Bind All AP-1 and AICE Motifs on Nfil3,
miR155hg and Wnt10a
(A -D) ChIP-qPCR was performed using chromatin isolated from wild type, BatfKI/KI, and
BatfZ/Z B cells stimulated with LPS and IL-4 for 7hrs or 48hrs. n=4 mice for each time
point. BATF binding (A) was detected in wild type B cells using -BATF antibody and
quantified as a fold enrichment over background binding to an unoccupied site in Myb
(AP-1N). The level of acetylated histone at each site (B) was detected wild type B cells
using -H3K27ac antibody and was expressed relative to input. n=4 mice for time point.
(C and D) BATF binding was detected in BatfKI/KI and BatfZ/Z B cells using and -HA
antibody. The fold enrichment was quantified over background binding to an unoccupied
site in Myb (AP-1N). n=4 mice for each time point. Error bars represent the SEM. NS=
No Significance.
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Figure 3.15 JUNB Binds the Same AICE and AP-1 Motifs as BATF on Nfil3,
MiR155hg and Wnt10a.
B cells isolated from wild type spleens were stimulated for 7hrs or 48hrs with LPS and IL-4.
Chromatin was prepared and ChIP was performed to detect binding of BATF at the indicated
AP-1 or AICE motifs of the Nfil3, Mir155gh and Wnt10a genes (see Figure 3.11). An JUNB antibody was used for the IP. Myb gene (AP-1E) was used as a positive control and a
non-bound AP-1 site from Myb (AP-1N) was used as a normalization control for background.
n=4 for each time point. Error bars represent the SEM. **p<0.01; ***p<0.001; NS= No
Significance.
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7hrs post activation, but not at 48hrs (Figure 3.13A). In addition, no binding was observed on any
of the other identified AP-1 or AICE motifs of Nfil3, miR155hg, or Wnt10a in BatfKI/KI B cells
(Figure 3.14C). The ChIP-qPCR performed on B cells from BatfΔZΔZ mice indicated that the αHA antibody was specific to HA-BATF. No binding was observed on any of the positive AP-1 or
AICE motifs (Figure 3.13B) or negative AP-1 or AICE motifs (Figure 3.13C) of Nfil3, miR155hg,
or Wnt10a.
To further verify that these AICE and AP-1 motifs that were binding BATF complexes, a
ChIP experiment was performed using an α-JUNB antibody in wild type B cells activated for 7hrs
or 48hrs. ChIP-qPCR indicated that JUNB bound that same AP-1 and AICE motifs as BATF. The
AP-1 (B) motif of miR155hg was bound by JUNB only at 48hrs post activation (Figure 3.15),
while the AICE (A) motif of Nfil3 and the AP-1 (A) motif of Wnt10a were only bound by JUNB
7hrs post activation (Figure 3.15). The other AP-1 and AICE motifs analyzed did not show JUNB
binding at 7hrs or 48hrs post activation (Figure 3.15).

3.2.5 Restoring AID Expression in BatfZ/Z B cells Using MSCV Retroviruses.
To determine the transduction efficiency of the MSCV-AID-GPF virus, the virus was
transduced into Hela cells. There were four experimental groups for this preliminary study. Group
1 was the controls. The cells in this plate were only treated with polybrene. In the three other
experimental groups, one was treated with 1 L of virus, the second with 2 L of virus, and the third
with 4 L of virus. After 48 hours of culture, the plates of Hela cells were imaged under white light
to determine cell number and GFP was imaged in dark field under a FITC filter to determine the
transduction efficiency.
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The control group had live cells, but, as expected, did not express any GFP (Figure 3.16A).
In the groups transduced with MSCV-AID, all had GFP+ cells but at different levels. The Hela
cells transduced with 1 L of virus showed very low transduction efficiency (Figure 3.16A). The
Hela cells transduced with 2 L and 4 L of virus also had low transduction efficiencies, but the
level was potentially high enough for analysis and sorting. B cells were subsequently transduced
with 4 L of the virus. The flow cytometry profile showed that 1.5% of the cells were GFP+
(Figure 3.16B). This population of B cells was sorted by FACS and RNA was isolated for
analysis.
MSCV-AID restored robust AID expression in Batf Z/Z B cells without altering expression
of IRF4 or BATF (Figure 3.17A). Expression of Nfil3, miR155hg, and Wnt10a was not restored
(Figure 3.17B) indicating that these BATF target genes are regulated upstream of AID. Media
from B cells transduced with MSCV-AID and cultured with LPS and IL-4 stimulation for 72hrs
was analyzed for surface expression of class switched Ig in Batf Z/Z B cells and BatfKI/KI B cells.
Interestingly, although AID is the enzyme responsible for CSR in B cells, MSCV-AID did not
rescue CSR in BatfZ/Z B cells, while BatfKI/KI B cells transduced with MSCV or MSCV-AID
expressed IgG1 and IgE (Figure 3.17C). This indicates that expression of AID without BATF is
not able to activate the program of CSR. BATF and the BATF-mediated regulation of its target
genes (ie. Nfil3, miR155hg, and Wnt10a) are absolutely necessary for AID to work as the major
enzymatic activity required for B cell CSR.
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Figure 3.16 Determining the Transduction Efficiency of MSCV-AID.
(A) Hela cells were transduced with different concentrations of MSCV-AID and cultured
for 48hrs. Cells were imaged for GFP+ cells. Scale Bars indicate 50 M. n=3 for each
group. (B) B cells isolated from spleens of Batf Z/Z mice were transduced with MSCV
or MSCV-AID, stimulated for 72 hrs, stained and profiled by flow cytometry. Plots
show gating for GFP+ B cells from each group. n=4 mice for each group.
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Figure 3.17 AID Re-expression in BatfZ/Z B Cells Fails to Restore Gene Expression and CSR.
(A) B cells from BatfKI/KI and BatfZ/Z spleens were activated with LPS and IL-4 and transduced with
MSCV or MSCV-AID retroviruses. Transduced cells (GFP+) were isolated by FACS and extracts
immunoblotted to detect the indicated proteins. Each sample is from one mouse. A representative blot
is shown. The experiment was repeated 2 times using 2 mice for each genotype and treatment. (B) RNA
was isolated from BatfKI/KI and BatfZ/Z B cells that were activated, transduced and sorted as in A. RTqPCR was used to detect the indicated transcripts, in duplicate. n=6 for each genotype and treatment.
Results are expressed relative to levels in unstimulated, BatfKI/KI B cells (set to 1.0 and not shown). (C)
B cells from BatfKI/KI and BatfZ/Z spleens cultured as in A were profiled for surface expression of class
switched Ig by flow cytometry. n=6 for each group. Error bars represent the SEM. *p<0.05; **p<0.01;
***p<0.001; NS= No Significance.
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3.2.6 Positioning BATF and Its Targets Within the CSR Network.
These studies suggest that BATF functions during the early stages of CSR to regulate the
expression of molecules that will subsequently coordinate transcription (NFIL3), modulate cellular
signaling pathways (WNT10A) and influence the efficiency of mRNA accumulation and/or
translation (miR155). In an effort to position these BATF targets in the CSR network relative to
each other and downstream of BATF, retroviruses were generated for Nfil3, miR155, and Wnt10a
as described in Chapter 2. In addition, an
Irf4 retrovirus was generated as a control. IRF4 expression is not directly regulated by BATF but
is required for CSR.
Three separate experiments were performed as controls. First, Hela cells were transduced
with MSCV-NFIL3, MSCV-WNT10A, or MSCV-IRF4 and protein was harvested after 24hrs.
Immunoblotting confirmed that the viruses generated protein (Figure 3.18A). Second, BatfZ/Z B
cells and BatfKI/KI B cells were transduced with the MSCV or MSCV-miR155 plasmid and miRNA
isolated. RT-QPCR was used to confirm that miR155 was expressed by the virus (Figure 3.18B).
Third, each virus was subsequently transduced into primary B cells and the transduction efficiency
determined by analyzing expression of Thy1.1 using flow cytometry. B cells proliferate normally
when transduced with each virus including MSCV-WNT10A (Figure 3.18C). All four viruses
had a high transduction efficiency, with MSCV transducing 88.9% of B cells, MSCV-IRF4
transducing 70% of B cells, MSCV-NFIL3 transducing 69.3% of B cells, MSCV-miR155
transducing 41% of B cells, and MSCV-WNT10A transducing 78.3% of B cells (Figure 3.18D).
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Figure 3.18 Retroviruses Efficiently Drive Expression of NFIL3, WNT10A and
MiR155 in Cells.
(A) HeLa cells were transduced with MSCV-IRF4, MSCV-NFIL3, or MSCV-WNT10A.
After 24 hrs, protein extracts were prepared and immunoblotted to detect expression of the
indicated mouse proteins. Detection of human HSP90 was used as a loading control. Two
independent experiments were performed, and samples were transduced in duplicate. A
representative blot is shown. n=8. (B) miRNA was isolated from B cells transduced with
MSCV or MSCV-miR155. miRNA155 was quantified by RT-qPCR and results expressed
relative to levels detected in MSCV transduced BatfKI/KI B cells (set to 1.0). n=4 mice in each
group. (C) B cells isolated from spleens of Batf Z/Z mice were transduced with the indicated
retrovirus, stimulated for 72 hrs and stained for profiling by flow cytometry. Plots show gating
for THY1.1+ B cells from each group. n=6. Error bars represent the SEM. NS=No
Significance.
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MSCV-IRF4 was transduced into primary BatfZ/Z B cells as described in Chapter 2 to
determine if virus infection and expression of exogenous proteins had any off target affects
resulting in AID expression and CSR. IRF4 is not regulated by BATF and should not restore CSR
in BatfZ/Z B cells. Immunoblotting revealed increased IRF4 expression in transduced B cells and
the inability of that virus transduction event to restore BATF or AID expression (Figure 19A).
RNA analysis revealed a significant increase in Irf4 expression in MSCV-IRF4 transduced
BatfZ/Z B cells (Figure 19B), and confirmed that IFR4 over-expression did not change the status
of Batf, Aicda, Pax5, Nfil3, miR155hg, and Wnt10a mRNA (Figure 19C). As expected, Pax5
expression, a control gene, was not affected by IRF4 (Figure 19C). Flow cytometry for cell surface
Ig confirmed that MSCV-IRF4 could not rescue IgG1 or IgE in BatfZ/Z B cells (Figure 19D).
To further understand how the CSR-deficient phenotype of BatfZ/Z B cells relies on the
function of BATF target molecules, we employed MSCV-Thy1.1 vectors expressing NFIL3,
WNT10A and miR155 (Figure 3.18A and B) to restore NFIL3 and miR155 in BatfZ/Z B cells or
constitutively express WNT10A in wild type (BatfKI/KI) B cells. Transduction with these viruses
had no deleterious effect on B cell proliferation in response to LPS and IL-4 (Figure 3.18C).
Exogenous expression of NFIL3 or miR155 in stimulated BatfZ/Z B cells rescued Aicda mRNA
expression (Figure 3.20A) within 48 hrs and allowed for the production of both IgG1 and IgE by
96 hrs (Figure 3.20B).

Similarly, expression of WNT10A in BatfKI/KI cells blocked Aicda

expression and CSR (Figure 3.20A and 3.20C), despite the cells retaining normal levels of BATF.
Expression of γ1 and GLT was assayed and transcripts were detected in the cells
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Figure 3.19 Over-expression of IRF4 in BatfZ/Z B cells Does Not Restore Nfil3,
MiR155hg, or Wnt10a Expression or CSR.
(A) B cells from BatfKI/KI and BatfZ/Z spleens were activated with LPS and IL-4 and
transduced with MSCV or MSCV-IRF4 retroviruses. Transduced cells (Thy1.1+) were
isolated by FACS and extracts immunoblotted to detect the indicated proteins. Each
sample is from one mouse. A representative blot is shown. n=6 for each genotype and
treatment. (B-C) RNA was isolated from BatfKI/KI and BatfZ/Z B cells that were activated,
transduced and sorted as in A. RT-qPCR was used to detect the indicated transcripts, in
duplicate. n=6 for each genotype and treatment. Results are expressed relative to levels in
unstimulated, BatfKI/KI B cells (set to 1.0 and not shown). (D) B cells from BatfKI/KI and
BatfZ/Z spleens cultured as in A were profiled for surface expression of class switched Ig
by flow cytometry. n=6 for each group. Error bars represent the SEM. *p<0.05; **p<0.01;
***p<0.001; NS=No Significance
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Figure 3.20 NFIL3, MiR155 and WNT10A Impact Aicda Expression and CSR.
(A) B cells from BatfKI/KI and BatfZ/Z spleens were activated with LPS and IL-4 and
transduced with the indicated retroviruses. Transduced cells (Thy1.1+) were isolated by
FACS, RNA prepared and RT-qPCR used to detect expression of the transcripts
indicated. In this case, expression is normalized to the level in stimulated, MSCVtransduced BatfKI/KI B cells (set to 1.0). n=6 for each group. (B and C) BatfKI/KI and
BatfZ/Z B cells transduced with the indicated retroviruses were sorted for Thy1.1+ cells
and profiled for surface Ig expression by flow cytometry. n=6 for each group. Error bars
represent the SEM. *p<0.05; **p<0.01; ***p<0.001; ns=no significance.
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transduced with MSCV-NFIL3 and MSCV-miR155 (Figure 3.20D).

Interestingly, for the

WNT10A expressing cells, where AID is fully silenced, a low level of GLT expression was
retained (Figure 3.20E). Together, these results indicate that BATF regulates a number of genes,
each critical, in their own right, for events leading to CSR.
RNA samples isolated from BatfZ/Z B cells transduced with MSCV-NFIL3 or MSCVmiR155 and from Batf

KI/KI

cells transduced with MSCV-WNT10A were examined for the

expression of all three molecules. As shown in Figure 3.21, restoring NFIL3 expression does not
alter the pattern of Wnt10a or miR155hg expression in these cells, allowing for the positioning of
NFIL3 as a proximal inducer of AID expression, γ1 and GLT expression and CSR (Figure 3.20B
and D). On the other hand, restoring miR155 also restores the normal pattern of Nfil3 induction
and Wnt10a repression in BatfZ/Z B cells (Figure 3.21), suggesting that miR155 can substitute
for BATF as an initiator of the process. Interestingly, expression of WNT10A in BatfKI/KI B cells
has no impact on the normal induction of Nfil3 or miR155hg (Figure 3.21), although its elevated
expression efficiently blocks CSR and γ1 and GLT expression (Figure 3.20A and 3.20C). This
points to opposing roles for WNT10A and NFIL3 in events proximal to the induction of CSR and
suggests that the relative levels of each protein in cells may dictate the dominance of one pathway
over the other.

3.3 Discussion
It is well appreciated that dozens of molecular events are required for CSR and that these
events are coordinated in a network that initiates with a B cell stimulus and culminates with the
production of class switched Ig. Previous studies demonstrated a
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Figure 3.21 NFIL3, miR155 and WNT10A Influence Expression of Each
Other.
(A) BatfKI/KI and BatfZ/Z B cells were activated and transduced with the indicated
retroviruses. Sorted, Thy1.1+ cells were cultured for an additional 48hrs in LPS and
IL-4. RNA was prepared and RT-qPCR was used to detect the indicated transcripts,
in duplicate. Transcripts are normalized using the level of expression in stimulated
BatfKI/KI B cells transduced with MSCV (set to 1.0). n=6 for each group. Error bars
represent the SEM. *p<0.05; **p<0.01; ***p<0.001; ns=no significance.
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critical role for BATF in the antibody response (Betz et al., 2010; Ise et al., 2011). In this chapter,
I have established the requirement for BATF expression very early in the process. Following B
cell stimulation, BATF protein is expressed in a biphasic pattern, with an early spike followed by
a rapid decline and a more steady accumulation as IgM producing B cells begin to express AID
and acquire the ability to produce IgG and IgE.
A similar pattern of BATF mRNA and protein induction was described first in a model
system of myeloid differentiation where BATF is required for the cells to respond to stimulation,
cease proliferating and begin expressing macrophage markers (Liao et al., 2011).

Since then,

biphasic patterns of BATF induction have been described for Th17cells (Ciofani et al., 2012), CD8
T cells (Godec et al., 2015) and Type 1 regulatory T cells (Karwacz et al., 2017). This has led to
categorizing BATF as a pioneering transcription factor responsible for reshaping the genetic
landscape of differentiating T cells. The results from our current work support the role of BATF
as a pioneer transcription factor in B cells. Whereas the induced deletion of Batf at the time of
stimulation completely blocks CSR, deletion after only 6 hours of stimulation allows the B cells
to express AID and to produce class switched antibodies.
To shed light on the function of BATF in the early events leading to CSR, we identified
transcripts that were mis-regulated in BatfZ/Z B cells and chose two genes and one microRNA to
investigate further. Both NfIl3 and miR155gh have been shown to be important to CSR in B cells
(Kashiwada et al., 2010; Teng et al., 2008; Vigorito et al., 2007), although a link to direct regulation
by BATF had not been described. A study has demonstrated the importance of Wnt genes in CSR.
High expression of WNTs prevents B cells from differentiating in to ASCs (Sertorio et al., 2014).
Regulation of Wnt10a by the BATF pathway has not previously been demonstrated and therefore
the link between Wnt10a¸ Batf and CSR was of interest. Restoring BATF expression in BatfZ/Z
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B cells resulted in the appropriate induction, or repression, of these BATF targets. Demonstrating
that BATF binds to consensus DNA in all three loci provided evidence that BATF directly
regulates the expression of these molecules. All three targets, when expressed individually in Batf
Z/Z

B cells (NFIL3 and miR155hg) or in wild type B cells (WNT10A), are capable of inducing

or repressing CSR as expected. Perhaps most interesting was the observed response of these
targets to the expression of one another. For miR155, expression in BatfZ/Z B cells resulted in
Wnt10a repression and Nfil3 induction, apparently through a BATF-independent mechanism.
Expression of NFIL3 exerted no influence on the high levels of Wnt10a mRNA or the low levels
of miR155hg in BatfZ/Z B cells, yet robustly restored CSR.

Similarly, when WNT10A was

expressed constitutively in wild type cells, CSR did not occur, despite the normal induction Batf,
Nfil3 and miR155gh transcripts.
This information can be assembled into a model that attempts to explain the function and
relationship among the molecules I have studied (Figure 3.22). I propose a hierarchy within the
CSR network regulated by BATF, with the more widespread impact of a microRNA (miR155)
functioning at a level equivalent to BATF, while NFIL3 and WNT10A function downstream in
distinct, antagonistic pathways impacting CSR. As shown in Figure 3.21, restoring NFIL3
expression does not alter Wnt10a or miR155hg mRNA levels in these cells, allowing for the
positioning of NFIL3 as a proximal inducer of GLT, AID and CSR (Figure 3.22). On the other
hand, MSCV-miR155 expression (which is not reflected as endogenous miR155gh mRNA)
rescues induction of Nfil3 and leads to a significant repression of Wnt10a in BatfZ/Z B cells
(Figure 21), suggesting that miR155 can substitute for BATF as an initiator of all of these events
(Figure 22). Interestingly, expression of WNT10A in BatfKI/KI B cells has no impact on Batf
(Figure 7A), Nfil3 or miR155hg expression (Figure 3.21), although it was shown to efficiently
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block AID induction and CSR (Figure 3.20A and C). The ability of WNT10A to suppress GLT
in BatfKI/KI cells is not complete, however, implying there are differences in the pathways used by
NFIL3 and WNT10A to influence GLT. On the other hand, the effects of WNT10A and NFIL3
on AID point to opposing roles for these two molecules in the event most proximal to the induction
of CSR (Figure 3.22), suggesting that the relative levels of each protein in cells may dictate the
dominance of one pathway over the other. Experiments in which the levels of NFIL3 and WNT10A
are varied relative to each other will be necessary to test this model. The ability of miR155 to
restore the pattern of Nfil3 and Wnt10a gene expression in the absence of BATF is intriguing.
Future studies to define the mechanism underlying this observation might also help to explain how
the expression profile of these two genes (and not miR155gh) is maintained in CSR when BATF
is experimentally silenced.
Although the process of CSR in B cells is complex, my work has clarified the role of BATF
in the process. The positioning of BATF as an early, or pioneering, regulator of gene expression
that in turn controls additional transcription events through NFIL3, post- transcriptional events via
miR155, and cellular signaling by repressing WNT10A is very exciting. The role of canonical
WNT signaling in the negative regulation of CSR has not been extensively explored until now and
the availability of recombinant WNT10A and WNT pathway inhibitors should facilitate future
study of this pathway. Finally, as
BATF, NFIL3 and miR155 are known regulators of Th2, Th17 and Tfh cell differentiation and
function (Betz et al., 2010; Ise et al., 2011; Male, Nisoli, Gascoyne, & Brady, 2012; Rodriguez et
al., 2007; Schraml et al., 2009), I also tested if the BATF targets studied here are also misregulated
in BatfZ/Z CD4+ T cells (See Chapter 5).

Clearly, the next challenge will be to define the

composition of the pioneering complexes containing BATF and to understand how these
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complexes function to reshape the landscape of the genome in ways that allow additional signals
to drive cells toward different fates.

Figure 3.22 Hierarchy of BATF, NFIL3, MiR155 and WNT10A in
regulating CSR.
Model depicting the primary site of action of the molecules examined in this
study (top) and the hierarchy of these actions in inducing AID expression and
class-switch Ig production in B cells (bottom).
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CHAPTER 4. GENERATION OF A B CELL CONDIATIONAL BATF
KNOCKOUT MOUSE TO STUDY THE ROLE OF BATF DURING B CELL
ACTIVATION

4.1 Introduction
The biphasic pattern of BATF expression in stimulated B cells is consistent with
observations in other immune cell types (Liao et al., 2011) (Ciofani et al., 2012); (Godec et al.,
2015) (Karwacz et al., 2017) and certainly supports the current notion that BATF is a “pioneering”
transcription factor, reshaping the genetic landscape of differentiating immune cells for subsequent
gene expression events (Ciofani et al., 2012; Kurachi et al., 2014). This notion was put forth as a
result of studies in T cells. For this part of my work, I sought to investigate this model using a B
cells.
BatfZ/Z mice are an excellent model system to study the phenotypes of immune cells. In
addition, these mice have proved useful for isolating BATF regulated genes and for identifying
how BATF participates in a network of signaling events leading to B cell CSR (Chapter 3).
BatfZ/Z mice are not, however, an ideal model for studying the function of BATF in specific cell
lineages. BatfZ/Z mice were generated using an E2A Cre transgene, which eliminates the Batf
gene during the earliest stages of embryogenesis. Therefore, there is a possibility that the
phenotypes observed in these mice could be due to secondary events unrelated to the intrinsic role
of BATF in B cell or T cells. The goal of my work in this chapter was to generate a mouse model
to target the deletion of BATF specifically to the B cell lineage.
Initially, I chose to generate a B cell specific conditional knockout mouse using the Batf
KI/KI

mouse line in crosses with a line carrying a B cell specific transgene (CD19-Cre). This was

not successful. A second attempt was made using Cre expressed from a lentiviral vector to
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eliminate Batf in B cells cultured from Batf

KI/KI

mice. This too was not successful. In a third

attempt, I generated a conditional BatfZ/Z mouse by crossing the Batf

KI/KI

to a line carrying a

UBC-CreERT2 transgene that is inducible by treating the mice, or cells isolated from the mice, with
tamoxifen.

Fortunately, this approach was successful and I was able to obtain data to further

support the role of BATF as a “pioneering transcription factor” in B cells.

4.2 Results
4.2.1 Generation and Characterization of BatfKI/KI;RosamTmG/+;CD19Cre/+ Mice.
To generate a conditional knockout of Batf specifically in B cells, I crossed a BatfKI/KI;
RosamTmG/+ mouse with a BatfKI/KI;CD19Cremouse. CD19 is only expressed in B cells and therefore
should effectively delete Batf in B cells without affecting BATF expression in any other immune
cell lineage. With this breeding scheme, I expected 25% of the mice would be BatfKI/KI, 25% of
the mice would be BatfKI/KI; RosamTmG/+, 25% of the mice would be BatfKI/KI;CD19Cre, and 25% of
the mice would be BatfKI/KI; RosamTmG/+;CD19Cre. I called the latter mice Bzt and their genotype
was confirmed using PCR.
Inclusion of the mT/mG reporter gene allowed me to sort cells which presumably had
deleted Batf since the presence of Cre would allow for GFP to be expressed (Figure 1A).
Unfortunately, recombination in the B cells was not highly efficient. Flow cytometry was able to
detect only about 5% of the splenocytes as GFP+ and that number dropped to 4% when profiled
for the co-expression of the B cell marker, B220 (Figure
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Figure 4.1 Profile of B Cells in Bzt Mice.
(A) Splenocytes from BatfKI/KI mice and Bzt mice were isolated and RBCs were lysed. Flow
cytometry was performed to detect B cells (B220+) expressing Cre (GFP+) or not expressing Cre
(RFP+) as an indicator of the recombination of the Batf KI alleles. Representative flow plots are
shown. Cumulative data from 6 experiments are shown in the bar graph on the right. (B) GFP+
B220+ cells and RFP+ B220+ were isolated by FACS and cultured in media or LPS and IL-4 for
48hrs. RNA was prepared and RT-qPCR performed in duplicate to detect the indicated transcripts.
Results are expressed relative to unstimulated B cells (1.0). n=4 mice of each genotype. Error bars
indicate mean +/- SEM. **p<0.01; ***p<0.001; ns = not significant.
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4.1A). Despite the low number, the GFP+ B220+ cells were isolated using FACS and cultured in
media or media supplemented with LPS and IL-4. RNA analysis revealed that the B cells which
were GFP+ did effectively delete Batf and even though cells continued to express Pax5 and Irf4,
they were unable to activate expression of Aicda (Figure 4.1B).
CD19 should only be expressed in B cells and for this reason, we chose CD19Cre to generate
this mouse model. While CD19Cre+ did recombine the RosamTmG/+ reporter gene in the Bzt mice,
this targeting turned out not to be B cell specific. Immunofluorescence showed widespread GFP
expression in Bzt sections of the thymus, spleen, pancreas and liver of Bzt mice (Figure 4.2A).
Flow cytometry revealed that 1.5% of splenocytes were GFP+ CD4+ T cells (Figure 4.3A). To
verify that the GFP+ T cells had deleted Batf, splenocytes were plated on -CD3 coated plates and
cultured in T cell media supplemented with -CD28 to activate T cells. GFP+ and RFP+ CD4+ T
cells were sorted 3 days after activation, and RNA isolated for analysis. RFP+ cells expressed Batf
mRNA while GFP+ cells did not (Figure 4.3B). The GFP+ T cells also did not express Il-4, Il-17a,
and Il-21 (Figure 4.3B). No defect was observed in Irf4 or T-Bet expression (Figure 4.3B). I
cannot explain why these animals display such leaky expression of CD19Cre but as a result, we
could not use this mouse model as a means to study the impact of Batf deletion on the B cell
lineage.

4.2.2 Generation a BATF KO B Cells using FIV3.2 Cre-Luciferase.
My second approach to delete Batf only in B cells used a replication-defective feline
immunodeficiency virus, expressing a Cre-luciferase fusion gene from the human
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Figure 4. 2 CD19 Cre Is Not Specific to B Cells.
The spleen, thymus, pancreas, and liver from control (BatfKI/KI RosamT/mG) and Bzt mice (n=6)
were fixed, embedded in paraffin, sectioned and stained with -RFP or -GFP antibodies. DAPI
was used to visualize nuclei. The spleen and thymus are imaged at 60x. The pancreas is imaged
at 40x, and the liver is imaged at 10x. Representative images are shown. The bars in each image
represent 50 M.
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Figure 4.3 Profile of Splenic T Cells in Bzt Mice.
(A) Splenocytes from BatfKI/KI mice and Bzt mice were isolated and RBCs were lysed. Flow
cytometry was performed to detect mature T cells (TCR+) expressing Cre (GFP+) or not
expressing Cre (RFP+) as an indicator of the recombination of the Batf KI alleles.
Representative flow plots are shown. Cumulative date from 6 experiments is shown in the bar
graph on the right. (B) Splenocytes were harvested from BatfKI/KI and Bzt mice and activated
using -CD3 coated plates and treatment with -CD28 for 3 days. GFP+ TCR+ cells and RFP+
TCR+ cells were isolated by FACS, and RNA was harvested. QPCR was performed in
duplicate to detect the indicated transcripts. Results are expressed relative to RFP+ T cells (1.0).
n=4 mice of each genotype. Error bars indicate mean +/- SEM. **p<0.01; ***p<0.001; ns =
not significant.
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cytomegalovirus (CMV) promoter (FIV 3.2 CMV Cre-luciferase). A second virus, FIV 3.2 CMVGFP was used as a control to monitor the effects of infection without expression of Cre. Both
viruses were obtained by Dr. Andrea Kasinski’s laboratory (Purdue University) from the
University of Iowa Gene Vector Transfer Core) and she provided me with titered virus
supernatants. However, in order to make sure that the viruses could be useful for transduction in
our lab, Hela cells were transduced with different amounts of the GFP-expression control FIV
vector and the cells imaged to observe the intensity of GFP staining. Results indicated that
transduction with 2 L of virus supernatant was efficient and generated a good number of GFP+
cells (Figure 4.4A). The HeLa transduction experiment was repeated using the same volumes of
supernatant from the FIV 3.2 CMV Cre-luciferase virus preparation, but in this case, cell lysates
were prepared to measure luciferase activity. Results show that transduction with 2 L of the
preparation generated a high level of luciferase activity (Figure 4.4B), suggesting that this
lentivirus should be capable of expressing a high level of Cre-luciferase protein in cells.
To test if the lentivirus approach could be used to delete Batf, B cells from Batf

KI/KI

RosamT/mG mice were transduced using a 1 hour spinfection protocol with 2uL of the FIV3.2-Creluciferase supernatant at the time of activation (0hr) or after 12hrs after activation.

After

transduction, the cultures were maintained in growth medium with LPS and IL-4 for an additional
48hrs. The percent of B cells transduced at 0rs and 12hrs after activation is shown in Figure 5.
The first thing noted was the high rate of mortality in the cultures. In contrast to the HeLa cultures,
approximately 80% of the B cells died when
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Figure 4.4 FIV3.2 Transduction of HeLa Cells.
HeLa cells were cultured in DMEM, and transduced with FIV3.2 Luciferase-Cre or FIV3.2 CreGFP when they reached 70% confluency. (A) Cells were imaged at 10x using a GFP filter to
visualize the number of transduced cells or imaged at 10X under bright field to determine the
total number of cells. A representative image is shown (n=3). (B) Lysates were harvested and
mixed with either renilla luciferin or firefly luciferin and measured in a luminometer. The data
were normalized internally using firefly luciferase/renilla luciferase ratio. Samples were
measured in triplicate. n=3. Error bars indicate mean +/- SEM.
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Figure 4.5 FIV3.2 Does Not Effectively Transduce B Cells.
(A) B cells were isolated from the spleen of BatfKI/KI RosamTmG/+ mice and transduced with the
indicated virus before activation or 12hrs post activation with LPS and IL-4. At 48hrs post
activation, flow cytometry was used to assess the % of GFP+ cells. Representative flow plots
are shown (left) along with the cumulative data from 3 experiments assayed in duplicate (right).
(B) B cells isolated and cultured as described above were isolated using FACS. RNA was
harvested, converted into cDNA and qPCR was used to assay for the indicated transcripts.
Samples were assayed in duplicate and normalized to RFP+ unstimulated cells (set to 1.0).
(n=3) Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; ns= not significant.
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exposed to the supernatant. Nevertheless, the surviving cells were analyzed by flow cytometry for
the number of GFP+ cells. The results showed that only 2% of the cells transduced at 0hr were
GFP+; 6 % of the cells transduced at 12 hr were GFP+ (Figure 4.5A).

RFP and GFP positive

cells were isolated by FACS and RNA prepared. Despite having many fewer GFP+ cells than
RFP+ cells from the experimental groups, RT-qPCR revealed that recombination of the Batf loci
had occurred in the GFP+ cells (Figure 4.5B) and that deletion of Batf had resulted in the inability
of the cells to express Aicda when the cells were transduced 0hrs post activation. Surprisingly, a
low level of Aicda expression was observed when cells were transduced with FIV-Luciferase-Cre
12hrs post activation. Expression of Irf4 and Pax5 remained transduced with a control virus
(FIV3.2-GFP).

So, although the FIV3.2 Cre approach did work, the overall efficiency of the

approach was low. The level of cell death in these assays was a concern and together with the
realization that it was not going to be easy to use this transduction approach to set up a time course
study that would produce meaningful results, I decided to try yet a different model.

4.2.3 Generation and Characterization of a Conditional Batf Knockout Mouse using an
Inducible Cre Transgene.
The third attempt to engineer a mouse to study the cell intrinsic effects of Batf deletion in
B cells was successful. For this mouse, I crossed a BatfKI/KI; RosamTmG/+ mouse with a BatfKI/KI;
UBCCer-ERT2 mouse to produce pups that are BatfKI/KI; Rosa26mTmG/+; UbcCre-ERT2. I called these
mice Izt. With this mouse model, I wanted to confirm that the phenotype of BatfZ/Z B cells was
intrinsic to B cells and to test if the
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Figure 4.6 In Vivo Treatment of Izt Mice with TAM Deletes Batf.
(A) Schematic showing TAM-treatment schedule of Izt mice by oral gavage. (B) Spleen,
thymus and pancreas from control and TAM treated Izt mice (n=4) were fixed, sectioned and
stained with -RFP or -GFP antibodies. DAPI was used to visualize nuclei. Representative
images are shown. The bars in each image represents 50 M. (C) GFP+ B cells were sorted
from Izt mice and along with B cells from non-TAM treated Izt mice and Batf Z/Z mice
(controls). The gating strategy for each group is Figure 4.7A. Each group of cells were
stimulated with LPS and IL-4 for 48 hrs. n=4 mice for each genotype. RNA was prepared
and RT-qPCR used to quantify the indicated transcripts, in duplicate. Results are normalized
to -actin and expressed relative to the levels in the Izt non-TAM control (set to 1.0). Error
bars indicate mean +/- SEM. ***p<0.001; ns=not significant.
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early spike in BATF expression I observed in stimulated wild type cells (Figure 3.4) has functional
significance with regard to CSR in B cells.
To initially determine if IzT mice efficiently recombined the Batf loci, mice were treated
with tamoxifen (TAM) daily over a five day period in vivo (Figure 4.6A) This led to the Cremediated recombination of the mT/mG gene and the appearance of GFP in all tissues tested (Figure
4.6B). To establish if the floxed Batf alleles were recombined, RNA was isolated from TAMtreated IzT mice that had been sorted as GFP+. RNA from BatfKI/KI splenocytes and from BatfZ/Z
splenocytes were used as controls. Results show normal levels of Irf4 and Pax5 transcripts but, as
expected, no expression of Batf or Aicda (Figure 4.6C). This demonstrated that the Izt mice could
possibly be used for further in vitro studies to examine the intrinsic role of Batf in B cell signaling
events.

4.2.4 Using Izt B cells in vitro to study the role of BATF in B cell activation and CSR.
Using Izt mice, B cells were isolated and experiments performed to test if tamoxifen treatment
would recombine the BatfKI/KI alleles in vitro. A time course experiment was set up to vary the
time of exposure to TAM (Figure 4.7A). B cells stimulated with LPS and IL-4 and treated with
ethanol instead of TAM served as the control. The Δ0 group are B cells depleted for Batf at the
time of stimulation and should behave as Batf ΔZ/ΔZ B cells. The Δ12 group preserves the induction
of Batf expression during the first 6hrs post-stimulation, but should not be able to support the
second wave of Batf expression that begins after 24 hrs.

At the termination of the treatment

protocol (72hrs), flow cytometry revealed that approximately 14% of Δ0 B cells and approximately
12% of Δ12 B cells recombined switching from RFP+ to GFP+ (Figure 4.7B).
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Figure 4.7 In Vitro Treatment of Izt Mice with TAM.
(A) Schematic of how TAM was used to delete Batf in Izt B cells. (B) B cells from isolated
from control, 0 and 12 Izt spleens, stimulated for 72hrs, and profiled for GFP by flow
cytometry. A representative plot is shown (n=6 of each genotype).
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The GFP+ B cells from the 0 and 12 groups were then purified by FACS and RNA
harvested from all three groups. As expected, Batf mRNA was undetectable in both the 0 and
12 groups, while Irf4 and Pax5 mRNA levels were equivalent to the untreated control (Figure
4.8A). Interestingly, Aicda mRNA was not induced in the 0 cells, but was induced in 12 cells
to about 50% of control levels. To confirm that this reduced level of Aicda expression was
sufficient to drive CSR, flow cytometry was used to compare IgM, IgG1 and IgE on 0 and 12
B cells sorted as GFP+ (no Batf) or RFP+ (retaining Batf) (Figure 4.8B). The expression of IgM
was the same for all of the groups. However, class switched IgG1 and IgE were barely detectable
on 0 cells, yet the 12 cells displayed levels equivalent to the control (Figure 4.8B).
Additionally, RNA isolated from GFP+ cells was purified from the three groups of cells and was
analyzed to detect germ line transcripts (GLT) from I-region promoters of immunoglobulin genes
(Figure 4.8C). All three groups transcribe the

promoter region representing IgM, as expected.

On the other hand, transcripts representing 1 (IgG1) and (IgE) were detected only in the control
and 12 B cells. This GLT was not detected in 0 cells. These results indicate that preserving
the early peak of BATF expression following B cell stimulation is not just necessary (0), but
sufficient (12) to set in motion a program of B cell gene expression that culminates in the
expression of AID and the production of class switched antibodies.
As discussed in Chapter 3. BATF regulates Nfil3, miR155hg, and Wnt10a to influence
Aicda expression and CSR. The success of the experiments above allowed me to test when during
B cell activation BATF was required for the regulation of these three genes. To do this, I utilized
TAM treatment of Izt B cells as outlined in Figure 4.7A to examine if the expression pattern of
each of these genes could be sustained only by the early spike in BATF expression. The results
were dramatic. Both the induction of Nfil3 mRNA and the repression of Wnt10a transcripts
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Figure 4.8 Early Expression of Batf Is Necessary and Sufficient for CSR.
(A) Splenic B cells, cultured and exposed to TAM as in Figure 4.7, were sorted for GFP+
cells. RNA was harvested from control, 0 and 12 GFP+ cells converted to cDNA, and
analyzed by qPCR for the indicated transcripts, in duplicate. n=4 mice for each group.
Results are normalized using -actin and expressed relative to levels in the Izt control (set
to 1.0). (B) 0 and 12 B cells were surface stained for IgM, IgG1, and IgE and profiled
by flow cytometry. The percent of each Ig detected for GFP+ Izt B cells was normalized
to the percent for RFP+ cells (set to 1.0). n=6 for each group. (C) RT-qPCR was used to
detect the expression of the indicated GLTs in RNA extracted from control, 0 and 12
GFP+ IzT B cells. Transcripts assayed in duplicate were normalized to Gapdh. GLT
expression is graphed relative to control B cells (set to 1.0). n=6 for each group. The gating
strategy is shown in Figure 4.7B. Error bars indicate mean +/- SEM. **p<0.01; ns = not
significant.
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Figure 4.9 Batf Expression for 12hrs after B Cell Activation Is Sufficient for Expression of
Nfil3 and Wnt10a but not MiR155hg.
Splenic B cells, cultured and exposed to TAM as in Figure 4.7A, were sorted for GFP+ cells. RNA
harvested from control, 0 and 12 GFP+ cells was converted to cDNA and analyzed by qPCR for
the indicated transcripts, in duplicate. n=4 mice for each group. Results are normalized using actin and expressed relative to levels in the IzT control (set to 1.0). Error bars indicate mean +/SEM. *p<0.05; **p<0.01; ns = not significant.
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required BATF expression at 6 hrs, but did not rely on sustained BATF expression after that time
(Figure 4.9A).

In contrast, miR155hg RNA was repressed in both the 0 and 12 treatment

groups, suggesting that a continuous level of BATF activity is required to maintain miR155hg
expression (Figure 9A).

The result with miR155gh was not totally unexpected, however, as

miR155hg RNA accumulates gradually in B cells after stimulation (Chapter 3, Figure 3.7).
Furthermore, this miRNA was not identified by the RNA-Seq and instead was selected for analysis
through a different set of experiments.

4.3 Discussion
The events that coordinate the molecular network culminating in Ig class switch
recombination have been intensely studied. This process, which is initiated with a B cell stimulus
and culminates with the production of class switched Ig, requires a change in the expression of
many genes including Pax5, Irf4, Bcl6, and Prdm1. While none of these genes are affected by
the loss of Batf in BatfZZ B cells, Batf expression is required for B cells to produce class switched
antibodies (Betz et al., 2010; Ise et al., 2011). In this study, I sought to test if BATF expression is
required very early in the process. The rationale for this question came from the observation that
Batf mRNA and BATF protein expression is biphasic following B cell stimulation, with an early
spike followed by a rapid decline and a more steady accumulation as IgM producing B cells begin
to express AID and acquire the ability to produce IgG and IgE (Chapter 3, Figure 3.4). Thus, it
was an obvious question to ask if this early activation of Batf expression plays an important role
in B cell CSR.
To accomplish my goal, it was critical to generate a mouse where BATF expression could
be controlled. While the first attempts to generate a conditional B cell knockout mouse failed
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either due to low recombination rates or leaky Cre expression, my final attempt succeeded. Using
the Izt mouse with TAM treatment, I was able to not only conditionally delete Batf in vivo, but in
cultured B cells as well. Furthermore, the TAM treatment allowed for the deletion of Batf at
different time points following B cell activation. This enabled us to study the role of BATF early
after B cell activation (<12hrs) and later as B cell Ig class switch recombination is initiated
(>12hrs).
BATF has an important role within hours after B cell activation and during CSR. When
BATF expression is maintained during the first 12hrs of stimulation, B cells are still capable of
expressing a low level of AID and undergoing CSR. On the other hand, when BATF is absent
from time 0hr of B cell activation, the B cells are incapable of inducing Aicda expression and
undergoing CSR. These results imply that BATF regulates events that set in motion other events
that are required for class switched antibodies to be arranged. Among those early events are the
activation of Nfil3, and miR155hg expression and the repression of Wnt10a expression. While
deletion of Batf later in the process (12) cannot influence how the early regulation of Nfil3 and
Wnt10a are impacted by BATF, it appears as though miR155hg transcription requires the
continued presence of BATF.
A biphasic pattern of Batf mRNA and protein expression was described first in a model
system of myeloid differentiation where BATF is required for the cells to respond to stimulation,
cease proliferating and begin expressing macrophage markers (Liao et al., 2011).

Since then,

biphasic patterns of BATF induction have been described for Th17 cells (Ciofani et al., 2012),
CD8+ T cells (Godec et al., 2015) and Type 1 regulatory T cells (Karwacz et al., 2017). These
observations have led others to categorize BATF as a “pioneering” transcription factor responsible
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for reshaping the genetic landscape of differentiating T cells (Ciofani et al., 2012; Karwacz et al.,
2017).
The results from my work support the role of BATF as a “pioneering” transcription factor
in B cells.

Whereas the induced deletion of Batf at the time of stimulation completely blocks

CSR, deletion after 12 hours of stimulation allows the B cells to initiate a full program of gene
expression involving dozens of gene activating and repressing events that culminate in the
expression of Aicda and CSR. I have shown that at least three components in this B cell program
of gene expression depend on this early induction of BATF and that only one (miR155hg) requires
the sustained expression of Batf. This would suggest that whatever BATF is doing early after
activation permanently changes the composition of the chromatin associated with Nfil3 and
Wnt10a to allow for continued expression (Nfil3) or repression (Wnt10a) in its absence.
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CHAPTER 5. GENERATION AND CHARACTERIZATION OF A T CELL
SPECIFIC CONDITIONAL BATF KNOCKOUT MOUSE

5.1 Introduction
Expression of BATF is restricted to the immune system, but has widespread roles in many
immune cell types (Murphy et al., 2013; Sopel et al., 2016). As a bZIP transcription factor, BATF
regulates genes by forming heterodimers with the JUN AP-1 proteins and binding AP-1 and AICE
consensus DNA. While BATF:JUN complexes repress transcription on AP-1 motifs, these
complexes can recruit IRF4 and activate transcription on AICE motifs. BATF deficiency is
associated with an inability of T cells to respond to stimulation and differentiate. Overexpression
of BATF skews the development of CD4+ T cell subsets, causes the overproduction of antibodies
by B cells, and accelerates CD8+ T cell exhaustion in response to infection (Betz et al., 2010; Ise
et al., 2011; Leavy, 2011; Logan et al., 2012; Quigley et al., 2010; Williams et al., 2001).
CD4+ Th cells, also known as T helper cells, assist the function of the immune system by
secreting cytokines. The Th cell subsets differentiate based on their own cytokine environment
and are characterized by the cytokines they secrete and the transcription factors they express (Zhou
et al., 2009; Zhu, Yamane, & Paul, 2010). Using Batf knockout mice, Batf expression was shown
to be essential for the CD4+ T helper (Th) 2, Th17 and T follicular helper (Tfh) cell lineages (Betz
et al., 2010; Schraml et al., 2009). Most recently, BATF function has been shown to be critical
for Th9 cells (CD4+ T cells that secrete IL-9) (Jabeen et al., 2013). Because BATF functions in
CD4+ T cell subsets to enable the cells to produce their signature cytokines, eliminating Batf or
blocking Batf expression with siRNA is associated with a deficiency in cytokine production. The
absence of cytokines can actually protect animals against inflammation, autoimmune and allergic
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disease (Jabeen et al., 2013; Rhee et al., 2017; Schraml et al., 2009; C. Wang et al., 2013), Batf
deficiency also has been shown to extend the survival of tissue allografts (Yang et al., 2016).
In order to understand the role of BATF in T cells, other labs have performed ChIP-Seq to
define the BATF regulatory network specifying Th0 cells (Karwacz et al., 2017), Th17 cells
(Ciofani et al., 2012) and Th2 cells (Vahedi et al., 2012). One important outcome of these studies
was the discovery of BATF’s interaction with IRF4 as the means through which BATF:JUN
heterodimers activate gene expression (Glasmacher et al., 2012). Interestingly, two of the genes
identified in my B cell studies (Chapter 3; Nfil3 and miR155hg) are important in T cells (Banerjee,
Schambach, DeJong, Hammond, & Reiner, 2010; Kamizono et al., 2009; Kashiwada, Cassel,
Colgan, & Rothman, 2011; Yao et al., 2012; Yu et al., 2013) and were noted in Chip-Seq studies
(Ciofani et al., 2012; Glasmacher et al., 2012; P. Li et al., 2012). A role for Wnt10a has not been
described in T cells. Therefore, it was of interest to see how these B cell targets of BATF regulation
function to mediate the phenotypes associated with the loss of Batf in CD4+ Th cells
As mentioned previously, the commonly employed mouse models to study BATF function
in T cells include two global knockout lines (Batf

-/-

and Batf

Z/Z

) (Betz et al., 2010; Ise et al.,

2011; Schraml et al., 2009) and two BATF transgenic mouse lines in which the protein is
dramatically overexpressed (p56lck-BATF and CD2-HA-BATF) (Logan et al., 2012; Thornton et
al., 2006; Williams et al., 2003). The Batf

-/-

and Batf

Z/Z

mouse lines were generated by

homozygous deletion of Batf early in embryogenesis and have been maintained for generations,
with the exception of periodic back-crosses, as homozygous knockouts. The absence of BATF
does not have widespread effects on mouse viability or development, but does affect multiple cell
types of both the innate and adaptive immune systems. In fact, new observations with regard to
these Batf knockout mice are being made all the time. Therefore, in my studies, I sought to develop
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a mouse line that would eliminate Batf expression only in T cells. In this way, I would have a
knockout model that would allow me (1) to confirm or refute the T cell phenotypes previously
attributed to BATF using models in which Batf is eliminated throughout the entire immune system
and anywhere else in the mouse Batf might be expressed that we do not yet know about, (2) to test
the role of the BATF target genes identified in Chapter 3 in the phenotypes of Batf knockout T
cells, and (3) to generate a knockout model whose mis-expression pattern better matches the
overexpression models previously generated by our lab and others.
To generate the T cell conditional Batf knockout mouse, I utilized a CD4Cre transgene that
would recombine the floxed Batf KI/KI alleles at the double positive stage of T cell development in
the thymus. My first attempt to generate this mouse through genetic crosses was successful and I
call the mouse Tzt. The studies in in this chapter show that defects in CD4+ Th17, Th2, Th9 and
Tfh cells are observed in Tzt mice as well. The impact of the functional loss of these T cell subsets
in Tzt mice blocks the ability of B cells to produce antibodies in response to a TD antigen.
However, unlike what was observed in the global Batf knockout mice, the TI antigen response of
B cells remains intact. Additionally, I investigated the roles of the B cell gene targets identified in
Chapter 3 using Tzt T cells and was able to show that the products of these genes mediate BATF
function in Th cells as well. The studies in this chapter precisely define a function for BATF in
T cells using a T cell-specific knockout approach and have extended knowledge of the BATF
transcriptional network that functions to control the development and function of the CD4+ Th17,
Th9, Th2 and Tfh cell subsets.
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5.2 Results
5.2.1 Generation and Characterization of a T Cell Conditional Batf Knockout Mouse.
In order to engineer a mouse that would eliminate Batf expression specifically in T cells,
I exploited expression of Cre recombinase driven by the T cell specific CD4 promoter. Early in
thymic T cell development, the T cells exist as double positive (DP) cells where they express both
CD4 and CD8 receptors. By expressing Cre from the CD4 promoter, all of the T cells in the mouse
will delete Batf, but no other cell types should be affected. In order to distinguish the cells that
have recombined the Batf locus, we employed a RosamTmG/+ reporter gene. The mT/mG expression
cassette will express RFP (Tomato) in all of the cells of the mouse until the cassette is recombined
by Cre to express GFP (green fluorescent protein). The assumption, which I will verify at the
molecular level, is that the appearance of GFP will indicate that the floxed Batf KI/KI alleles are also
recombined. To generate this mouse, a BatfKI/KI; RosamTmG/+ mouse was crossed to a BatfKI/KI
mouse previously bred to carry the CD4Cre transgene (Figure 5.1). Using this breeding scheme,
25% of the pups generated are BatfKI/KI (no Cre; no mTmG), 25% of the mice are BatfKI/KI; CD4Cre
(no mT/mG), 25% of the mice were BatfKI/KI; RosamTmG (no Cre) (these are used as control animals)
and 25% of the mice were BatfKI/KI; RosamTmG/+; CD4Cre. This latter group of animals are the Tzt
mice.
To confirm that CD4Cre expression was restricted to T cells, immunofluorescent antibody
staining was performed. The spleen, thymus and pancreas were harvested from control mice and
Tzt mice (Figure 5.1), fixed and embedded in paraffin. Sections from each organ were reacted
with labeled antibodies to detect RFP or GFP as described in Chapter 2. Sections from control
mice demonstrated a strong red fluorescence and only background green fluorescence (Figure5.2).
As expected, the thymus and spleen of the Tzt mice were GFP+, but the pancreas showed no green
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Figure 5.1 Breeding Scheme to Generate Tzt Mice.
To generate conditional T cell knockout mice, BatfKI/KI RosamT/mG mice are crossed to Batf KI/KI
CD4Cre/+mice. 25% of the pups are Tzt and will have combined exon 3 of Batf as well as the
RosamTmG reporter gene to now express GFP.
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fluorescence. The lack of GFP expression in the pancreas confirmed that only organs rich in T
lymphocytes were expressing the CD4Cre transgene.
To examine the profile of T cells present in Tzt mice, the lymphocyte cellularity of the
spleen was investigated.

No difference was noted in overall white blood cell count from the

spleens of Tzt, Batf KI/KI or from BatfZ/Z mice (Figure 5.3A). To examine if the CD4Cre activity
in Tzt mice was restricted to T cells, flow cytometry was employed (Figure 5.3B). By profiling T
cells (TCR+) and B cells (B220+) for RFP or GFP, the data show that T cells from the Tzt spleen
are predominantly GFP+, while T cells from the control mice were RFP+. In the case of splenic B
cells, the profile from mice of both genotypes were RFP+ and GFP- (Figure 5.3B).
The flow profiles suggested that CD4Cre was working in Tzt cells and should have
efficiently recombined the Batf loci. To verify this, splenocytes were cultured on plates coated
with -CD3 in media supplemented with -CD28 to stimulate gene expression in T cells. After
3 days, GFP+ TCR+ cells were sorted for the Tzt cultures; RFP+ TCR+ cells were sorted from
Batf

KI/KI

mice. RNA was isolated and RT-qPCR was performed. As a control, analysis of Irf4

mRNA expression showed no difference in expression between the two groups (Figure 5.3C). In
contrast, Batf mRNA was not detected in Tzt T cells (Figure 5.3C).
At this point, it had been established that Th17, Tfh and to a lesser extent Th2 cells require
BATF (Betz et al., 2010; Ise et al., 2011; Schraml et al., 2009). To characterize key CD4+ T cell
subsets in Tzt mice, flow cytometry was performed to examine if the phenotype of BatfZ/Z mice
was duplicated in Tzt mice.

Splenocytes from Tzt and control mice were stained for markers

specific for the indicated Th cell lineages and profiled using flow cytometry. Batf KI/KI splenocytes
were profiled as the control. Details of the surface and intracellular staining protocols are found
in Chapter 2.
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Figure 5.2 CD4 Cre Is Expressed in Tzt T Cells.
Spleen, thymus and pancreas from control (BatfKI/KI; RosamT/mG) and Tzt mice (n=6) were fixed,
sectioned and stained with -RFP or -GFP antibodies. DAPI was used to visualize nuclei.
Representative images are shown. Images of the spleen and thymus were taken at 60x while
images of the pancreas were taken at 10x. The bars in each image represents 50 M.
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Figure 5.3 Profile of Splenic Lymphocytes in Tzt Mice.
(A) Splenocytes from the indicated genotypes were isolated and RBCs lysed. The total
number of white blood cells per spleen were counted. n=8. (B) Flow cytometry was
performed to detect T cells (TCR+) or B cells (B220+) expressing Cre (GFP+) or not
expressing Cre (RFP+) as an indicator of the recombination of the Batf KI alleles.
Representative flow plots are shown on the left. Cumulative date from 8 experiments is
shown in the bar graph on the right. (C) GFP+ TCRβ+ cells were isolated by FACS. RNA
was prepared and RT-qPCR performed qPCR performed in duplicate to detect the indicated
transcripts. Results are expressed relative to -actin and normalized to BatfKI/KI samples
(set to 1.0). n=4 mice of each genotype. Error bars indicate mean +/- SEM. **p<0.01;
***p<0.001; NS = not significant.
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In agreement with what was noted previously (Betz et al. 2010), there was no statistically
significant reduction in the number of Th1 (IFN+) and Th2 (IL-4+) lineages in the Tzt mice
(Figure 5.4A). However, profiling for Th17 (IL-17+) and Tfh (CXCR5+;PD1+) revealed a severe
deficiency of both cell types the Tzt mice.
RNA was isolated from RFP+ Batf

KI/KI

Interestingly, as was noted in BatfZ/Z mice, when

T cells and GFP+ Tzt T cells that had been stimulated in

vitro with -CD3 and -CD28, expression of Il4 and Gata3 mRNA (the signature transcripts of
Th2 cells) were very low (Figure 5.4B) indicating that the Th2 lineage was functionally impaired
by the loss of BATF. As expected from the flow profiles, Il17 and Rort mRNA (signatures of
Th17 cells) and Il21 mRNA (signature of Tfh cells) were very low. In contrast, the Tzt cells
expressed Ifn and T-bet mRNA (the signature transcripts of Th1 cells) equally well as the control
(Figure 5.4B). These studies confirm that the major Th cell phenotypes in Batf KO mice (Betz et
al., 2010; Ise et al., 2011; Schraml et al., 2009) are observed in the Tzt mice.

5.2.2 Testing the Antigen Response of Tzt Mice.
In the adaptive immune system, CD4+ T cells (specifically CD4+ Tfh cells) are largely
responsible for activating B cells to secrete antibodies (King, 2009). Tfh cells secrete IL-21 and
IL-4, two cytokines that are deficient in Batf KO mice and, as I have just shown, in Tzt mice as
well (Figure 5.4B). Tfh cells also express CXCR5 and use that to home to follicular B cells in the
spleen and lymph nodes (Kim et al., 2001; Nurieva et al., 2008; Vogelzang et al., 2008). It is the
interaction of the Tfh cells and B cells, that leads to germinal center formation, the induction of
AID expression in B cells and the program of B cell CSR (Boller & Grosschedl, 2014). B cells
can also be activated to produce antibodies independently of T cells but, in this case, germinal
centers do not form and B cells can only produce a few of the different class switched antibodies.
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Figure 5. 4 Profile of CD4+ T Cell Subsets in Tzt Mice.
(A) Splenocytes from the indicated genotypes and activated for 72hrs. Flow cytometry
was performed to detect T cells (IFN for Th1, IL-4 for Th2, IL-17 for Th17, CXCR5:PD1 for Tfh cells). Quantification of each T cell subset is presented as the % CD4+
splenocytes. Representative flow plots are shown on the left. n=6 mice of each genotype.
(C) GFP+ TCR+ cells were isolated by FACS. RNA was converted to cDNA and qPCR
performed in duplicate to detect the indicated transcripts. Results are normalized to actin and expressed relative to BatfKI/KI splenocytes (set to 1.0). n=6 mice of each
genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not
significant.
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I used these two different methods of B cell activation (TD - T dependent and TI - T independent)
to test how Tzt mice would respond since only T cells are deficient in BATF in this model.
To test the response of Tzt mice to a TD antigen, Tzt mice and BatfKI/KI mice were injected
with SRBCs or mock injected with an equal volume of PBS (see Chapter 2 for details). After 7
days, serum was isolated and spleens were fixed and sectioned for staining.

Using both

immunochemistry or immunofluorescent antibody staining to detect PNA (a marker for germinal
centers), results showed the conspicuous absence of PNA positive cells in the Tzt spleen, while
control spleen tissue that had been injected in parallel showed strong PNA staining (Figure 5.5A).
Additional tissue sections from these animals were stained using antibodies reactive with SRBCspecific, IgG1 and IgG2c. These are immunoglobulins that would have to be generated by CSR.
As shown in Figure 5.5B, positive cells were noted in the BatfKI/KI tissue, but not in the Tzt tissue.
Circulating Ig in serum was quantified using ELISA (Figure 5.5C). As expected, no difference
was noted in -SRBC IgM in Tzt mice compared to BatfKI/KI mice. This is because IgM production
does not depend on CSR. On the other hand, anti-SRBC IgG1 was essentially undetectable in the
serum from the Tzt mice (Figure 5.5C).

The conclusion is that the defects in T helper cells

described for Tzt mice severely inhibit the ability of the Tzt B cells in vivo to respond to a TD
antigen and produce class switched immunoglobulin.
Next, to assess if B cells in Tzt mice are able to respond to TI antigen, the above experiment
with Tzt and BatfKI/KI control mice above was repeated using TNP-LPS (a known TI antigen)
(Fidler, 1979) or an equal volume of PBS as a control. After 5 days, serum was isolated and
spleens were fixed and processed for detection of -TNP-LPS antibodies by immunostaining.
Results show that all mice produce IgG1 and IgG2c class switched antibodies (Figure 5.6A).
ELISA were performed to quantify circulating Ig and no statistically significant differences were
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Figure 5.5 Tzt Mice Do Not Respond to T Cell Dependent Antigen In Vivo.
(A) IHC and IF was performed to visualize germinal centers in BatfKI/KI mice and Tzt
mice injected with SRBCs or mock injected with PBS. n=6 for each genotype and
treatment. Scale bars indicate 50 M. Representative images are shown. (B) BatfKI/KI
mice and Tzt mice were injected with SRBCs or mock injected with PBS. IHC and IF
was performed on the spleen sections to visualize class switched Ig. Representative
images are shown. Scale bars indicate 50 M. n=6 mice of each genotype and
treatment. (C) Serum was collected from BatfKI/KI mice and Tzt mice used in A and B.
An ELISA was performed to quantify SRBC specific secreted Ig. Assays were
performed in triplicate. n=6 mice of each genotype and treatment. Error bars indicate
mean +/- SEM. **p<0.01; ***p<0.001; NS = not significant.
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Figure 5.6 Tzt Mice Respond to T Cell Independent Antigen In Vivo.
(A) IHC and IF were performed to visualize class switched Ig in BatfKI/KI mice and
Tzt mice injected with TNP-LPS or mock injected with PBS. n=6 for each genotype
and treatment. Scale bars indicate 50 M. Representative images are shown. (B)
Serum was collected from BatfKI/KI mice and Tzt mice used in A. An ELISA was
performed to quantify TNP-LPS specific secreted Ig. Assays were performed in
triplicate. n=6 mice of each genotype and treatment. Error bars indicate mean +/SEM. **p<0.01; NS = not significant.
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Figure 5.7 The B Cell Compartment Is Normal in Tzt Mice.
(A) RNA prepared from the B cells of Tzt and BatfKI/KI mice was assayed for the expression
of key genes by RT-qPCR. Transcripts assayed in duplicate, normalized to -actin, and
expressed relative to unstimulated BatfKI/KI B cells. (n=4 mice for each genotype and
treatment) (B) Splenic B cells from the indicated genotypes (in duplicate) were isolated by
MACS and activated for 48 hours with 20 mg/mL LPS and 20 ng/mL IL-4. Lysates were
prepared and the expression of the indicated proteins detected by immunoblotting. Protein was
normalized to HSP90 and expressed relative to BatfKI/KI B cell protein. A representative blot
is shown. (C) B cells from the indicated genotypes were cultured and media collected 48 hours
after stimulation. ELISA were performed to quantify production of IgM and IgG1. No
differences were observed. (n =4) Error bars indicate mean +/- SEM. **p<0.01; ***p<0.001;
NS = not significant.
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noted in the levels of IgM or IgG1 (Figure 5.6B). These data confirm that the B cells in the Tzt
mice can produce antibodies in response to TI antigen. Recall that BatfZ/Z mice do not respond
to TD or TI antigen stimulation in vivo (Betz et al., 2010).
These data would suggest that the B cells in Tzt mice are competent for antibody
production. Just to confirm that, B cells were isolated from the spleens of Tzt mice and activated
for 48hrs in media supplemented with LPS and IL-4. Tzt B cells express the same level Batf
mRNA (Figure 5.7A) and BATF protein (Figure 5.7B) as the control BatfKI/KI B cells.
Furthermore, Tzt B cells were able to express Aicda mRNA (Figure
5.7A) and AID protein (Figure 5.7B), equivalent to the control. For this immunoblot, protein
from BatfZZ B cells was included as a negative control. An ELISA performed on media from Tzt
B cells and BatfKI/KI B cells that were cultured with stimulation for 72hrs showed that IgM and
class switched IgG1 antibodies were being produced from both cultures (Figure 5.7C). These
experiments demonstrate that Tzt B cells have no defects in B cell activation or in CSR when
cultured in vitro.

5.2.3 Characterizing the Transcriptional Network in CD4+ T Helper Cells.
Many labs have been characterizing the transcriptional network that operates to control the
differentiation of T helper cell subsets. Chip-Seq analyses of Th2 and Th17 cells have identified
an array of genes which BATF potentially regulates directly (Ciofani et al., 2012; Glasmacher et
al., 2012; P. Li et al., 2012; Vahedi et al., 2012). I have analyzed results of an RNA-Seq comparing
B cells from wild type mice and BatfZ/Z mice and my work has focused on three genes, Nfil3,
miR155hg, and Wnt10a, which are directly regulated by BATF in B cells (see Chapter 3). Two of
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these genes (Nfil3 and miR155hg) have been shown to have a role in T cells. As far as I am aware,
Wnt10a has not been studied in CD4+ T helper cells.
To examine if the data from other studies might be useful for my studies on Tzt T cells,
ChiP-Seq data was compared (Ciofani et al., 2012; Glasmacher et al., 2012; Vahedi et al., 2012).
An analysis of naïve T cells (Th0), Th2, and Th17 cells activated for 48hrs showed that BATF
bound to regulatory regions of Nfil3, miR155hg, and Wnt10a. BATF bound the same regions in
Th0, Th2, and Th17 cells (Figure 5.8A). In addition, I found that BATF was bound to the same
AICE and AP-1 motif sites in Nfil3, miR155, and Wnt10a as I had mapped using B cells (Chapter
3 Figure 3.11). These other studies in T cells did detect BATF on additional sites in Nfil3.
Additionally, in Th2 and Th17 cells, BATF bound an AICE motif located in the exon of miR155hg
encoding miR155.
These data suggest that BATF does bind to Nfil3, miR155hg, and Wnt10a in three T cell
subsets. BATF has biphasic expression in B cells and binds Nfil3, miR155hg, and Wnt10a at
different time points after B cell activation. To examine if BATF may show differential binding to
these target genes at different times following T cell activation, I compared ChIP-Seq data from
Th17 cells activated for 16hrs, 42hrs, and 48hrs. The analysis indicated no difference in BATF
binding to AP-1 or AICE motifs at the different time points (Figure 5.8B). BATF is known to be
important early in Th17 cell differentiation (Ciofani et al., 2012), but it would appear from these
data that BATF is required continuously throughout the Th17 process to regulate expression of the
targets I have identified.
To further investigate the importance of Nfil3, miR155hg, and Wnt10a in T cell
differentiation, splenocytes from BatfKI/KI and Tzt mice were plated on -CD3 coated plates and
cultured in media supplemented with -CD28. GFP+ CD4+ Tzt cells and RFP+ CD4+ BatfKI/KI
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Figure 5.8 BATF Binding Sites in Nfil3, miR155hg, and Wnt10a.
(A-B) ChIP-seq data from GEO was analyzed for BATF binding to determine if (A) BATF
bound Nfil3, miR155hg, or Wnt10a differently in different T cells subsets, or (B) if BATF
bound AP-1 and AICE motifs of Nfil3, miR155hg, or Wnt10a differently in Th17 cells at
different time points.
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Figure 5.9 Tzt T cells Show Altered Expression of Nfil3, miR155hg, and Wnt10a.
Splenocytes cells cultured from BatfKI/KI mice and Tzt mice spleen were harvested for RNA
following stimulation with -CD3 and -CD28. RNA was converted to cDNA and qPCR
performed in duplicate to detect the indicated transcripts. Results are normalized to -actin
and expressed relative to levels in BatfKI/KI splenocytes (set to 1.0). n=4 mice. Error bars
indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not significant.
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cells were isolated by FACS and RNA was prepared for analysis by RT-qPCR. As I observed in
B cells, Batf deficient Tzt T cells do not expression Batf, Nfil3, or miR155hg and overexpress
Wnt10a (Figure 5.9). As a control, Irf4 mRNA was analyzed and there was no difference in Irf4
expression in GFP+ Tzt T cells when compared to BatfKI/KI T cells (Figure 5.9).
Naïve CD4+ T cells respond to cytokine cues in their environment and differentiate into
distinct T cell lineages. This process of skewing T cells toward
different fates can be replicated with cultured T cells (see Chapter 2 for details).

It was

demonstrated by Betz et al. (2010) that BatfZ/Z naïve T cells skewed in vitro to the Th2 or Th17
lineages do not express their signature cytokine or TF genes, while Th1 differentiation occurs
normally. By skewing naïve GFP+ and RFP+ CD4+ T cells to become Th1, Th2, and Th17 cells, I
wanted to determine if GFP+ Tzt CD4+ T cells have the same defects as observed in polarized
BatfZ/Z CD4+ T cells. Results showed that GFP+ Tzt CD4+ T cells cannot be directed to the Th2
or Th17 cell lineages (Figure 5.10). These cells expressed low levels of Gata3, Il4, Rort and
Il17a. The RFP+ BatfKI/KI CD4+ T cells differentiated well and expressed all of these Th2 andTh17
signature transcripts (Figure 5.10). As a control, I examined Th1 cell polarization for both
genotypes and found no defect in T-bet, or Ifn mRNA expression.
The ChIP-Seq data from T cells showed that BATF was bound to regulatory elements in
Nfil3, miR155hg, and Wnt10a in Th0, Th2, and Th17 cells, and I confirmed that these BATF target
genes are mis-expressed in Tzt splenocytes (Figure 5.9). To test if mis-regulation of these genes
was a feature of one, or several, CD4+ Th subsets, RNA prepared from Th1, Th2, and Th17 GFP+
and RFP+ BatfKI/KI T cells was used for RT-qPCR. Th1, Th2, and Th17 of the GFP+ CD4+ T cell
lineages showed altered expression of Nfil3 and miR155hg (Figure 11A). Interestingly, while
Wnt10a was over-expressed Th2 and Th17 GFP+ Tzt cells, there was no defect in Wnt10a
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Figure 5.10 Tzt T Cells Are Deficient in Gene Expression Associated with Specific
CD4+ T Cell Subtypes.
Naïve CD4+ Th cells were skewed to become Th1, Th2 or Th17 cells. RT-qPCR was used to
assay RNA harvested from the cells for the indicated transcripts. Assays were run in duplicate.
Results are normalized to -actin and expressed relative to levels in BatfKI/KI splenocytes (set
to 1.0) n=4 mice of each genotype. Error bars indicate mean +/- SEM. **P<0.01; ***p<0.001;
NS = not significant.
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Figure 5.11 Tzt Th2 and Th17 Cells Have Defects in Expression of Nfil3, miR155hg,
and Wnt10a.
Naïve CD4+ Th cells were stimulated to become Th2 or Th17 cells. After 5 days in culture,
RNA was harvested and converted into cDNA. QPCR was used to assay for indicated
transcripts. Assays were run in duplicate. Results are normalized to -actin and expressed
relative to levels in BatfKI/KI splenocytes (set to 1.0). n=4 mice of each genotype. Error bars
indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not significant.
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expression observed in Th1 cells (Figure 5.11A). In addition, RFP+ CD4+ Th1, Th2, and Th17
cells normally expressed Nfil3, miR155hg, and Wnt10a (Figure 5.11A).
To determine if the defects observed in the Tzt T cells are due to a lack of BATF, naïve
CD4+ T cells from Tzt and BatfKI/KI mice were cultured for 24hrs under polarizing conditions after
which they were transduced with a control MSCV-Thy1.1 retrovirus or with MSCV-Thy1.1BATF. After an additional 4 days in culture under polarizing conditions, Thy1.1+ RFP+ T cells
from BatfKI/KI cultures and Thy1.1+ GFP+ T cells from Tzt cultures were isolated by FACS. As was
observed in B cells, the MSCV-BATF retrovirus fully restored BATF protein expression in the Tzt
cells (Figure 5.12A). In addition, RT-qPCR using RNA isolated from the cultures confirmed that
MSCV-BATF restored Batf mRNA to levels observed in control cells (Figure 5.12B).
To investigate if retroviral expression of BATF could restore regulation of Nfil3, Wnt10a
and miR155hg in the Tzt T cells, RNA was prepared from cultures transduced with MSCV or
MSCV-BATF. As shown in Figure 5.13, expression of both Nfil3 and miR155hg were restored
in transduced Tzt cells to even greater levels than seen in MSCV transduced control cells.
Furthermore, MSCV-BATF expression resulted in a dramatic reduction of Wnt10a mRNA.
To test if transduction with MSCV-BATF could restore the expression of genes that
represent each of the CD4+ T cell lineages, splenocytes from Tzt or control BatfKI/KI mice were
plated on -CD3 coated plates and cultured in media supplemented with -CD28. After 24 hrs, the
splenocytes were transduced with MSCV or MSCV-BATF and returned to culture for an additional
two days. RFP+ BatfKI/KI T cells and GFP+ Tzt T cells were isolated by FACS. RNA was prepared
form the cells and RT-qPCR performed. For the Tzt cells, MSCV-BATF fully restored both TF
expression and cytokine expression representing Th2, Th17, Tfh and Th9 lineages (Figure 5.14).
Introduction of MSCV into BatfKI/KI T cells did not alter the expression of any of the genes.
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Figure 5.12 MSCV-BATF Restores BATF Expression in Tzt CD4+ T Cells.
Splenocytes from BatfKI/KI and Tzt mice were harvested, activated with -CD3 and -CD28,
transduced with the indicated virus, and harvested after 3 days. Thy1.1+ GFP+ CD4+ T
cells and Thy1.1+ RFP+ CD4+ cells and isolated by FACS. (A) Protein from cells was
harvested and immunoblotting was used to detect BATF. HSP90 serves as the loading
control. Cells from 2 spleens were pooled for each blot. n=8 mice. A representative blot
is shown. (B) RNA was harvested and converted into cDNA. qPCR was used to assay for
indicated transcripts. Results are normalized to -actin and expressed relative to MSCV
transduced BatfKI/KI cells transduced with MSCV. Assays were run in duplicate. n=4 mice
of each genotype. Error bars indicate mean +/- SEM. ***p<0.001; NS = not significant.
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Figure 5.13 MSCV-BATF Restores Nfil3, miR155hg, and Wnt10a Expression in TzT
CD4+ T Cells.
Splenocytes from BatfKI/KI and Tzt mice were transduced with the indicated retrovirus and
harvested 72 hours post activation. Thy1.1+ GFP+ CD4+ T cells and Thy1.1+ RFP+ CD4+ T cells
were isolated by FACS isolated. RNA was converted into cDNA and qPCR was used to assay
for indicated transcripts. Results are normalized to -actin and expressed relative to MSCV
transduced BatfKI/KI cells. Assays were run in duplicate. n=4 mice of each genotype. Error bars
indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not significant.
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Figure 5.14 MSCV-BATF Restores Cytokine Gene Expression Profiles in Tzt
CD4+ T Cells.
Splenocytes from BatfKI/KI and Tzt mice were transduced with the indicated retrovirus
and harvested after 3 days in culture activated by -CD3 and -CD28. Thy1.1+ GFP+
CD4+ T cells and Thy1.1+ RFP+ CD4+ T cells and were isolated by FACS. RNA was
converted into cDNA and qPCR was used to assay for indicated transcripts. Results
are normalized to -actin and expressed relative to control BatfKI/KI cells transduced
with MSCV. Assays were run in duplicate. n=4 mice of each genotype. Error bars
indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not significant.
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Furthermore, MSCV or MSCV-BATF did not alter the expression of T-bet or Ifn which represent
the Th1 lineage.
The next experiment was designed to test if the Th cell deficient phenotype of Tzt mice
could be rescued through readjusting expression of the BATF target genes, Nfil3, miR155hg and
Wnt10a in Tzt or BatfKI/KI T cells. To do this, MSCV -Thy1.1 retroviruses were constructed that
expresses NFIL3, miR155 and WNT10A. These viruses were described and the expression of
their proteins or miRNA verified previously (see Chapter 3, Figures 3.13A and 3.13B). The
positive targets of regulation by BATF (Nfil3 and miR155hg) were tested first using the identical
stimulation, transduction and sorting protocol as above. RNA was isolated from RPF+ Batf KI/KI
T cells and GFP+ Tzt T cells and RT-qPCR used to analyze expression of the signature TFs and
cytokine genes from Th1, Th2, Th17, Tfh and Th9 cells (Figure 5.15). The exogenous expression
of NFIL3 or miR155 was capable of restoring Gata3, Il4, CxCR5, Rort, Il17a, and Il9 mRNA
expression (Figure 5.15 and 5.16) indicating that these molecules are adequate substitutes for
BATF in these T cell lineages. Levels of these transcripts in Batf KI/KI and Tzt T cells transduced
with MSCV were used as the positive and negative controls, respectively.

Additionally,

exogenous expression of NFIL3 or miR155 had no effect on the expression of T-bet or Ifn mRNA
by Th1 cells (Figures 5.15 and 5.16).

These results demonstrate that NFIL3 or miR155 are

adequate substitutes for BATF during the differentiation of all of these T cell lineages. They also
suggest that these molecules play critical, and perhaps duplicative, roles downstream of BATF in
the pathways that lead to the differentiation T helper cell lineages.
To analyze if elevated expression of WNT10A was able to suppress T helper cell
differentiation, the experiment was repeated with BatfKI/KI T cells as our experimental group.
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Figure 5.15 MSCV-NFIL3 Restores Cytokine Gene Expression of the CD4+ Th
Subsets in Tzt Mice.
Splenocytes from BatfKI/KI and Tzt mice were transduced with the indicated retrovirus and
harvested after 3 days. Thy1.1+ GFP+ CD4+ T cells and Thy1.1+ RFP+ CD4+ T cells and
were isolated by FACS. RNA was converted into cDNA and qPCR was used to assay for
indicated transcripts. Results are normalized to -actin and expressed relative to control
BatfKI/KI cells transduced with MSCV. Assays were run in duplicate. n=4 mice of each
genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not
significant.
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Figure 5.16 MSCV-miR155 Restores Cytokine Gene Expression of the CD4+ Th
Subsets in Tzt Mice.
Splenocytes from BatfKI/KI mice and Tzt mice were transduced with the indicated retrovirus
and harvested 72 hours post activation. Thy1.1+ GFP+ CD4+ T cells and Thy1.1+ RFP+ CD4+
and were isolated using FACS. RNA was converted into cDNA and QPCR was used to
assay for indicated transcripts. Results are normalized to -actin and expressed relative to
transcript levels in BatfKI/KI samples. Assays were run in duplicate. n=4 mice of each
genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not
significant.
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Figure 5.17 Over-expression of WNT10A in BatfKI/KI CD4+ T Cells Does Not
Duplicate the Effects of Batf Deletion in All CD4+ Th Subsets.
Splenocytes from BatfKI/KI mice and Tzt mice were transduced with MSCV or MSCV-WNT10A
retrovirus and harvested after 3 days in culture. Thy1.1+ CD4+ cells were isolated by FACS from
BatfKI/KI splenocytes, and Thy1.1+ GFP+ CD4+ T cells were isolated by FACS from Tzt
splenocytes. RNA was converted into cDNA and qPCR was used to assay for indicated
transcripts. Results are normalized to -actin and expressed relative to BatfKI/KI MSCV
transduced CD4+ T cells. Assays were run in duplicate. n=4 of each genotype. Error bars
indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS = not significant.
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Again, MSCV BatfKI/KI and Tzt T cells were used as controls. The same stimulation, transduction
and sorting protocol as above were used here. Interestingly, the analysis of RNA transcripts from
cells now overexpressing WNT10A showed that WNT10A had no effect on the TF or cytokine
expression profiles for the Th2, Tfh and Th9 cells, but was able to duplicate the effect on Batf
deletion on the Th17 lineage. Rort and Il17a mRNA expression are dramatically reduced
compared to control (Figure 5.17). WNT10A expression had no influence on the expression of
T-bet or Ifn.

It may be that in T cells, WNT10A signaling is not able to override the BATF

program that leads to the specification of Th2, Th9 and Tfh cells, but apparently can override
whatever BATF regulates to induce a Th17 cell program. This, in turn, implies that the observed
repression of Wnt10a expression in wild type T cells is especially critical for the differentiation of
Th17 cells.
My studies on the role of BATF target genes in B cells indicated that Nfil3, miR155hg and
Wnt10a function with BATF in a complex network necessary for regulating B cell CSR (Chapter
3, Figure 3.22). In an effort to position NFIL3, miR155, and WNT10A in a T cell network
regulating Th cell differentiation and function, I examined how expression of each of these
retroviruses in Tzt or BatfKI/KI T cells influenced expression of the other two genes. The RNA
prepared from the transduced cells profiled for gene expression in Figures 5.15, 5.16 and 5.17
were used for this analysis. In Tzt T cells, overexpression of NFIL3 did not significantly alter the
reduced expression of miR55hg or the overexpression of Wnt10a, although I have shown that it
rescues all of the Th deficiencies noted in the noted in the Tzt mice (Figure 5.15). For miR155,
expression restores Nfil3 mRNA levels and represses Wnt10a mRNA and, as shown in Figure
5.16, miR155 rescues all defective Th phenotypes. The endogenous miR155hg gene, however, is
not expressed, just as it also remains silent in the MSCV-NFIL3 transduced cells.
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Figure 5.18 Nfil3, miR155hg, and Wnt10a Influence Each Other’s Expression in Tzt
CD4+ Th Cells.
Splenocytes from BatfKI/KI mice and Tzt mice were cultured on plates coated with -CD3 and in
media supplemented with -CD28, transduced with the indicated retrovirus, and harvested after
3 days in culture. Thy1.1+ CD4+ T cells were isolated by FACS from BatfKI/KI splenocytes, and
Thy1.1+ GFP+ CD4+ T cells were isolated by FACS from Tzt splenocytes. RNA was converted
into cDNA and qPCR was used to assay for indicated transcripts. Results are normalized to actin and expressed relative to BatfKI/KI MSCV transduced CD4+ T cells. Assays were run in
duplicate. n=4 mice of each genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01;
***p<0.001; NS = not significant.
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Together, these results seem to suggest that miR155 functions upstream of NFIL3 and
perhaps can substitute for BATF in positively influencing the differentiation of T cell subsets.
When I examined what happened when WNT10A was overexpressed in BatfKI/KI T cells, I
observed no impact on how the Batf, Nfil3 or miR155hg genes are expressed (Figure 5.18). All
remained highly expressed and are effective to induce the genes that represent the Th2, Th9 and
Tfh lineages (Figure 5.17). However, this otherwise normal pattern of expression is powerless to
override WNT10A and the signals it directs to block Th17 differentiation. This would imply that
these molecules, although operating in a network that influences expression of one another, play
different roles in different cell types. Sorting out these signals and these interactions in T cells
will present a challenge.

5.3 Discussion
The importance of BATF in T cell differentiation and cytokine expression was shown using
BatfΔZ/ΔZ and Batf-/- mice. Studies from our laboratory and others demonstrated that BATF is
required for Th17 cell differentiation and for the expression of the signature Th17 transcripts, Rort
and Il17a (Betz et al., 2010; Ivanov et al., 2006; Schraml et al., 2009). In addition, BATF
expression is essential for Il4 production by Th2 cells, for the differentiation of Tfh cells and
expression of Il21, and for the differentiation of Il9 secreting Th9 cells (Betz et al., 2010; Ise et
al., 2011; Jabeen et al., 2013; Schraml et al., 2009). Th17 and Tfh deficiency have a major impact
on the ability of the B cells in Batf deficient mice to produce class switched antibodies, yet because
these mouse models were missing BATF in all cells (including B cells), there were questions as to
whether these phenotypes were intrinsic to the cells being studied, or were due to some other effect
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caused by the absence of BATF in all cells of the mouse. In Chapter 3, I generated the Izt mouse
model to examine the cell intrinsic effects of Batf deletion in B cells. In this chapter, I have
generated the Tzt mouse model to examine the cell intrinsic effect of Batf deletion in T cells.
The T cell phenotypes of Tzt T cells were identical in all respects to what had been seen
previously using Batf deficient mice. BATF has been shown to have a function in HSC (J. Wang
et al., 2012). BATF is upregulated in response to DNA damage or ageing and functions to limit
HSC self-renewal and promote lymphocyte differentiation.

My work shows that losing these

early roles of BATF in Batf deficient mice is not a factor in the later roles of BATF in T cell
development and differentiation. Deletion of Batf alleles at the DP T cell stage blocks the ability
of the cells to differentiate into functional CD4+ Th2, Th17, Tfh and Th9 cells. Although not tested
by my studies, these Th cell defects would suggest that Tzt mice would be unresponsive to certain
types of infections and resist inflammatory disease, allergies and asthma. My studies did show
that Tzt mice cannot response to a TD antigen, although their response to TI antigens is normal.
In Chapter 3, I identified three genes that were direct targets of BATF regulation in B cells.
Using ChIP-Seq data from other groups (Ciofani et al., 2012; Glasmacher et al., 2012; Vahedi et
al., 2012), I noted that Nfil3, miR155hg, and Wnt10a were bound by BATF in T cells as well. Tzt
T cells did not induce expression of Nfil3 or mir155hg and expressed elevated levels of Wnt10a,
just as I had observed in B cells. Furthermore, when MSCV-BATF was used to re-express BATF
in Tzt T cells, the normal pattern of expression of these genes was restored. Interestingly, my
analysis of data obtained for BATF binding to these genes at different time points after stimulation
of Th17 differentiation (Ciofani et al., 2012) did not show what I saw in B cells with the Nfil3 and
Wnt10a genes. In T cells, BATF localizes to these genes at all time points, not just early after
activation. Since it was the work in these T cells that first suggested that BATF is a “pioneering”
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TF that changes chromatin to allow for others gene regulatory events to occur (Ciofani et al., 2012;
Kurachi et al., 2014), it is puzzling that my BATF ChIP data in B cells supports this model better
than the data in T cells. However, since a complete analysis of BATF-containing complexes that
are present on genes at different times after activation has not been performed for either cell type,
how BATF actually regulates the expression of any gene (positively or negatively) is still not
known.
I employed the MSCV retroviruses containing NFIL3, MiR155, and WNT10A to test the
role of these three BATF target genes in T cell differentiation and cytokine secretion. Both NFIL3
and miR155 can substitute for BATF in restoring the T cell phenotypes of the Tzt mice (Figures
5.15 and 5.16). As observed in B cells, miR155 can substitute for BATF. Transduction of MSCVmiR155 in Tzt solenocytes leads to the appropriate regulation of both Nfil3 and Wnt10a. Neither
MSCV-NFIL3 rescue gene expression in Tzt solenocytes (Figure 5.18 and 5.19). Interestingly,
overexpression of WNT10A can only block Th17 differentiation (Figure 5.17).

Although,

overexpression of WNT10aA does not inhibit the entire T cell program (Figure 5.18 and 5.19).
NFIL3 can overcome high levels of WNT10A and low levels of miR155 in Tzt cells to restore
Th17 differentiation. Further experiments will be needed to generate a model to understand the
role of BATF and the genes BATF is regulating in each of the CD4+ T cell subsets.
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Figure 5.19 Hierarchy of BATF, NFIL3, miR155 and
WNT10A in Regulating T Cell Differentiation.
Model depicting the primary site of action of the molecules
examined in this study (top) and the hierarchy of these actions
in inducing T cell differentiation (bottom).
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CHAPTER 6. ASSESSING THE IMPACT OF BATF PHOSPHORYLATION
ON ITS ROLE IN B CELLS AND T CELLS

6.1 Introduction
The AP-1 family of bZIP transcriptions factors was first identified as inducible regulators
of growth and development and AP-1 activity is indispensable in all mammalian cells (Foletta,
Segal, & Cohen, 1998). Classically, AP-1 transcription factors form dimers consisting of two
compatible bZIP proteins of the JUN (c-JUN, JUND, and JUNB) family and FOS (c-FOS, FOSB,
FRA1, and FRA2) family (Chinenov & Kerppola, 2001). AP-1 dimers bind with high affinity to
a seven nucleotide DNA sequence referred to as a TRE (TPA responsive element) or an AP-1
motif (Angel et al., 1987; Angel & Karin, 1991). JUN:FOS AP-1 dimers can function to activate
or inhibit gene expression depending on the target gene (Karin & Smeal, 1992; Vinson, Acharya,
& Taparowsky, 2006)
BATF, an immune specific AP-1 transcription factor, forms dimers with JUN proteins and
activates or inhibits gene transcription depending on the binding motif (Dorsey et al., 1995; Echlin
et al., 2000; Glasmacher et al., 2012). BATF was first demonstrated to be an effective inhibitor of
gene expression on AP-1 DNA sites (Echlin et al., 2000; Williams et al., 2001). Later it was
discovered that when BATF:JUN dimers bind to AICE motifs, IRF4 is recruited to the genes to
activate transcription (Glasmacher et al., 2012; P. Li et al., 2012).
The expression and function of AP-1 proteins are influenced by a variety of signaling
events. JNK (c-JUN N-terminal kinase) phosphorylates c-JUN to increase c-JUN protein stability
and the transactivation potential of JUN containing AP-1 dimers (Hibi, Lin, Smeal, Minden, &
Karin, 1993). In addition, other bZIP factors such as FOS, ATF2 (activating transcription factor
2) and CREB (cAMP response element binding protein) are regulated similarly by discrete
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phosphorylation events (Kaminska, Pyrzynska, Ciechomska, & Wisniewska, 2000; Karin &
Smeal, 1992; McBride & Nemer, 1998). Post-translational modifications also influence bZIP
protein function.

Modification by ubiquitination, sumoylation, O-linked glycosylation and

reduction/oxidation (redox) have an impact on the activity of bZIP factors (Müller et al., 2000;
Stancovski, Gonen, Orian, Schwartz, & Ciechanover, 1995; Xanthoudakis & Curran, 1994). The
DNA binding domains of approximately 55% of mammalian bZIP factors contain a conserved
cysteine residue that is redox-regulated. DNA binding is inhibited when this cysteine is oxidized.
The reduction of this cysteine in both partners of the JUN:JUN or JUN:FOS complex is required
for these proteins to bind AP-1target DNA (Abate, Patel, Rauscher, & Curran, 1990).
A previous study in our laboratory demonstrated that BATF is highly phosphorylated in
vitro and in vivo (Deppmann et al., 2003). Several of the amino acids in BATF that are modified
by phosphorylation following the stimulation of mouse EL-4 T cells were mapped. The DBD of
BATF contains a phosphorylated serine at position 43 (Figure 1A). This residue is in a position
analogous to the aforementioned redox-regulated cysteines in FOS and JUN. By constructing
BATF proteins designed with mutations to mimic the phosphorylated (S43D) or unphosphorylated
(S43A) state of BATF at this residue, it was found that phosphorylation does not alter the ability
of BATF to form a dimer with JUN (Deppmann et al., 2003). JUN:BATF S43D complexes also
locate properly to the nucleus, but unlike the wild type BATF or the BATF S43A
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Figure 6.1 Function of BATF Phospho-mimics.
(A) Phosphorylation sites identified by Deppmann et al. 2003 for BATF. (B) Previously published
data by Deppmann et al. 2003. (C) Unpublished data by Deppmann and Taparowsky performed
as in Deppman et al. 2003.
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mutant, JUN complexes with BATF S43D are unable to bind to AP-1 target DNA (Deppmann et
al., 2003). Interestingly, both S43 mutations function in the same manner as wild type BATF and
block the transactivation of an AP-1 luciferase reporter gene in mouse fibroblasts (Figure 1B).
This was explained as due to the fact that an S43D mutation effectively sequesters JUN away from
DNA and thus reduces the cellular pool of JUN available to bind to FOS and generate JUN:FOS
dimers competent to bind the AP-1 reporter and activate gene expression (Deppmann et al., 2003):
Figure 1B).
Most bZIP transcription factors also have a hinge region composed of approximately 10
amino acids located between the DBD and the first leucine zipper repeat (Pu & Struhl, 1991). For
productive DNA binding, it is critical that there is proper spacing of the hinge regions (Pu & Struhl,
1991). One hypothesis is that this region plays a role in coordinating how magnesium contributes
to the strength of DNA binding specificity (Moll, Acharya, Gal, Mir, & Vinson, 2001;
Schumacher, Goodman, & Brennan, 2000) Another hypothesis is that amino acids in the hinge
region are critical for defining DNA target-site selection (Krylov, Olive, & Vinson, 1995; Szilák,
Moitra, & Vinson, 1997; Tzamarias, Pu, & Struhl, 1992). More research is required to fully
understand how regulatory events that impact the hinge region might function in the context of
individual bZIP proteins.
Our laboratory has previously mapped a threonine residue with the BATF hinge region that
is phosphorylated in stimulated EL-4 T cells (Deppmann et al., 2006).

BATF proteins were

generated that contain mutations to mimic the phosphorylated (T48D) and unphosphorylated
(T48A) state of BATF at this residue. A reporter gene assay in mouse fibroblasts revealed that the
T48D BATF variant was less efficient at inhibiting the expression of an AP- luciferase report
gene than wild type BATF or the T48A variant (Figure 6.1C and data not shown). Subsequent
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studies showed that, in fact, T48D was not able to dimerize with JUN as efficiently as T48A or
wild type BATF and would prefer to form a T48D:T48D homodimer. These BATF T48
homodimers were not capable of binding AP-1 DNA and thus, when expressed in cells, were selfsequestering, allowing the available pool of FOS and JUN in cells to form dimers that would
activate the AP-1 reporter gene. Interestingly, the studies of Christopher Deppmann in our lab
obtained evidence that the native BATF proteins expressed in stimulated EL-4 cells were
phosphorylated on S43 OR T48 and not on both residues at the same time (Deppmann et al. 2003;
Deppmann and Taparowsky unpublished data).

The roles of these different pools of BATF in

vivo is a topic of great interest and were a major motivation for the studies in this chapter.
The goal of work in this chapter is to use Batf ΔZ/ΔZ B cells and T cells, which are devoid of
wild type BATF, and test the effect of the S43D and T48D mutants on class switch recombination
in B cells, cytokine expression in T cells and on the proper expression of the BATF target genes
(Nfil3, miR155hg, and Wnt10a). With regard to this last goal, I made some predictions about what
I would observe based on the properties of the BATF mutant proteins described above. Those
properties and my prediction of how these mutant BATF proteins may function in gene regulation
are presented in Table 12.

6.2 Results
6.2.1 Construction of MSCV Retroviruses Expressing BATF Mutant Proteins.
To test the function of BATF mutant proteins in B cells and T cells, I used the MSCVThy1.1-BATF retroviral vector and a site-directed mutagenesis protocol (see Chapter 2). The
introduction of the desired mutations to change Serine 43 to Aspartic Acid 43 and Serine 43 to
Alanine 43 were confirmed by DNA sequencing. To insure that no additional mutations were
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introduced into the vectors by the mutagenesis protocol, each confirmed BATF variant cassette
was subcloned back into the parent MSCV-Thy1.1 vector and sequenced again. Virus supernatants
were prepared using these vectors. Spinfection was employed to transduce both activated B cells
and T cells in culture. Immunoblotting of extracts from transduced B cells and T cells confirmed
that these viruses were producing BATF protein. The procedures to analyze protein, gene
expression and immunoglobulin production from transduced cells were performed, unless
indicated otherwise, as described for B cells in Chapter 3 and for T cells in Chapter 5.

6.2.2. Assessing the Function of BATF S43 Variants in BatfZ/Z B Cells and T Cells.
B cells from BatfZ/Z mice were cultured, activated and transduced with MSCV-Thy1.1 or
with the MSCV retroviruses expressing BATF S43A or S43D. Both of these vectors expressed
protein in the B cells (Figure 6.2A). RNA was prepared from the cells and RT-qPCR used to
assess gene expression. Media from the cells was collected and assayed for the presence of
immunoglobulin by ELISA. While expression of MSCV-BATF-S43A in B cells fully restored
Aicda mRNA expression (Figure 6.3A)

Table 12. Predicted Properties and Effects of BATF Mutant Proteins
Properties of BATF
BATF Protein
WT
S43A
S43D
T48A
T48D

Protein Interaction
DNA Binding
Transcription Effects
Jun-Dimerizing BATF Recruitment AP-1 site AICE sites AP-1 Inhibition AICE Activation
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
no
no
yes*
no
yes
yes
yes
yes
yes
yes
reduced**
tbd
no
tbd
no
tbd

Predicted Effect
Nfil3 activated
Wnt10a Supressed
yes
yes
yes
yes
no
yes
yes
yes
tbd
no
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Figure 6.2 Expression of BATF S43D Does Not Restore Class Switched Ig
Production.
(A) B cells from spleens of BatfKI/KI and BatfZ/Z mice were transduced with the indicated
retrovirus 6hr after activation with LPS and IL-4. Cells were harvested 48hrs after activation.
Immunoblotting was used to detect the indicated proteins. Each sample is from 1 mouse. n=6
(B) B cells from spleens of BatfKI/KI and BatfZ/Z mice were cultured in media +/- LPS and
IL-4. Transduced cells were harvested 48hrs after activation. RT-qPCR was used to detect
the indicated transcript levels, in duplicate. Transcripts are normalized to -actin and levels
are expressed relative to those in unstimulated BatfKI/KI B cells (set to 1.0). n=4 for each
genotype. (C) Media from the stimulated cells in A were used to perform ELISA to measure
the indicated Ig. n=4 for each genotype Error bars indicate mean +/- SEM. **p<0.01;
***p<0.001; NS = not significant.
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in activated BatfZ/Z B cells, MSCV-BATF-S43D transduced BatfZ/Z B cells did not express
Aicda mRNA (Figure 6.2B). Transduction of the cells with the viruses had no effect on the
expression of Irf4 or Pax5 mRNA (Figure 6.3A). The ability of the S43A mutant, but not the
S43D mutant, to support production of class switched antibodies was demonstrated by ELISA
(Figure 6.3C). This result suggests a BATF protein that is phosphorylated in the DNA binding
domain cannot function to support a program of gene expression in activated B cells that leads to
CSR and Ig production.
BATF represses gene transcription when bound to AP-1 motifs and activates transcription
when bound to AICE motifs. While BATF-S43D: c-JUN dimers repressed AP-1 activity in a
luciferase assay by a mechanism involving the sequestration of JUN away from DNA, I tested if
it would function similarly in activated BatfZ/Z B cells. Genes regulated by BATF through both
AP-1 and AICE motifs were identified by our B cell RNA-Seq and were used for these studies.
Transduction of the BatfZ/Z cells with MSCV and MSCV-BATF-S43A were used as controls.
Expression of genes regulated through either AP-1 or AICE motifs were fully rescued in B cells
transduced with MSCV- BATF-S43A (Figure 6.3A). In agreement with what was previously
observed with an AP-1 reporter gene, MSCV-BATF-S43D expression was competent to repress
transcription of genes regulated by AP-1. On the other hand, MSCV-S43D BATF did not rescue
the expression of any genes whose regulation occurs through AICE motifs such as miR155hg and
Nfil3 (Figure 6.3B). Expression of miR155 was confirmed using qPCR for the miRNA. Indeed,
MSCV-BATF-S43D does not rescue miR155 expression in B cells (Figure 6.3C). These results
are consistent with previous data showing that BATF: JUNB heterodimers are forming with
BATF-S43D but that by sequestering JUNB away from DNA, that AP-1 and AICE motifs are not
able to direct gene expression. It also indicates that the
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Figure 6.3. Expression of BATF S43D Does Not Restore BATF Target Gene
Expression in BatfZ/Z B Cells.
(A and B) B cells from spleens of BatfKI/KI and BatfZ/Z mice were transduced with the indicated
virus and cultured in media +/- LPS and IL-4 for 48hrs. RT-qPCR was used to detect the
indicated transcript levels, in duplicate. Transcript levels are normalized to -actin and
expressed relative to those in unstimulated BatfKI/KI B cells (set to 1.0). n=4 for each genotype.
(C) miRNA was isolated from B cells of BatfKI/KI and BatfZ/Z mice transduced with the
indicated virus and cultured in media supplemented with LPS and IL-4 for 48hrs. Transcripts
were assayed in duplicated, normalized to RNU6, expressed relative to those in BatfKI/KI
MSCV transduced B cells. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01;
***p<0.001; NS = not significant.
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inability of the S43D mutant to direct CSR in B cells is linked to its inability to activate genes
though AICE motifs. Its ability to repress gene expression through AP-1 sites remains intact.
To test the function of BATF S43D in restoring gene expression to activated CD4+ T cells
isolated from mice, MSCV-Thy1.1 control and MSCV-Thy1.1-BATF S43A or BATF S43D were
used to transduce splenocytes that were pre-activated with -CD3 and -CD28 for 24 hours.
Following transduction, the cells were cultured for an additional 3 days under activating
conditions. Proteins and RNA were prepared from the cells and analyzed by immunoblotting and
RT-qPCR, respectively. As shown in Figure 6.4A, the viruses are capable of expressing both
mutant BATF proteins in Batf ΔZ/ΔZ T cells. In addition, transcripts from the Irf4 gene do not change
is response to infection with any of the three viruses (Figure 6.4B).
Just as was observed in the B cell experiments, while BATF S43A was able to restore
expression of genes associated with the Th2 (Gata2, Il4), Th17 ( Il17a) and Tfh cell lineages (Il21),
BATF S43D was not (Figure 6.4C). The S43D also was not able to reverse the mis- regulation
of Nfil3 or mir155hg as S43A did (Figure 6.4D).

As we know, both of these genes are

transactivated by the binding of IRF4:BATF:JUN complexes to an AICE motifs. On the other
hand, the elevated expression of Wnt10a, which is typical of T cells in which BATF is not
expressed (Batf ΔZ/ΔZ), is down-regulated by expression of either the S43A or S43D mutant, because
both proteins are able to dimerize with JUN to generate complexes that are unable to activate
transcription – either as a BATF S43A:JUN complex on DNA or as a BATF S43D:JUN complex
away from DNA. Under conditions where BATF is deleted, JUN is free to bind to other bZIP
proteins (e.g., FOS or itself) and activate gene transcription from AP-1 motifs.
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Figure 6.4 Expression of BATF S43D Does Not Restore BATF Target Gene Expression
in BatfZ/Z CD4+ Th cells.
(A-D) Splenocytes from BatfKI/KI and BatfZ/Z mice were transduced with the indicated virus and
cultured on -CD3 coated plates and in media supplemented with -CD28 for 3 days. (A)
Immunoblotting was performed to detect the indicated proteins. HSP90 was used as the loading
control. The experiment was performed 8 times using protein pooled from 2 mice of each
genotype and treatment for each experiment. A representative blot is shown. (B-D) RT-qPCR was
used to detect the indicated transcript levels, in duplicate. Transcript levels are normalized to actin and are expressed relative to those in MSCV transduced BatfKI/KI CD4+ T cells (set to 1.0).
n=4 for each genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS
= not significant.
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6.2.3 Assessing the Function of BATF T48 Variants in BatfZ/Z B Cells and T Cells.
I next turned to examining the consequences of expressing the BATF T48A and BATF
T48D mutants in Batf ΔZ/ΔZ B cells and T cells. An unpublished study that was part of the thesis
research of Christopher Deppmann in the laboratory characterized the threonine 48
phosphorylation site in BATF.

Generating a serine to aspartic acid mutation to mimic

phosphorylation at that site, he showed that T48D can still form a heterodimer with JUN and bind
to an AP-1 DNA site. However, using titration studies in vitro and bi-molecular fluorescence in
vivo, it was shown that T48D much prefers to form a homodimer and that this homodimer shows
no affinity for binding AP-1 DNA. As a result, expressing T48D in mouse fibroblasts, as opposed
to expressing wild type BATF or the T48A mutant, effectively releases a pool of JUN in the cell
that can dimerize with FOS or to other bZIP proteins. Since most alternative JUN dimers
transactivate AP-1 gene expression, T48D functions in vivo as a very weak inhibitor of AP-1
mediate gene expression.
Primary B cells were activated with LPS and IL-4 and transduced with MSCV-Thy1.1 or
MSCV viruses expressing BATF T48A or T48D. After48 hours of activation, Thy1.1 cells were
isolated by FACS and protein and RNA were harvested. Media was collected from the cultures to
use for ELISA. Immunoblotting confirmed that these BATF proteins were well expressed in the
cells (Figure 6.5A). Interestingly, both the T48A and T48D proteins were able to induce
expression of Aicda, while having no impact on the expression of the control genes, Pax5 and Irf4
(Figure 6.5B). To check if the expression of AID was enough to allow the cells to undergo CSR,
the media was assayed for IgG1 and IgE. A shown in Figure 6.5C, these class switched antibodies
are being produced by the cells expressing T48D. This would suggest that a BATF
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Figure 6.5 Expression of BATF T48D Restores Aicda Expression and CSR in BatfZ/Z B
Cells.
(A) B cells harvested from spleens of BatfKI/KI and BatfZ/Z mice were cultured in media
supplemented with LPS and IL-4. 48hrs after activation, transduced cells were harvested by FACS
and immunoblotting was performed to detect the indicated proteins. HSP90 was used as the loading
control. The experiment was performed 8 times using protein pooled from 2 mice of each genotype
and treatment for each experiment. A representative blot is shown. (B) BatfKI/KI and BatfZ/Z B
cells were transduced with the indicated retrovirus cultured in media supplemented with LPS and
IL-4 for 48hrs. RT-qPCR was used to detect the indicated transcript levels, in duplicate. Transcript
levels are normalized to -actin and expressed relative to those in unstimulated BatfKI/KI B cells (set
to 1.0). n=4 for each genotype and treatment. (C) Media from the stimulated cells in B were used
to perform ELISA to measure the indicated Ig. n=4 for each genotype Error bars indicate mean
Error bars indicate mean +/- SEM. ***p<0.001; NS = not significant.
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protein phosphorylated on T48 retains at least a partial ability to function as the wild type protein
and activate cellular pathway that drive B cells to express AID and undergo CSR.
I next wanted to test how the expression of T48D would impact the expression of specific
genes that are regulated through AP-1 or AICE motifs. Based on previous work with the AP-1
reporter gene, I predicted (Table 12) that T48 D would not function like BATF and would not be
able to inhibit the expression of AP-1 target genes in B cells. This is what I observed. For Wnt10a
and Il10, both were repressed by T48A in Batf ΔZ/ΔZ B cells, but remained highly expressed in the
presence of T48D (Figure 6.6A). For the AICE regulated genes, I did not know what to expect
since no one had studied how phosphorylation of T48 might impact how BATF participates in the
IRF4:BATF:JUN complex responsible for activating AICE-associated gene expression. I tested
six AICE containing genes and while all were activated when T48A was expressed in Batf ΔZ/ΔZ B
cells, five of the six genes, including Nfil3, remained silent when T48D was expressed (Figure
6.6B). Only miR155hg transcription was activated by T48D equivalently to T48A. To check if
this increase in mir155gh transcription led to more miR155 in the cells, microRNA was isolated
and analyzed by RT-qPCR. As shown in Figure 6.6C, miR155 does accumulate in the T48D
expressing cells.
It was of interest to repeat these experiments with Batf
isolated from Batf

ΔZ/ΔZ

ΔZ/ΔZ

T cells. Splenocytes were

mice and transduced with the viruses expressing BATF T48A or T48D.

After three days of growth in presence of -CD3 and -CD28, Thy1.1 cells were isolated by FACS
and RNA prepared. RT-qPCR was used to analyze gene expression. As expected, the BatfΔZ/ΔZ T
cells are now expressing mRNAs representing the BATF mutants, but do not alter their expression
of Irf4 (Figure 6.7A). For the other target genes, the results were not as clear as in the B cells.
The AP-1 gene target (Wnt10a) appears to be activated, although not strongly as it
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Figure 6.6 Expression of BATF Target Genes in BATF T48D Transduced BatfZ/Z B
Cells.
(A and B) B cells from spleens of BatfKI/KI and BatfZ/Z mice cultured in media +/- LPS and IL4 for 48hrs. 6hrs after activation, cells were transduced with the indicated retrovirus. RTqPCR was used to detect the indicated transcript levels, in duplicate. Transcript levels are
expressed relative to those in unstimulated BatfKI/KI B cells (set to 1.0). n=4 for each genotype.
Error bars indicate mean +/- SEM. ***p<0.001; NS = not significant.
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was in B cells (Figure 6.7B). One AICE target (Nfil3) remains silent. The other AICE target,
mi155gh, which was strongly activated by T48D in B cells, is activated to about 50% of the level
in the control cells expressing T48A (Figure 6.7B). When it came to looking at whether these
BATF proteins could rescue genes associated with the T cell phenotype of BatfΔZ/ΔZ T cells, BATF
T48A was effective, but all of the genes remained silent in the presence of T48D (Figure 6.7C).
I conclude that, unlike in B cells, a BATF protein phosphorylated at T48 cannot function as wild
type BATF to direct the differentiation of CD4+ Th subsets. However, the low level of expression
of mir155hg does support what was observed in B cells. The ability of the T48D mutant to activate
miR155hg expression suggests that the AICE-mediated regulation of this gene differs somehow
from the regulation of other AICE genes, such as Nfil3.
6.3 Discussion
Previous studies have demonstrated that BATF can be phosphorylated on serine 43 and
threonine 48. Both of these amino acids are phosphorylated on BATF molecules expressed in T
cells (Deppmann et al. 2003 and unpublished data). There is evidence to suggest that BATF is
phosphorylated on either S43 or T48, but not on both resides (Deppmann et al. 2003 and
unpublished data), yet there has been no successful attempt made to quantify how much of each
modified protein is present in the cells. Furthermore, since over 25% of the 125 amino acids that
make up BATF are serine, threonine and tyrosine residues, it is very likely that additional
phosphorylation sites are present on BATF and co- exist on proteins that are modified on S43 or
T48. The data presented in this chapter has to be viewed with this in mind.
Having access to BatfΔZ/ΔZ mice and cells has provided a way to test the role of BATF
mutant proteins in duplicating the effects of BATF in B cells and T cells. Among the mutants
available to test are the BATF variants that mimic the phosphorylation state of BATF S43 (S43A
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and S43D) or BATF T48 (T48A and T48). I therefore chose to express these proteins in BatfΔZ/ΔZ
cells and observe if they were able to rescue the BatfΔZ/ΔZ B cell phenotypes described in Chapter
3 or the BatfΔZ/ΔZ T cell phenotypes described in Chapter 5.
The BATF S43D protein can dimerize with JUN but cannot bind to DNA (Deppmann et
al., 2003). This mutant should be largely be a non-functional BATF, except that in the case where
BATF inhibits transcription from AP-1 sites where S43D is likely to duplicate BATF’s effects.
This is precisely what I observed.

S43D cannot direct B cells to undergo class switch

recombination. It cannot activate genes regulated by AICE where JUN:BATF serves as an anchor
to recruit IRF4 for gene activation (Glasmacher et al., 2012; P. Li et al., 2012). For AP-1 regulated
targets, S43D represses transcription, but by a mechanism that involves the sequestration of
complexes away from genes. For T cells, the same results were obtained. BATF S43D could not
support Th cell differentiation and could not activate AICE regulated genes. I conclude from these
experiments that the modification of BATF on serine 43 in vivo must function to inhibit BATFmediated pathways important in both B cells and T cells.
Phosphorylation at threonine 48 generates a BATF protein that has a preference of forming
a homodimer which does not bind to AP-1 DNA (Deppmann et al. 2006; Deppmann and
Taparowsky unpublished data). This behavior causes it to be a much less effective AP- inhibitor,
especially when expressed at very high levels in cells. I was not sure how T48 phosphorylation
would affect positive gene regulation by IRF4:BATF:JUN through AICE. These complexes were
only recently discovered. When tested for its ability to rescue CSR in BatfΔZ/ΔZ B cells, BATF
T48D was shown to have activity at a level close to the BATF T48A control mutant. T48D was
ineffective at repressing AP-1 activity, as expected, but it was also
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Figure 6.7 Expression of BATF T48 Restores miR155hg Expression but Does Not
Rescue BatfZ/Z CD4+ Th Cells.
(A-C) Splenocytes from BatfKI/KI and BatfZ/Z mice were transduced with the indicated virus and
cultured on -CD3 coated plates and in media supplemented with -CD28 for 3 days. RT-qPCR
was used to detect the indicated transcript levels, in duplicate. Transcript levels are normalized to
-actin and are expressed relative to those in MSCV transduced BatfKI/KI CD4+ T cells (set to 1.0).
n=4 for each genotype. Error bars indicate mean +/- SEM. *p<0.05; **p<0.01; ***p<0.001; NS
= not significant.
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ineffective at activating gene expression their AICE – except for one gene target, miR155hg. For
BatfΔZ/ΔZ T cells, the same pattern of gene regulation was noted for T48D but, unlike in B cells, Th
cell differentiation was blocked. Taken together, these results suggest that the action of T48D to
activate the expression of mi1R55hg (and perhaps other targets not tested here) must be sufficient
to allow activated B cells to undergo CSR, but not sufficient for T helper cell differentiation.
These studies in this chapter have shown that phosphorylation state of BATF does play a
role in its function in vivo. For S43, a modification at this amino acid could be used in vivo to shut
down the activities of BATF.

Neither T cell differentiation nor B cell CSR can progress with

BATF modified at S43. Since S43D does repress of AP-1 target genes (although by a different
mechanism that wild type BATF), my results would indicate that the AICE regulated genes are
most critical to B cell CSR. The essential role of AICE regulated genes in CSR is also supported
by the intriguing results with T48. In this case, the expression of T48D in both T cells and B cells
did not restore AP-1 target gene expression and did not restore expression of the majority of the
AICE genes - with the exception of one, miR155hg. Interestingly, T48D was as effective as its
control, T48A, in inducing expression of Aicda and CSR but was unable to activate the expression
of genes representing the Th cell lineages. This would suggest that miR155hg activity is sufficient
to drive B cells to CSR, although more work is needed to sort this out. My results did reveal a
qualitative difference between AICE with regard to how they might be regulated by BATF. The
observation that miR155hg is up-regulated in both B cells and T cells by T48D would suggest there
is something important here that warrants investigation.
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CHAPTER 7. CONCLUSTIONS AND FUTURE DIRECTIONS

BATF is part of an intricate pathway regulating B cell CSR and T cell differentiation and
function. (Betz et al., 2010; Ise et al., 2011; Logan et al., 2012; Murphy et al., 2013; Schraml et
al., 2009; Sopel et al., 2016; Williams et al., 2003). Previous studies have established phenotypes
associated with Batf deficient mice (Betz et al., 2010; Ise et al., 2011; Schraml et al., 2009) and
BATF over-expressing mice (Logan et al., 2012; Williams et al., 2003) BATF has been identified
as a pioneering TF in CD4+ and CD8+ T cells (Ciofani et al., 2012; Kurachi et al., 2014), and its
function is regulated by phosphorylation events (Deppmann et al., 2003; P. Li et al., 2012). My
work has built upon these studies and has further elucidated how BATF influences the different
stages of B cell activation and T cell differentiation. As outlined here, I have identified genes
directly regulated by BATF in B cells and CD4+ T cells (Nfil3, miR155hg, and Wnt10a), discovered
a biphasic expression pattern of BATF in B cells, elucidated the role of BATF at different time
points in regulating a transcriptional network critical to B cell CSR, and characterized the DNA
binding properties and transcriptional properties of BATF in regulating gene expression during B
cell CSR and T cell differentiation.

7.1 Gene Expression Analysis in BatfZ/Z Mice.
The severe phenotypes identified in BatfΔZ/ΔZ mice (Betz et al., 2010; Ise et al., 2011; Schraml

et al., 2009), result from a failure of BATF transcription complexes to direct gene expression in
the absence of BATF. While my work initially focused on the function of BATF initiating CSR in
B cells, it expanded to include BATF mediated gene regulation in CD4+ Th cell differentiation.
Through an RNA-seq experiment comparing gene expression in B cells from wild type and
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BatfZ/Z mice, I identified two genes and one microRNA that are regulated by BATF in B cell
CSR and CD4+ Th cell differentiation. Although these three genes had been linked to CSR in B
cells (Kashiwada et al., 2010; Sercan et al., 2010; Sertorio et al., 2014; Teng et al., 2008; Vigorito
et al., 2007), a direct relationship between these genes and BATF had not previously been
established. Although I identified these 3 genes through a B cell RNA-seq, I demonstrated that
BATF regulated the expression of these same genes in CD4+ T cells as well. While roles for Nfil3
and miR155hg have previously been identified in Th2 and Th17 cytokine secretion (Kashiwada et
al., 2011; Rothchild et al., 2016; Yosef et al., 2013; Yu et al., 2013), this is the first time a link
between these genes and BATF has been demonstrated. In addition, the role for these genes in
Th1, Tfh, and Th9 cells has not been studied. Neither a link between BATF and Wnt10a nor the
role for Wnt10a in CD4+ T cells has previously been described.
In Chapter 3, I proposed a hierarchy within the CSR network regulated by BATF. The
impact on miR155hg expression was the most widespread and functions at an equivalent level to
BATF. NFIL3 and WNT10A function downstream of BATF in antagonistic pathways, but both
still have a substantial influence on CSR. Re-expression of miR155hg restores expression of Nfil3
and Wnt10a and rescues class switched Ig production. Future studies utilizing Nfil3-/-, miR155-/-,
and Wnt10a over-expressing mice to compare gene expression patterns at 6hrs and 72hrs after B
cell activation to Batf-/- and wild type samples will greatly expand our understanding of how each
of these genes contributes to CSR. These studies would help us to understand the CSR network
regulated by BATF.
A previous student in the lab showed that miR155 was mis-expressed in BatfZ/Z B cells.
Therefore, although it was not identified in our RNA-seq, we chose to pursue miR155hg as a
potential BATF target. MiR155hg is not expressed until 12hrs after B cell activation which is why
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it was not present in our RNA-seq. Interestingly, literature presents conflicting roles for miR155
in B cell CSR. The original study using miR155hg-/- mice demonstrated that B cells from these
mice had a reduction in germinal center responses and failed to produce IgG1 (Vigorito et al.,
2007). Two different independent groups provided evidence indicating that miR155 is a negative
regulator of AID. These studies found that substitution of a single nucleotide in the miR155
binding site in the 3’ UTR of Aicda prolonged the half-life of the transcript and increased the
amount of AID protein in a cell (Dorsett et al., 2008; Teng et al., 2008). These data suggest that a
miR155hg deficient mouse would have an increase in class switch Ig. However, the in vivo mouse
model showed the opposite result (Rodriguez et al., 2007). My data agree with the miR155hg-/mouse model. BatfZ/Z mice do not express miR155 and do not undergo CSR. In addition, MSCVmiR155 restored CSR in BatfZ/Z mice providing additional evidence that miR155 is necessary for
B cells to produce class switched Ig. Additional experiments are necessary in order to understand
the role of miR155 in CSR. Comparing gene expression between Batf-/- and miR155-/- mice may
help us to delineate the mechanism through which BATF and miR155 function to enable B cell
CSR.
Using these three BATF target genes, my work tested their roles in T cell differentiation
using the same retroviral rescue approach I used for B cells. Like in B cells, both NFIL3 and
miR155 can substitute for BATF in restoring the T cell phenotypes of the Tzt mice (Figures 5.15
and 5.16) and again, like in B cells, miR155 leads to the appropriate regulation of both Nfil3 and
Wnt10a, while NFIL3 does not (Figure 5.18 and 5.19).

Unlike in B cells, however, the

overexpression of WNT10A can only block Th17 differentiation (Figure 5.17). Furthermore, I
tested how the expression of these three molecules influence the expression of one another. I
found that while NFIL3 can overcome high levels of WNT10A and low levels of miR155 in Tzt
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cells to restore Th17 differentiation, WNT10A overcomes the functions of NFIL3, BATF and
miR155 in wild type (Batf

KI/KI

) T cells to block Th17 cell differentiation only. WNT10aA

overexpression does not inhibit the entire T cell program (Figure 5.18 and 5.19). This is a
different result than in B cells and will require more experiments to sort out. Silencing each of
these targets in the context of different Th cell differentiation treatments of wild type and Tzt T
cells will be necessary to further refine my model.

7.2 Early Expression of BATF in B Cell CSR and CD4+ Th Cell Differentiation.
The mechanisms which control CD4+ Th cell differentiation involve gene expression
programs that help define the ‘epigenetic landscape’ of these cells, leading to additional changes
in gene regulation and expression (Josefowicz, 2013; Tripathi & Lahesmaa, 2014). Many labs in
recent years have been working to define the role of BATF in the differentiation of Th cell subsets.
In 2012, a study in Th17 cells combined genome-wide TF occupancy and an expression time series
to portray the Th17 global transcriptional regulatory network (Ciofani et al., 2012). This was the
first study to find that JUNB:BATF:IRF4 complexes contributed to initial chromatin accessibility.
This transcriptional program is required for expression of the Th17 lineage-specifying TF RORt,
and is why BATF was described as a “pioneering” TF (Ciofani et al., 2012). Since this study,
several others have shown BATF is expressed early and modulates the differentiation of CD8+ T
cells (Kurachi et al., 2014) and T regulatory cells (Karwacz et al., 2017). Recently, a study
provided evidence that epigenetic changes controlled the differentiation of Tfh cells with BATF
and IRF4 (Qiu, Wu, Chan, Lau, & Lu, 2017). This early induction of BATF has not only been
observed in T cells. Liao et al. (2011) found that BATF mRNA and protein was induced early in
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a model system of myeloid differentiation. My work agrees with these studies demonstrating the
importance of early BATF expression in the immune system.
Although it had been shown that B cells, CD8+ T cells, and many of the CD4+ Th cells
express BATF early during activation or differentiation, the role of BATF at these early time points
had not been fully established. For BATF to function as a ‘pioneering TF’, this protein needs to
have a role in reshaping the chromatin landscape. Several experiments still need to be performed
to assess chromatin remodeling and accessibility comparing wild type and Batf-/- mice at these
early time points. Most of the work in the CD4+ th cell lineage has been performed in Th17 cells.
Additional ChIP experiments and gene expression studies need to be performed comparing wild
type and Batf-/- Th1, Th2, Th17, Tfh, Th9, and T-reg cells to determine if Batf is expressed early
in all of the CD4+ Th cell subsets and establish the role of BATF in remodeling the chromatin in
these cells.
Within B cells (Chapter 3) and myloid leukemia cells (Liao et al., 2011), BATF has a
biphasic expression pattern. My work has shown that BATF is regulating different genes at
different time points during B cell activation, and the role of BATF early in B cell activation is
critical for class switch Ig production (Chapter 3). The work with BATF in CD4+ Th cells has
only exploited Batf-/- mice and conditional T cell knockout mice. Utilizing our Izt mouse (Chapter
4), it would be possible to define the role of BATF throughout the differentiation of CD4+ T cells
into their different subsets. Because the Izt mouse allows for temporal control of BatfKI/KI deletion
it is possible to utilize this system to examine the transcriptional impact of BATF-loss at specific
time points during CD4+ T cell differentiation. By comparing the expression of the T cell gene
signature of wild type and BATF-null cells at different time points throughout the differentiation
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process, it would be possible to determine when BATF expression is critical and to elucidate its
role in T cell differentiation.
While my work supports the role of BATF as a pioneer transcription factor in B cells,
additional studies are needed to characterize BATF throughout B cell activation. While induced
deletion of Batf at the time of stimulation completely blocks CSR, deletion after only 6 hours of
stimulation allows the B cells to express AID and to produce class switched antibodies.
Unfortunately, the IzT mice used in this study do not allow for the further fine-tuning of BATF
expression during this process. The use of an in vivo tetracycline-regulated system (Tet-off) of
BATF expression would enable us to study B cell CSR in both an in vivo and in vitro system. With
this mouse model, we would be able to activate the B cells to produce class switch antibodies with
SRBCs or TNP-LPS through IP injections and vary the time after the injections that the mouse
received tetracycline. Another interesting experiment would be to treat B cells activated with LPS
and IL-4 in culture with Tetracycline. This model would elucidate the role of BATF throughout
B cell activation and enable us to investigate the effect of re-expressing BATF at different timepoints during B cell activation on CSR.

7.3 Characterizing the Impact BATF Phosphorylation in B Cells and T Cells.
In vitro and in vivo studies have shown BATF is phosphorylated on these sites, and my
work demonstrates the effect phosphorylation has on BATF target gene expression, B cell CSR,
and CD4+ Th cell differentiation.Post translational modifications of TFs can have large scale
effects on the genes they regulate. Phosphorylation of BATF on S43 affects its ability to generate
DNA binding heterodimers. When BATF S43D is used to restore BATF expression in BatfZ/Z
mice, expression of AP-1 regulated genes, such as Wnt10a, are restored, while AICE regulated
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genes, such as Nfil3 and miR155hg, remain silenced.

When BATF cannot bind to DNA,

JUN:BATF complexes cannot recruit IRF4 to activate transcription of genes BATF regulates
through AICE motifs. This results in B cells which do not express Aicda and do not produce class
switched Ig.
As expected, expression of BATF S43D in BatfZ/Z CD4+ T cell does not rescue the
defects observed in any of the BatfZ/Z CD4+ T cell subsets. In Chapter 5, I demonstrated that the
AICE regulated genes Nfil3 and miR155 are critical for CD4+ Th cell differentiation and cytokine
secretion. BATF S43 phosphorylation prevents AICE regulated genes from being expressed
blocking CD4+ Th cell differentiation as well as production IL4, IL17, and IL9. The circumstances
under which T cell or B cell signaling leads to S43 phosphorylation will be important to define
since targeting these could serve as a way to activate (through blocking phosphorylation) or inhibit
(though inducing phosphorylation) BATF function in cells.
BATF T48D re-expression has a more convoluted effect on B cells and T cells. My results
using MSCV-BATF T48D suggest that the AICE of miR155gh is qualitatively different than the
other AICEs in the way it is regulated by BATF. While some of the AICE regulated genes, such
as miR155hg are restored, others such as Nfil3 remain silenced. Genes, such as Wnt10a, that are
regulated through AP-1 motifs remain over-expressed in BatfZ/Z B cells and T cells. The restored
expression of miR155 enables Aicda to be expressed and these B cells can produce class switched
Ig. Interestingly, although miR155hg expression is restored none of the T cell phenotypes are
rescued through expression of BATF T48D in BatfZ/Z CD4+ Th cells. Taken together, these data
demonstrate the phosphorylation of BATF on T48 would initiate a program of B cell
differentiation that involves up-regulation of miR155 and the down-regulation of AP-1 targets like
Wnt10a, but appears to bypass the up-regulation of other AICE genes, including Nfil3. This is

171
interesting since in Chapter 3, I showed that forced expression of mir155 leads to the up-regulation
of Nfil3 in B cells. In this case up-regulation of miR155 through the actions of BATF T48D does
not. More studies will be needed to reconcile these two opposing results.
In addition to the S43A, S43D, T48A, and T48D BATF phospho-mimics, I have also
generated double mutants of BATF (S43A:T48A and S43D:T48D) for future experiments. I
predict that S43A:T48A double mutants will mimic WT BATF and normally regulate gene
expression. BatfZ/Z B cells transduced with MSCV-S43A:MSCV-T48A will express AID and
produce class switch Ig and CD4+ Th cells will differentiate normally upon stimulation. On the
other hand, I predict that MSCV-S43D:MSCV-T48D will mimic the phenotypes observed in both
B cell and T cell in BatfZ/Z mice. MSCV-S43D:MSCV-T48D protein will form BATF:BATF
homodimers that cannot bind DNA. Therefore it AP-1 regulated genes will be properly regulated,
but AICE regulated genes, such as Nfil3 and miR155 will be mis-expressed.
A group identified another mutation in BATF that affects it function (P. Li et al., 2012).
When BATF is phosphorylated on H55Q, BATF cannot recruit IRF4 to AICE motifs. Without
the formation of the JUNB:BATF:IRF4 complexes, genes regulated by these complexes cannot be
activated. Therefore, I have generated an MSCV-Thy1.1-IRES-H55Q-BATF virus to study the
impact of this mutation in vivo. As with the other MSCV viruses I have used, I would transduce
BatfZ/Z B cells or CD4+ Th cell with the virus and analyzed gene expression patterns. I would
predict that Nfil3 and miR155 would not be able to be activated, while AP-1 regulated genes, such
as Wnt10a, will have a wild type expression pattern. If Nfil3 and miR155 are mis-regulated, there
will be defects in both B cell CSR and CD4+ Th cell differentiation.
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